Page last updated: 2024-11-04

dactinomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dactinomycin, also known as actinomycin D, is a natural antibiotic produced by the bacterium Streptomyces parvulus. It is a potent anti-cancer drug that works by inhibiting DNA synthesis and RNA transcription, thereby preventing the growth and proliferation of cancer cells. Dactinomycin is used in the treatment of various types of cancer, including Wilms tumor, Ewing sarcoma, and rhabdomyosarcoma. Its effectiveness in treating these cancers stems from its ability to bind to DNA and prevent its transcription. However, Dactinomycin has significant side effects, including nausea, vomiting, and bone marrow suppression. Researchers continue to study dactinomycin to understand its mechanism of action, explore ways to improve its therapeutic efficacy, and minimize its toxic effects.'

Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefozopran: RN given refers to the (6R-(6alpha,7beta(Z)))-isomer; RN for cpd without isomeric designation not available 10/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefozopran : A fourth-generation cephalosporin antibiotic having imidazo[1,2-b]pyridazin-1-ium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID457193
CHEMBL ID1554
CHEBI ID27666
SCHEMBL ID3844
MeSH IDM0005644
PubMed CID156599131
MeSH IDM0005644
PubMed CID2019
CHEMBL ID427947
CHEBI ID125400
SCHEMBL ID6152
MeSH IDM0005644

Synonyms (207)

Synonym
2-amino-4,6-dimethyl-3-oxo-n,n'-bis[(6s,9r,10s,13r,18as)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1h-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3h-phenoxazine-1,9-dicarboxamide
einecs 200-063-6
actinomyein-theo-val-pro-sar-meval
actinomycin x i
ad (van)
stereoisomer of n,n'-((2-amino-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-diyl)bis(carbonylimino(2-(1-hydroxyethyl)-1-oxo-2,1-ethanediyl)imino(2-(1-methylethyl)-1-oxo-2,1-ethanediyl)-1,2-pyrrolidinediylcarbonyl(methylimino) (1-oxo-2,1-ethanediyl)))bis(n-methyl
ai3-26374
specific stereoisomer of n,n'-((2-amino-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(n-methyl-l-valine) dilactone
dactinomyein d
3h-phenoxazine-1,9-dicarboxamide, 2-amino-n,n'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1h-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-
dactinomycinum [inn-latin]
nsc 3053
(-)-actinomycin d
dactinomicina [inn-spanish]
dactinomycine [inn-french]
actinomycin cl
meractinomycin
actinomycin x 1
nci-c04682
nsc-3053
actd
CHEBI:27666 ,
2-amino-4,6-dimethyl-3-oxo-1-n,9-n-bis-[(18as)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1h-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-9c-yl]-3h-phenoxazine-1,9-dicarboxamide
2-amino-n,n'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1h-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarboxamide
lyovac-cosmegen
cosmegen lyovac
dtxsid9020031 ,
act d
2-amino-n1,n9-bis[(3r,6s,7r,10s,16s)-3,10-diisopropyl-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-phenoxazine-1,9-dicarboxamide
actinomycin i1
actinomycin x1
actinomycin i(sub 1)
actinomycin 11 cosmegen
actinomycin c1
actinomycin iv
dilactone actinomycin d acid
actinomycin i
ccris 9
actinomycin a iv
hsdb 3220
chounghwamycin b
NCGC00090796-01
UPCMLD-DP055:001
smr000469227
MLS001424196 ,
dactinomycin
actinomycin d, from streptomyces sp., suitable for cell culture, >=95%
actinomycin d, from streptomyces sp., ~98% (hplc)
actinomycin d, from streptomyces sp., >=95% (hplc)
DB00970
UPCMLD-DP055
UPCMLD-DP055:002
NCGC00161622-02
NCGC00161622-01
ACTINOMYCIN-D ,
HMS2052O17
bdbm50089528
2-amino-4,6-dimethyl-3-oxo-1-n,9-n-bis[(3r,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
CHEMBL1554
dactinomycinum
gnf-pf-2290 ,
NCGC00260031-01
dtxcid5031
cas-50-76-0
tox21_111997
tox21_202482
dactinomycine
dactinomicina
CCG-101134
act [antibiotic]
unii-1cc1jfe158
1cc1jfe158 ,
dactinomycin [usan:usp:inn:ban]
actinomycin d [jan]
actinomycin d [iarc]
3h-phenoxazine-1,9-dicarboxamide, 2-amino-n,n'-bis(hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1h-pyrrolo(2,1-i)(1,4,7,10,13)oxatetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-
dactinomycin [usp-rs]
dactinomycin [usan]
dactinomycin [inn]
dactinomycin [usp monograph]
dactinomycin [mart.]
n,n'-((2-amino-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-diyl)-bis(carbonylimino(2-hydroxypropylidene)carbonyliminoisobutylidenecarbonyl-1,2-pyrrolidinediylcarbonyl(methylimino)methylenecarbonyl))bis(n-methyl-l-valine) dilactone
dactinomycinum [who-ip latin]
dactinomycin [mi]
dactinomycin [who-ip]
dactinomycin [hsdb]
dactinomycin [orange book]
actinomycin d [who-ip]
dactinomycin [who-dd]
dactinomycin [vandf]
S8964
BRD-K70578146-001-01-8
AB00514445-05
2-amino-n,n''''-bis[(3r,6s,7r,10s,16s)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
2-amino-n,n''-bis[(3r,6s,7r,10s,16s)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
cid_457193
glycopeptide, 4a
2-amino-4,6-dimethyl-3-oxo-n1,n9-bis[(3r,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
NC00384
2-amino-n,n''''''''-bis[(3r,6s,7r,10s,16s)-3,10-diisopropyl-2,5,9,12,15-pentaketo-7,11,14-trimethyl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-3-keto-4,6-dimethyl-phenoxazine-1,9-dicarboxamide
2-azanyl-4,6-dimethyl-3-oxidanylidene-n1,n9-bis[(3r,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentakis(oxidanylidene)-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
bdbm43866
SCHEMBL3844
NCGC00271789-02
tox21_111997_1
RJURFGZVJUQBHK-IIXSONLDSA-N
mfcd00005033
1-n,9-n-bis[(6s,9r,10s,13r,18as)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1h-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarboxamide
SR-01000763161-4
sr-01000763161
actinomycin d, for fluorescence, >=90% (hplc), from streptomyces sp.
dactinomycin, united states pharmacopeia (usp) reference standard
AKOS030228553
Q186127
BRD-K70578146-001-04-2
BP-25384
2-amino-4,6-dimethyl-3-oxo-1-n,9-n-bis-((18as)-10c,14,17-trimethyl-5,8,12,15,18-pentaoxo-6c,13t-di(propan-2-yl)-18ar-hexadecahydro-1h-pyrrolo(2,1-i)(1,4,7,10,13)oxatetraazacyclohexadecin-9c-yl)-3h-phenoxazine-1,9-dicarboxamide
dactinomycin (mart.)
dactinomycin (usan:usp:inn:ban)
dactinomycin (usp monograph)
actinomycin-(thr-val-pro-sar-meval)
dactinomycine (inn-french)
2-bis(cyclo(n-methyl-l-valyl-sarcosyl-l-prolyl-d-valyl-l-threonyl))-1,9 dimethyl-4,6 3h-phenoxazinone-3
act (antibiotic)
l01da01
nci-co4682
dactinomycin (usp-rs)
3h-phenoxazine-1,9-dicarboxamide, 2-amino-n,n'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11, 14-pentaoxo-1h-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6 -dimethyl-3-oxo-
dactinomycinum (inn-latin)
dactinomicina (inn-spanish)
actinomycin d (iarc)
EN300-7480748
n1,n9-bis[(6s,9r,10s,13r,18as)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-bis(propan-2-yl)-hexadecahydro-1h-pyrrolo[2,1-i]1-oxa-4,7,10,13-tetraazacyclohexadecan-10-yl]-2-amino-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarboxamide
113359-04-9
cefozopran
sce-2787
CBIOL_002056
BRD-A42383464-001-05-5
HMS3267F05
HMS3394O17
BRD-A42383464-001-02-2
NCI60_030539
c62h86n12o16
actinomycin d (jp17)
cosmegen (tn)
D00214
dactinomycin (usp)
BIO1_000831
BIO1_000342
BIO1_001320
ACON0_000471
NSC3053 ,
BCBCMAP01_000155
NEURO_000003
SMP1_000005
10,10'-[(2-amino-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-diyl)bis(carbonylimino)]bis-[dodecahydro-6,13-diisopropyl-2,5,9-trimethyl-1h-pyrrolo-(2,1-1)(1,4,7,10,13)oxatetra-azacyclohexadecine]-1,4,7,11,14
oncostatin k
o)-(1-oxo-1,2-ethanediyl)]bis(n-methyl)l-valine
2-amino-n,n'-bis-[hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1h-pyrrolo(2,1-1)(1,4,7,10,13)oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarb
cosmegen
actinomycin 7
bis(xi-lactone)n,n'-[(2-amino-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-diyl)bis-[carbonylimino(3-hydroxy-1-oxobutylidene)imino(3-methyl-1-oxobutylidene)(tetrahydro-1h-pyrrole-1,2-diyl)carbonyl(methylimin
antibiotic from streptomyces parvullus
actinomycindioic d acid, dilactone
d actinomycin
hbf 386 meractinomycin
dactinomycin d
4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarboxamide
actinomycin aiv
-pentone
dilactone actinomycindioic d acid
actinomycin-(threo-val-pro-sar-meval)
actinomycin d deriv. of 3h-phenoxaocardazine
actinomycin c(sub1)
actinomycin d deriv. of 1h-pyrrolo(2,1-1)(1,4,7,10,13)oxatetra-azacyclohexadecine
l-3-oxo-
acto-d
3h-phenoxazine-1,9-dicarboxamide, 2-amino-n,n'-bis[hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1h-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethy
1h-pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine
x 97
2-amino-n,n'-bis[hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1h-pyrrolo(2,1-1)(1,4,10,13)oxatetraazacyclohexadecin-10-yl]-
lyovac cosmegen
C06770
nsc-684906
nsc684906
nsc-191297
nsc191297
NCGC00025059-02
MEGXM0_000350
ACON1_001004
NCGC00169767-01
LMPK14000005
CHEBI:125400
CHEMBL427947
gnf-pf-1977 ,
2-amino-4,6-dimethyl-3-oxo-1-n,9-n-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide
NCGC00025059-03
NCGC00025059-04
SCHEMBL6152
2-amino-(n,n)-1-bis(hexadecahydro-6,13-diisopropyl-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-1h-pyrrolo[2,1]-[1,4,7,10,13] oxatetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3h-phenoxazine-1,9-dicarboxamide
RJURFGZVJUQBHK-UHFFFAOYSA-N
HB1477
AC-31936
AKOS024456475
AMY10317
HMS3872H13
actinomycin d (dactinomycin)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" More data concerning the magnitude of the toxic effects when 2 modalities are used in conjunction is needed."( Simultaneous radiation and drug therapy: tumor response and toxicity.
Afridi, MA; Douglass, H; Friedman, M; Wallace, JH, 1977
)
0.26
"Actinomycin D, when encapsulated within liposomes, has been previously shown to be less toxic to mice than nonencapsulated actinomycin D, but to retain its tumoricidal activity."( Mechanisms of reduction of antitumor drug toxicity by liposome encapsulation.
Ainsworth, EJ; Bharucha, J; Hanson, WR; Jaroslow, BN; Rahman, YE, 1978
)
0.26
"The action and toxic effects of Actinomycin D are discussed."( [Actinomycin D: toxic effects with special reference to hepatic injury].
Mihevc-Srakar, N; Petrić-Grabnar, G, 1979
)
0.26
" This suggests that occult vascular lesions may have been present in the allograft which were exacerbated when exposed to the irritant vascular effects of contrast media, producing a mild, reversible toxic nephritis."( Adverse effects of meglumine diatrizoate on renal function in the early post-transplant period.
Etheredge, EE; Hill, G; Light, JA; Perloff, LJ; Spees, EK, 1975
)
0.25
"Prostaglandins (PGs) have been shown to cytoprotect various tissue types against the toxic effects of many chemicals."( The cytoprotective properties of prostaglandin E2 against the toxic effects of actinomycin C on embryonic neural retina cells.
Dymond, JB; Kalmus, GW, 1992
)
0.28
" Regardless of the exact toxic mechanisms involved, additional studies on neurotoxicity of calcium channel antagonists seem warranted since some of these compounds are currently being clinically used."( Programmed cell death: its possible contribution to neurotoxicity mediated by calcium channel antagonists.
Cotman, CW; Koh, JY, 1992
)
0.28
"The nephrotoxic side effect of Cis-platin was investigated in 38 patients with testicular tumors."( [Cisplatin-induced nephrotoxic side effects of cytostatic chemotherapy of testicular tumors].
Oehlmann, U; Rebmann, U; Warnack, W, 1990
)
0.28
" The rarity of hepatic failure following treatment for Wilms' tumor raises the possibility of an increased susceptibility to toxic injury in the presence of AAT accumulation."( Severe chemotherapy-related hepatic toxicity associated with MZ protease inhibitor phenotype.
Horn, M; Ruchelli, ED; Taylor, SR, 1990
)
0.28
" The decreases in LD50 were 100-fold, 125-fold and 16-fold with galactosamine (GalN), actinomycin D (AcD) and lead acetate (PbAc) respectively and the animals died within 1-2 days."( Effect of hyperreactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice.
Furman, BL; Sidey, FM; Wardlaw, AC, 1989
)
0.28
" The frequency of severe hematologic toxic episodes was reduced (30 of 64 or 47% for babies receiving full doses [FD], and six of 48 or 13% for those given reduced doses [RD])."( Chemotherapy-related toxicity in infants treated according to the Second National Wilms' Tumor Study.
Baum, E; Breslow, N; D'Angio, G; Morgan, E; Takashima, J, 1988
)
0.27
" Toxic effects were low, and no increased toxicity was observed in pts treated with high, single-dose ACT-D."( Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma.
Carli, M; Ceci, A; De Bernardi, B; Di Tullio, M; Grotto, P; Madon, E; Paolucci, G; Pastore, G; Perilongo, G; Pianca, C, 1988
)
0.27
" The mean lethal dose values of heated and unheated pertussis vaccines were similar in the actinomycin D enhancement assay, but the unheated vaccine was significantly more toxic in the mouse weight gain test."( Determination of endotoxicity in bacterial vaccines.
Chan, YK; Feeley, JC; Miller, CE; Wong, KH, 1973
)
0.25
" We found that MTX-CF is the least toxic single agent chemotherapeutic regimen in the management of GTN."( Methotrexate with citrovorum factor rescue: reduced chemotherapy toxicity in the management of gestational trophoblastic neoplasms.
Berkowitz, RS; Bernstein, MR; Goldstein, DP; Jones, MA; Marean, AR, 1980
)
0.26
" Although the neurotoxic effects produced by different cytostatics present a different appearance and are partly of only sporadic or slight clinical importance, there is hardly a cytostatic which does not exercise a side effect on the nervous system."( [Neurotoxic side effects of cytostatic therapy (author's transl)].
Maurach, R; Strian, F, 1981
)
0.26
" No toxic side effects from G-CSF were noted."( Use of granulocyte colony stimulating factor to reduce the toxicity of super-VAC chemotherapy in advanced solid tumours in childhood.
Jones, CA; Shaw, PJ; Stevens, MM, 1995
)
0.29
"2 g/m2 had a toxic death."( Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Gehan, E; Maurer, H; Newton, WA; Ruymann, FB; Vietti, T; Wharam, M; Wiener, E, 1995
)
0.29
" We now present evidence that the toxic action of glutamate may correspond to programmed cell death because it is blocked by either actinomycin D or cycloheximide."( Cycloheximide and actinomycin D block the toxic effect of glutamic acid on PC12 cells.
Duval, D; Froissard, P; Serghini, R; Sola, B, 1994
)
0.29
" Unexpectedly, combination of CY and Act D did not result in prolongation of mice survival, due mainly to substantial cumulative toxic effects that led to death in several cases."( Combination of immunotherapy with cyclophosphamide/actinomycin D chemotherapy potentiates antileukemic effect and reduces toxicity in a L1210 leukemia model in mice.
Jakóbisiak, M; Lasek, W; Sora, M; Wańkowicz, A, 1995
)
0.29
" Our initial studies have demonstrated a direct adverse effect of individual glucocorticoids and cytotoxic agents on the proliferative capacity of rat tibial growth-plate chondrocytes in vitro."( Glucocorticoid pretreatment reduces the cytotoxic effects of a variety of DNA-damaging agents on rat tibial growth-plate chondrocytes in vitro.
Anderson, E; Eden, O; Isaksson, O; Robson, H; Shalet, S, 1998
)
0.3
" So we compared VAC protocol and ifosfamiide for toxic effects."( Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide).
Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998
)
0.3
"VAC protocol is more toxic for the liver, hematopoietic and peripheral neurologic system."( Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide).
Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998
)
0.3
" The mechanism by which toxic liver injury sensitizes hepatocytes to TNF-alpha cytotoxicity is unknown."( Glutathione modulates rat and mouse hepatocyte sensitivity to tumor necrosis factor toxicity.
Czaja, MJ; Jones, BE; Neufeld, DS; Xu, Y, 1998
)
0.3
" It is the authors' conclusion that the portable isolated limb perfusion system achieved all of the required parameters to provide safe and effective treatment for this type of melanoma."( Safe, compact and portable system for regional chemotherapeutic hyperthermic perfusion procedures.
Faddis, D; Fried, SJ; Miller, R; Weaver, FA, 1993
)
0.29
" Acyl glucuronides have toxic potential and may contribute to drug toxicity."( Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?
Armstrong, VW; Niedmann, PD; Oellerich, M; Schellhaas, U; Schütz, E; Shipkova, M; Wieland, E, 2000
)
0.31
"If M-2 promotes release of cytokines in vivo, these may mediate some of the toxic actions of MPA."( Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?
Armstrong, VW; Niedmann, PD; Oellerich, M; Schellhaas, U; Schütz, E; Shipkova, M; Wieland, E, 2000
)
0.31
" The primary end points were major adverse cardiac events (MACE) at 30 days, diameter stenosis by angiography, tissue effects, and neointimal volume by intravascular ultrasound (IVUS) at six months."( Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.
Bett, JH; Buszman, P; Coleman, L; de Feyter, P; den Heijer, P; Glogar, HD; Grube, E; Johnson, R; Marco, J; Miquel, K; Ormiston, JA; Pitney, M; Polonski, L; Schömig, A; Serruys, PW; Sianos, G; Sousa, JE; Suttorp, MJ; Thuesen, L; Veldhof, S; Virmani, R; Whitbourn, R; Wilkins, GT; Zeiher, AM, 2004
)
0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The objective of these studies was to test the hypothesis that the expression of core protein sensitizes hepatocytes to toxic injury and inhibits the induction of HO-1 in response to stress."( Hepatitis C core protein inhibits induction of heme oxygenase-1 and sensitizes hepatocytes to cytotoxicity.
Britigan, BE; Brown, KE; Schmidt, WN; Wen, F, 2008
)
0.35
"Several adverse health effects, including irritant and allergic contact dermatitis, have been reported among workers who are occupationally exposed to chromium-containing compounds."( Heme-oxygenase 1 gene expression is a marker for hexavalent chromium-induced stress and toxicity in human dermal fibroblasts.
He, Q; Joseph, P; Umbright, C, 2008
)
0.35
"ILI is a safe alternative to the more invasive and laborious ILP technique to treat melanoma confined to a limb."( Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kam, PC; Kroon, HM; Moncrieff, M; Thompson, JF, 2009
)
0.35
" P-Chem adverse effects were occasional and minor."( Prevention of postmolar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up
Ayub, AC; da Cunha, AG; Fajardo, Mdo C; Graudenz, Mda S; Rosa, MW; Schmid, H; Uberti, EM, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" The pharmacokinetics of melphalan and the clinical efficacy and adverse effects of ILI from various centres are summarised."( Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity.
Kam, PC; Thompson, JF, 2010
)
0.36
"Patient AMD and VCR dose and drug-related adverse event (AE) information from four rhabdomyosarcoma (RMS) and two Wilms tumor (WT) studies were assembled."( Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.
Arndt, CA; Barrett, JS; Langholz, B; Renbarger, J; Seibel, NL; Skolnik, JM; Zajicek, A, 2011
)
0.37
" We firstly established the illumination conditions that do not affect mitochondrial structure and calculated the maximum safe light dose to which the cells can be exposed."( Autofluorescence microscopy: a non-destructive tool to monitor mitochondrial toxicity.
Macko, P; Palosaari, T; Rodrigues, RM; Whelan, MP, 2011
)
0.37
"In this retrospective study, a chemotherapy protocol using dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) was evaluated for efficacy and adverse event profile as a first line rescue protocol in 86 client-owned dogs previously treated with a CHOP-based protocol."( The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Monteith, G; Parsons-Doherty, M; Poirier, VJ, 2014
)
0.4
" Taken together, potent MDR-modulating activity along with intracellular conversion into the natural flavonoid quercetin warrants development of the quercetin-amino acid conjugates as safe MDR modulators."( Water-soluble and cleavable quercetin-amino acid conjugates as safe modulators for P-glycoprotein-based multidrug resistance.
Chong, Y; Choo, H; Kim, MK, 2014
)
0.4
"The development of safe antimicrobial agents is important for the effective treatment of pathogens."( Cytotoxicity Assays as Predictors of the Safety and Efficacy of Antimicrobial Agents.
Kretschmer, D; Zipperer, A, 2017
)
0.46
" In contrast, 5d-IV Act-D had the highest probability of being the least toxic regimen in terms of nausea and vomiting."( The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis.
Li, J; Li, S; Lu, X; Wang, J; Xu, C; Yu, H, 2018
)
0.48
" No grades 4 and 5 adverse effects were experienced and the most common toxicity being grade 1 nausea (14."( Efficacy and Safety of Second-Line 5-Day Dactinomycin in Case of Methotrexate Failure for Gestational Trophoblastic Neoplasia.
Bolze, PA; Devouassoux, M; Golfier, F; Hajri, T; Lotz, JP; Massardier, J; Patrier, S; Prouvot, C; Schott, AM; You, B, 2018
)
0.48
"UL-ILI is safe to perform and effective, resulting in low limb toxicity."( Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study.
Barbour, A; Coventry, BJ; Henderson, MA; Kroon, HM; Serpell, J; Smithers, BM; Thompson, JF, 2019
)
0.51
" Complete remission to 4-day MEA and adverse effects were retrospectively evaluated."( The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia.
Ino, K; Kajiyama, H; Kikkawa, F; Kotani, T; Niimi, K; Nishino, K; Sato, S; Suzuki, S; Yamamoto, E, 2020
)
0.56
" The major adverse effects were leukocytopenia, anemia, and nausea."( The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia.
Ino, K; Kajiyama, H; Kikkawa, F; Kotani, T; Niimi, K; Nishino, K; Sato, S; Suzuki, S; Yamamoto, E, 2020
)
0.56
"The results suggest that the efficacy and the adverse effects of 4-day MEA for choriocarcinoma and high-risk GTN may be the same level as EMA/CO."( The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia.
Ino, K; Kajiyama, H; Kikkawa, F; Kotani, T; Niimi, K; Nishino, K; Sato, S; Suzuki, S; Yamamoto, E, 2020
)
0.56
"ILI is safe and effective to treat melanoma in-transit metastases."( Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.
Barbour, A; Beasley, GM; Coventry, BJ; Daou, H; Delman, KA; Farley, CR; Farma, JM; Farrow, NE; Henderson, MA; Kenyon-Smith, TJ; Kroon, HM; Lowe, MC; Miura, JT; Mosca, PJ; Mullen, D; Potdar, A; Serpell, J; Smithers, BM; Speakman, D; Sun, J; Teras, J; Thompson, JF; Tyler, DS; Zager, JS, 2020
)
0.56
"Febrile neutropenia (FN) is a serious side effect in patients undergoing cancer chemotherapy and frequently proves fatal."( Retrospective Cohort Study of Clinical Efficacy and Safety of Cefozopran for Treating Febrile Neutropenia during Chemotherapy in Patients with Lung Cancer.
Esumi, S; Higashionna, T; Kitamura, Y; Murakawa, K; Sendo, T; Ushio, S, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"The rationale and history of the development of physiologically based pharmacokinetic models are briefly reviewed in this paper."( Physiologically based pharmacokinetic models for anticancer drugs.
Chen, HS; Gross, JF, 1979
)
0.26
" The results are discussed in relation to the pharmacokinetic availability of drugs in the plasma compartment of patients treated by different therapuetic regimens."( Pharmacokinetic approach to in vitro testing of ovarian cancer cell sensitivity.
Balconi, G; D'Incalci, M; Erba, E; Garattini, S; Morasca, L; Ottolenghi, L; Salmona, A, 1980
)
0.26
" The objective of this study was to develop an initial population pharmacokinetic model to describe actinomycin-D disposition in children and young adults from which a prospective study could be designed."( Population pharmacokinetic investigation of actinomycin-D in children and young adults.
Adamson, PC; Barrett, JS; Boddy, AV; Cole, M; Gastonguay, MR; Gibiansky, L; Mondick, JT; Skolnik, JM; Veal, GJ, 2008
)
0.35
" Drug contamination from the dosing central venous line (CVL) can impact the reporting of pharmacokinetic (PK) results and analysis."( Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.
Barrett, JS; Dombrowsky, E; Edwards, AY; Patel, D; Skolnik, JM, 2012
)
0.38
"To develop a population pharmacokinetic model of actinomycin-D (AMD) in children with cancer incorporating expressions for drug contamination from PK samples obtained via indwelling CVLs and to evaluate the efficiency of a catheter clearing procedure in removing contamination as well as the impact of contamination on PK results."( Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.
Barrett, JS; Dombrowsky, E; Edwards, AY; Patel, D; Skolnik, JM, 2012
)
0.38
"6 mg/m(2)) were used to characterise a population pharmacokinetic model."( Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.
Boddy, AV; Cole, M; Errington, J; Hill, CR; Malik, G; Veal, GJ, 2014
)
0.4
" There was substantial inter-subject variation in all pharmacokinetic parameters (coefficients of variation 53-81 % for non-normalised values)."( Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.
Boddy, AV; Cole, M; Errington, J; Hill, CR; Malik, G; Veal, GJ, 2014
)
0.4
"We have defined the pharmacokinetics of Act D in a paediatric patient population, providing robust estimates of key pharmacokinetic parameters."( Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.
Boddy, AV; Cole, M; Errington, J; Hill, CR; Malik, G; Veal, GJ, 2014
)
0.4
" A paucity of actinomycin D pharmacokinetic data make it challenging to develop a sound rationale for defining dosing regimens in younger patients."( Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.
Boddy, AV; Bonner, JJ; Ghazaly, EA; Gribben, JG; Johnson, TN; Neuhoff, S; Veal, GJ; Walsh, C, 2016
)
0.43
"Using pharmacokinetic parameters obtained from 385 drug administrations in 352 children aged from 1 month to 18 years, treated with five drugs (dactinomycin, busulfan, carboplatin, cyclophosphamide and etoposide), individual exposures (area under the plasma drug concentration versus time curve; AUC) obtained using doses rounded according to the published NHSE tables were calculated and compared with those obtained by standard dose calculation methods."( Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.
Boddy, AV; Chatelut, E; Osborne, C; Paci, A; Veal, GJ; White-Koning, M, 2018
)
0.48
"Based on pharmacokinetic data for these five drugs, the results generated support the implementation of NHSE dose-banding tables."( Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.
Boddy, AV; Chatelut, E; Osborne, C; Paci, A; Veal, GJ; White-Koning, M, 2018
)
0.48
"Actinomycin D is used for treatment of paediatric cancers; however, a large inter-patient pharmacokinetic (PK) variability and hepatotoxicity are significant limitations to its use and warrant further investigation."( The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients.
Boddy, AV; Kim, HY; Veal, GJ; Zhou, F, 2018
)
0.48
"The pharmacokinetic properties of SCE-2787 administered intravenously at a dose of 20 mg/kg of body weight were studied with mice, rats, rabbits, dogs, and monkeys and were compared with those of ceftazidime, cefpirome, and cefclidin in mice and dogs."( Comparative pharmacokinetics of SCE-2787 and related antibiotics in experimental animals.
Imada, A; Kita, Y; Yamazaki, T, 1992
)
0.28
" Pharmacokinetic studies."( [Pharmacokinetic, bacteriological and clinical studies on cefozopran in children].
Abe, T; Hagiwara, N; Iizuka, T; Kawashima, S; Kondo, Y; Kubota, K; Negishi, S; Tajima, T, 1994
)
0.29
"We conducted pharmacokinetic and clinical studies on cefozopran (CZOP, SCE-2787), an aminothiadiazolmethoxyiminoacetamido cephalosporin, and obtained the following results."( [Pharmacokinetic and clinical evaluation of cefozopran in the pediatric field].
Hatakeyama, K; Ishihara, T; Kawamura, K; Nakamura, H; Sano, T; Seo, K; Toyonaga, Y, 1994
)
0.29
"We conducted a pharmacokinetic and clinical studies on cefozopran (CZOP), a new cephem antibiotic for injection."( [Pharmacokinetic and clinical evaluation of cefozopran in the pediatric field].
Iwai, N; Miyazu, M; Nakamura, H; Taneda, Y; Watanabe, Y, 1994
)
0.29
"Cefozopran (CZOP) was administered intravenously to 22 infants (aged 3 months to 15 years) with infections excluding suppurative meningitis in doses of 10 to 40 mg/kg 3 to 4 times daily for periods of 3 to 16 days and its efficacy and safety in infantile infections as well as pharmacokinetic parameters were determined."( [Pharmacokinetic and clinical studies of cefozopran in the field of pediatrics].
Azuma, E; Ihara, T; Itoh, M; Kamiya, H; Kitamura, K; Sakurai, M, 1994
)
0.29
" These values for pharmacokinetic parameters obtained in the bioassay were similar to those obtained using HPLC."( [Pharmacokinetic, bacteriological and clinical studies on cefozopran in the pediatric field].
Aramaki, M; Handa, S; Motohiro, T; Oda, K; Oki, S; Sakata, Y; Sasaki, H; Yamada, S; Yamashita, F; Yoshinaga, Y, 1994
)
0.29
" Pharmacokinetic parameters were calculated both with a noncompartmental analysis and on the basis of an open two-compartment model (drugs are administered into and eliminated from a central compartment only."( Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.
Borner, K; Koeppe, P; Lode, H; Müller, HJ; Paulfeuerborn, W, 1993
)
0.29
" As a result of above pharmacokinetic and clinical investigations, CZOP is considered to be highly useful in the treatment of indicated infections in neonates and premature infants."( [Pharmacokinetic, bacteriological and clinical studies on cefozopran in neonates and premature infants. A study of cefozopran in the perinatal co-research group].
Abe, T; Fujii, R; Fujita, K; Funamoto, N; Hashira, S; Inyaku, F; Kakuya, F; Kantake, M; Kawaoi, Y; Kondoh, Y; Maruyama, S; Meguro, H; Nagai, S; Nakazato, Y; Nishimura, S; Okuno, A; Sakata, H; Sugimori, S; Sugiura, M; Sunakawa, K; Tajima, T; Takeuchi, Y; Terashima, I; Yagisawa, M; Yoshimura, K, 1996
)
0.29
" In 11 patients in whom pharmacokinetic investigations were performed, peak serum concentrations of CZOP administered at doses of 10, 20 and 40 mg/kg by 30-min."( Pharmacokinetics and clinical effects of cefozopran in pediatric patients.
Abe, T; Fujii, R; Meguro, H; Tajima, T; Terashima, I, 1996
)
0.29
" Cmax was lower in the patient aged 0 day."( [Pharmacokinetic, bacteriological and clinical studies on cefozopran in neonates].
Abe, T; Funamoto, N; Hashira, S; Kawaoi, Y; Kondoh, Y; Nagai, S; Nakazato, Y; Nishimura, S; Sugimori, S; Sugiura, M; Tajima, T; Yoshimura, K, 1997
)
0.3
" The pharmacokinetic evaluation was made in 3 of the 12 patients."( [Pharmacokinetic, bacteriological and clinical studies on cefozopran in neonates].
Kantake, M; Meguro, H; Takeuchi, Y; Terashima, I, 1997
)
0.3
" Based on this analysis, the average pharmacokinetic parameters of CZOP and the variabilities of them in different morbid pharmacological backgrounds and in different subjects were evaluated."( [Pharmacokinetic analysis of cefozopran in neonatal infections--population pharmacokinetics using nonmem].
Fujii, R; Hiramatsu, N; Hishikawa, T; Hujimaki, T; Kuwahara, M; Nagasaki, M; Sagara, Y; Sakurai, Y, 1999
)
0.3
"This study aimed to examine the peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran."( Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients.
Ikawa, K; Ikeda, K; Matsuda, S; Morikawa, N; Ohge, H; Sueda, T; Takesue, Y, 2007
)
0.34
"To establish a cefozopran (a fourth-generation cephem) population pharmacokinetic model using patient data and use it to explore alternative dosage regimens that could optimize the currently used dosing regimen to achieve higher likelihood of pharmacodynamic exposure against pathogenic bacteria."( Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
Fujimoto, Y; Fujita, N; Ikawa, K; Ikeda, K; Kanbayashi, Y; Komori, T; Matsumoto, Y; Morikawa, N; Nomura, K; Shimazaki, C; Shimizu, D; Shimura, K; Taniguchi, K; Taniwaki, M, 2008
)
0.35
" The Monte Carlo simulation was performed to assess the pharmacodynamic exposure based on the population pharmacokinetics and MIC."( Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
Fujimoto, Y; Fujita, N; Ikawa, K; Ikeda, K; Kanbayashi, Y; Komori, T; Matsumoto, Y; Morikawa, N; Nomura, K; Shimazaki, C; Shimizu, D; Shimura, K; Taniguchi, K; Taniwaki, M, 2008
)
0.35
" A total of 145 plasma concentration samples from 32 adult patients were used for a population pharmacokinetic modeling and Monte Carlo simulation to assess the probability of attaining the PK-PD target (70% of the time above the minimum inhibitory concentration for the bacterium)."( Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients.
Ikawa, K; Ikeda, K; Morikawa, N; Nomura, K; Ohge, H; Sueda, T; Taniwaki, M, 2008
)
0.35
" The drug concentrations in plasma and PF were determined and analyzed using population pharmacokinetic modeling."( Development of breakpoints of cephems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in the peritoneal fluid of patients.
Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sueda, T, 2008
)
0.35
" The assay has been applied to therapeutic drug monitoring of cefozopran in both plasma and peritoneal fluid and has contributed to peritoneal pharmacokinetic studies in patients."( Determination of total cefozopran concentrations in human peritoneal fluid by HPLC with cefepime as an internal standard: Comparative pharmacokinetics in the fluid and plasma.
Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sueda, T, 2009
)
0.35
"The aims of this study were to develop a population pharmacokinetic model for cefozopran in pediatric patients, and to use this model to evaluate the pharmacodynamics of cefozopran regimens against common bacterial populations."( Population pharmacokinetic modeling and pharmacodynamic assessment of cefozopran in pediatric patients.
Ikawa, K; Ikeda, K; Kobayashi, R; Kozumi, T; Morikawa, N, 2009
)
0.35
"0 was used to fit the concentration-time data and to calculate the pharmacokinetic parameters."( [Pharmacokinetics of injected cefozopran hydrochloride in healthy volunteers].
Guo, WW; Liang, MZ; Miao, J; Nan, F; Qin, YP; Shen, Q; Wang, L; Wang, Y; Xiang, J; Yu, Q, 2012
)
0.38
"The main pharmaeokinetic parameters for a single injection of low, middle and high doses of cefozopran were as follows: Cmax (48."( [Pharmacokinetics of injected cefozopran hydrochloride in healthy volunteers].
Guo, WW; Liang, MZ; Miao, J; Nan, F; Qin, YP; Shen, Q; Wang, L; Wang, Y; Xiang, J; Yu, Q, 2012
)
0.38
" The main pharmacokinetic parameters have no significant gender differences, and there is no drug accumulated with multiple doses of injection."( [Pharmacokinetics of injected cefozopran hydrochloride in healthy volunteers].
Guo, WW; Liang, MZ; Miao, J; Nan, F; Qin, YP; Shen, Q; Wang, L; Wang, Y; Xiang, J; Yu, Q, 2012
)
0.38
" Plasma and urine pharmacokinetic samples were assayed by a validated high-performance liquid chromatography-tandem mass spectrometry method."( Pharmacokinetics of cefozopran by single and multiple intravenous infusions in healthy Chinese volunteers.
Hu, XJ; Liu, J; Shentu, JZ; Wu, GL; Wu, LH; Zhou, HL; Zhu, MX, 2015
)
0.42

Compound-Compound Interactions

Tumor necrosis factor (TNF), a peptide produced by macrophages with cytostatic and cytolytic effects, demonstrated single agent antitumor activity and synergistic effect when administered with dactinomycin.

ExcerptReferenceRelevance
" In addition, the dye is valuable in combination with phycoerythrin (PE)-fluorescence dual-color flow cytometry on a single argon laser instrument, since its emission in the far red can easily be separated from the emission of PE; 7-AAD was used on fluoresceinisothiocyanate (FITC) and PE surface-labeled human thymocytes for characterization of the dying subpopulation of cells which is undergoing programmed cell death."( Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry.
Braun, J; Giorgi, JV; Krall, WJ; Schmid, I; Uittenbogaart, CH, 1992
)
0.28
" The majority of patients with this subtype t-AML had prior cytotoxic therapy with topoisomerase II-reactive drugs including anthracyclines, epipodophyllotoxins, or actinomycin D, combined with either an alkylating agent or cisplatin."( Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation.
Albain, KS; Le Beau, MM; Schumacher, H; Ullirsch, R, 1990
)
0.28
" However, it produced statistically significant synergistic activity against P388 leukemia when used in combination with cyclophosphamide (CY)."( Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
DeKoning, TF; Li, LH; Wallace, TL, 1987
)
0.27
" One hundred and fifty-one patients have been randomized to receive either the drug combination bleomycin + cyclophosphamide + dactinomycin (BCD) or cisplatinum (CPL) within a course of sequential multidrug chemotherapy including adriamycin (ADR) and high dose methotrexate (HDMTX)."( Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study.
Beck, J; Beck, W; Beron, G; Brandeis, W; Ebell, W; Erttmann, R; Göbel, U; Havers, W; Henze, G; Hinderfield, L; Höcker, P; Jobke, A; Jürgens, H; Kabisch, H; Kotz, R; Landbeck, G; Preusser, P; Prindull, G; Ramach, W; Ritter, J; Salzer-Kuntschik, M; Sekera, J; Treuner, J; Winkler, K; Wüst, G, 1983
)
0.27
"The case of a 6-year-old boy with rhabdomyosarcoma of the larynx, treated by laser surgery combined with external radiotherapy and chemotherapy, is presented."( Rhabdomyosarcoma of the larynx treated by laser surgery combined with radiotherapy and chemotherapy.
Ben-Arieh, Y; Joachims, HZ; Kedar, A; Kuten, A; Yudelev, M, 1983
)
0.27
"5 degrees/120 min, and both in combination with Actinomycin D by an autoradiographic in vitro method in 19 solid tumors of children: 6 Wilms' tumors, 5 neuroblastomas, 4 osteogenic sarcomas, and 4 different tumors."( The effect of hyperthermia alone or in combination with actinomycin D on the RNA metabolism of solid tumors in children.
Willnow, U, 1981
)
0.26
"The Intergroup Rhabdomyosarcoma Study (IRS) initiated an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an ifosfamide (Ifos), Vcr, and Amd combination regimen (VAI)."( Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Gehan, E; Maurer, H; Newton, WA; Ruymann, FB; Vietti, T; Wharam, M; Wiener, E, 1995
)
0.29
"Surgery combined with chemotherapy was applied in 34 out of 178 patients (19."( Chemotherapy combined with surgery in the treatment of gestational trophoblastic disease (GTD).
Kietlińska, Z; Sablińska, B; Zieliński, J, 1993
)
0.29
" Various degrees of synergistic enhancement cytotoxicities of DDP or KSM in combination with rHTNF were assessed."( [Cytotoxicity of recombinant human tumor necrosis factor (rHTNF) alone and in combination with chemotherapeutic agents on human ovarian cancer cells].
Zhao, EF, 1993
)
0.29
" For cell surface antigen staining, allophycocyanin was combined with pH-independent Alexa488 instead of fluorescein-isothiocyanate (FITC) because FITC is pH sensitive."( Detection of cell cycle subcompartments by flow cytometric estimation of DNA-RNA content in combination with dual-color immunofluorescence.
Cole, SW; Giorgi, JV; Korin, YD; Schmid, I; Zack, JA, 2000
)
0.31
"To estimate the antitumor activity and toxicity of irinotecan alone and in combination with vincristine when administered as window therapy and in combination with standard chemotherapy in pediatric patients with newly diagnosed metastatic rhabdomyosarcoma."( Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
Breitfeld, P; Crews, KR; Donaldson, SS; Houghton, P; Lyden, E; Meyer, WH; Pappo, AS; Parham, D; Wiener, E, 2007
)
0.34
"Tumor necrosis factor (TNF), a peptide produced by macrophages with cytostatic and cytolytic effects, demonstrated single agent antitumor activity and synergistic effect when administered with dactinomycin in in vitro tumor cell lines, in vivo xenograft models, and adult and pediatric phase 1 clinical trials."( Phase 2 trial of recombinant tumor necrosis factor-alpha in combination with dactinomycin in children with recurrent Wilms tumor.
Finklestein, JZ; Kelleher, J; Meany, HJ; Reaman, G; Sato, J; Seibel, NL; Sondel, P; Sun, J, 2008
)
0.35
"To evaluate the efficacy of surgical management combined with chemotherapy in the treatment of drug-resistant gestational trophoblastic neoplasm (GTN) patients, and investigate factors influencing the outcome of the surgery combined with chemotherapy."( [Efficacy of surgical management combined with chemotherapy in the treatment of drug-resistant gestational trophoblastic neoplasm].
Cao, Y; Feng, FZ; Li, L; Wan, XR; Xiang, Y; Yang, XY, 2008
)
0.35
"Medical records of 42 patents with drug-resistant GTN who were treated by chemotherapy combined with surgical management at Peking Union Medical College Hospital from Jan 1996 to Jan 2006 were reviewed."( [Efficacy of surgical management combined with chemotherapy in the treatment of drug-resistant gestational trophoblastic neoplasm].
Cao, Y; Feng, FZ; Li, L; Wan, XR; Xiang, Y; Yang, XY, 2008
)
0.35
"Surgical management combined with chemotherapy is effective in the treatment of drug-resistant GTN."( [Efficacy of surgical management combined with chemotherapy in the treatment of drug-resistant gestational trophoblastic neoplasm].
Cao, Y; Feng, FZ; Li, L; Wan, XR; Xiang, Y; Yang, XY, 2008
)
0.35
"To evaluate the therapeutic effect of preoperative transcatheter arterial chemoembolization (TACE) combined with short-term systematic chemotherapy in the treatment of advanced Wilms tumor."( A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy.
Huang, Y; Li, MJ; Tang, DX; Tang, HF; Wu, DH; Xu, S; Zhang, YY; Zhou, YB, 2011
)
0.37
" Twenty patients were treated with conventional preoperative chemotherapy (PC group) using vindesine, actinomycin D, and pirarubicin for 4 weeks; 21 patients were treated in the TACE group with preoperative renal arterial chemoembolization using Lipiodol-pirarubicin-vindesine emulsion; and 25 patients were treated with preoperative chemoembolization combined with short-term systematic chemotherapy (T+S) for 2 weeks."( A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy.
Huang, Y; Li, MJ; Tang, DX; Tang, HF; Wu, DH; Xu, S; Zhang, YY; Zhou, YB, 2011
)
0.37
"From our experience, preoperative chemoembolization combined with short-term systematic chemotherapy is able to achieve higher rates of complete tumor resection and relapse-free survival in the treatment of advanced Wilms tumor."( A retrospective study of the preoperative treatment of advanced Wilms tumor in children with chemotherapy versus transcatheter arterial chemoembolization alone or combined with short-term systemic chemotherapy.
Huang, Y; Li, MJ; Tang, DX; Tang, HF; Wu, DH; Xu, S; Zhang, YY; Zhou, YB, 2011
)
0.37
"5‑30 µM) alone, with phototherapy (PDT, 488 nm) or in combination with vincristine (VCR) or dactinomycin (DAC)."( Antitumor effects of curcumin in pediatric rhabdomyosarcoma in combination with chemotherapy and phototherapy in vitro.
Bortel, N; Ellerkamp, V; Fuchs, J; Schmid, E; Sorg, C, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" Our results support the hypothesis that intracellular tetrahydrobiopterin levels are tightly linked to tyrosine hydroxylation and that tetrahydrobiopterin bioavailability modulates catecholamine synthesis."( Vasoactive intestinal peptide induces both tyrosine hydroxylase activity and tetrahydrobiopterin biosynthesis in PC12 cells.
Anastasiadis, PZ; Bezin, L; Blitz, J; Gordon, LJ; Imerman, B; Kuhn, DM; Levine, RA, 1998
)
0.3
" In biological fluids, they associate non-covalently with high-affinity binding proteins (IGFBPs) which control their bioavailability and modulate their action."( Retinoic acid stimulates IGF binding protein (IGFBP)-6 and depresses IGFBP-2 and IGFBP-4 in SK-N-SH human neuroblastoma cells.
Babajko, S; Chambéry, D; de Gallé, B, 1998
)
0.3
" These data suggest that downregulation of IGFBP-4 expression in VSMCs may play a critical role in vascular growth response to Ang II and thrombin in normal and diseased states, by increasing the bioavailability of IGF-I for its cell-surface receptor."( Insulin-like growth factor binding protein-4 expression is decreased by angiotensin II and thrombin in rat aortic vascular smooth muscle cells.
Anwar, A; Delafontaine, P; Phillips, L; Zahid, AA, 2000
)
0.31
" This effect of TGF-beta on IGF-I bioavailability may promote local bone formation."( Transforming growth factor-beta regulation of the insulin-like growth factor binding protein-4 protease system in cultured human osteoblasts.
Bale, LK; Chen, BK; Conover, CA; Ortiz, CO; Overgaard, MT; Oxvig, C, 2003
)
0.32
" Besides the regulation of the bioavailability of TGF-betas, LTBPs are secreted as free forms and they associate with extracellular fibrillar structures."( Expression of latent TGF-beta binding protein LTBP-1 is hormonally regulated in normal and transformed human lung fibroblasts.
Keski-Oja, J; Koli, K; Weikkolainen, K, 2003
)
0.32
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Dactinomycin (AMD) and vincristine (VCR) have been used for the treatment of childhood cancer over the past 40 years but evidence-based dosing guidance is lacking. A novel five-drug combination was evaluated for high-risk patients. The dosage schedule used was: bleomycin 12 mg/m2/day, cyclophosphamide 600 mg/ m2/ day, and dact inomycin 450 microgram/m 2/day.

ExcerptRelevanceReference
" The dosage schedule used was: bleomycin 12 mg/m2/day, cyclophosphamide 600 mg/m2/day, and dactinomycin 450 microgram/m2/day."( Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma.
Caparros, B; Gutierrez, M; Mosende, C; Rosen, G, 1977
)
0.26
" The ultimate goal will be to utilize this basic information to design an optimal dosage regimen and treatment schedule for the safe and effective cancer chemotherapy of each individual patient."( Physiologically based pharmacokinetic models for anticancer drugs.
Chen, HS; Gross, JF, 1979
)
0.26
" A Wistar/Furth Wilms' tumor model was treated with four dosage levels of actinomycin D and vincristine in single and multiple courses of treatment immediately after tumor injection."( The effects of chemotherapy on the Wistar-Furth Wilms' Tumor.
Murphy, GP; Williams, PD, 1975
)
0.25
"Using the very well investigated and sensitive microsomal monooxynogenase aryl hydrocarbon hydrolase (AHH), we investigated the dose-response relations between an inducer, 3-methylcholanthrene (3-MC), and an inhibitor of transcription, actinomycin D (ACT D), in 10 days old rats."( In vivo and in vitro inhibition of 3-methylcholanthrene-induced aryl hydrocarbon hydroxylase activity in rat liver by actinomycin D and 7,8-benzoflavone.
Grohmann, G; Kleeberg, U; Klinger, W; Steinert, H; Volkmann, R,
)
0.13
" Spirolactone (SC-26304), a potent anti-mineralocorticoid, abolished the effect of aldosterone on amino acid incorporation into medullary proteins when administered at a 100-fold higher dosage [i."( Effect of aldosterone on incorporation of amino acids into renal medullary proteins.
Edelman, IS; Law, PY, 1978
)
0.26
" At the normal therapeutic dosages, methotrexate is eliminated by the kidneys as the unchanged drug; appropriate dosage modifications are mandatory if renal function is compromised."( Clinical pharmacology of systemic chemotherapeutic agents in skin neoplasms.
Hall, SW; Loo, TL, 1978
)
0.26
" The results strongly suggest that an equivalent dose of actinomycin D, with dosage based on a body surface area basis, results in nearly equal tissue-drug exposure for most tissues in various mammalian species."( Tissue disposition of 3H-actinomycin D (NSC-3053) in the rat, monkey, and dog.
Galbraith, WM; Mellett, LB,
)
0.13
" Dose-response measurements established that direct introduction of actinomycin D into resistant cells by means of lipid vesicles resulted in a 200-fold reduction in the concentration of actinomycin D required to inhibit cellular RNA synthesis and a 120-fold reduction in the dose of actinomycin D required to produce a 50% inhibition of cell growth."( Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells.
Biedler, JL; Papahadjopoulos, D; Poste, G; Vail, WJ, 1976
)
0.26
" The dose-response curves of the steroids differed, however, in that cyproterone acetate produced a greater mean stimulation of the enzyme at concentrations less than approximately 25 muM, whereas, at higher concentrations, cyproterone was the more effective inducer."( Cyproterone-mediated stimulation of delta-aminolevulinic acid synthetase in chick embryo liver cells.
Gidari, AS; Lane, SE; Levere, RD, 1976
)
0.26
" The dosage used causes the complete destruction of all mature erythrocytes within twelve days."( The erythroid cells of anaemic Xenopus laevis. I. Studies on cellular morphology and protein and nucleic acid synthesis during differentiation.
Maclean, N; Thomas, N, 1975
)
0.25
" LTB4 induced an accumulation of IL-6 messenger RNA (mRNA) in treated monocytes with a dose-response similar to that of IL-6 protein production."( Leukotriene B4 enhances interleukin-6 (IL-6) production and IL-6 messenger RNA accumulation in human monocytes in vitro: transcriptional and posttranscriptional mechanisms.
Rola-Pleszczynski, M; Stanková, J, 1992
)
0.28
" Both phenotypic classes of PC12 cells respond to aurintricarboxylic acid with similar dose-response characteristics."( Nerve growth factor withdrawal-induced cell death in neuronal PC12 cells resembles that in sympathetic neurons.
Green, SH; Mesner, PW; Winters, TR, 1992
)
0.28
" A dose-response activation of ODC was observed with saponin at concentrations between 2 and 10 micrograms/ml."( Saponin effects of prolactin-like stimulation of ornithine decarboxylase activity in mouse mammary gland explants.
Koduri, PB; Rillema, JA, 1992
)
0.28
" Its dose-response ran roughly parallel to that of a bafilomycin A1-induced lysosomal pH increase."( Induction of neurite outgrowth of PC12 cells by an inhibitor of vacuolar H(+)-ATPase, bafilomycin A1.
Ohkuma, S; Tamura, H, 1991
)
0.28
" These in vitro results suggest that cisplatin is significantly more cytotoxic than carboplatin against human ovarian cancer cell lines and that cisplatin should not be replaced by carboplatin in the treatment of advanced epithelial ovarian cancer until randomized trials using maximum dosing of the cisplatin-containing regimen are performed."( Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay.
Biddle, WC; Crickard, K; Crickard, U; Fanning, J; Foon, KA; Goldrosen, M; Piver, MS, 1990
)
0.28
" The individual MTX excretion rate is of importance for tumor response, suggesting a dose-response relationship for HD MTX treatment."( Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.
Alvegård, TA; Elomaa, I; Holmström, T; Saeter, G; Solheim, OP; Stenwig, AE, 1991
)
0.28
" Dose-response studies found that HHT inhibited colony formation of myeloid cell lines (50% inhibitory dose range, 7 to 12 ng/ml), lymphocytic cell lines (50% inhibitory dose range, 4 to 7 ng/ml), and fresh leukemic cells (50% inhibitory dose range, 2 to 25 ng/ml)."( Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro.
Chen, DL; Koeffler, HP; Shen, ZS; Zhou, JY, 1990
)
0.28
" The dose-response curves for lactate production and DG uptake were similar."( Interleukin 1 stimulates hexose transport in fibroblasts by increasing the expression of glucose transporters.
Baldwin, SA; Bird, TA; Davies, A; Saklatvala, J, 1990
)
0.28
" A single dose of AZA-C (65 mg/kg, ip) produced increases in hepatic MT concentrations 8 hr after dosing that were still elevated at 48 hr."( Induction of hepatic metallothionein following 5-azacytidine administration.
Poirier, LA; Waalkes, MP, 1985
)
0.27
" That this increase in [3H]uridine transport was nuclear receptor-mediated is supported by the excellent correspondence of the L-T3 dose-response curve for [3H]uridine uptake and that for L-T3 binding to receptor."( Stimulation of facilitated [3H]uridine transport by thyroid hormone in GH1 cells. Evidence for regulation by the thyroid hormone nuclear receptor.
Samuels, HH; Stanley, F; Tsai, JS, 1986
)
0.27
" A model is presented here to explain the dose-response kinetics of this inhibition."( Sensitivity of RNA synthesis to actinomycin D inhibition is dependent on the frequency of transcription: a mathematical model.
Miller, MJ, 1987
)
0.27
" Low dosage Ara-C has been used with great success in several clinical trials."( Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells.
Hassan, HT; Rees, JK, 1989
)
0.28
" FETAX advantages include rapid data collection, the ability to measure stage-dependent effects, and the ability to use a large number of embryos to obtain excellent dose-response curves with narrow confidence limits."( Analysis of the activity of DNA, RNA, and protein synthesis inhibitors on Xenopus embryo development.
Bantle, JA; Courchesne, CL, 1985
)
0.27
" Here we report dose-response data on the mutagenicity and toxicity of m-AMSA in T4 rFC11."( Mutagenicity of topoisomerase-active agents in bacteriophage T4.
DeMarini, DM; Lawrence, BK, 1988
)
0.27
" The dose-response curves for stimulation of cytidylyltransferase activity in the supernatant fraction and specific nuclear binding of dexamethasone were similar and both plateaued at approx."( Glucocorticoid stimulation of choline-phosphate cytidylyltransferase activity in fetal rat lung: receptor-response relationships.
Chu, AJ; Dynia, DW; Gross, I; Ingleson, LD; Rooney, SA; Smart, DA; Wilson, CM, 1986
)
0.27
" Attenuation schedules and data relating to the total administered dosage should be provided."( Chemotherapy for soft tissue sarcoma.
Brennan, MF; DeCosse, JJ; Greenall, MJ; Magill, GB, 1986
)
0.27
" While all these hormones have the potential for stimulating BAT 5'-D, the dose-response relationships suggest that norepinephrine and insulin are the most potent."( Hormonal regulation of iodothyronine 5'-deiodinase in rat brown adipose tissue.
Larsen, PR; Silva, JE, 1986
)
0.27
" Using an experimental protocol identical to that of CY and bropirimine combination therapy, and using a more or less equally effective dosage of the drug for the initial reduction of tumor burden (i."( Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
DeKoning, TF; Li, LH; Wallace, TL, 1987
)
0.27
" Proteins were induced at extremely low interferon concentrations, and a dose-response effect was seen with increasing concentrations."( In vitro induction of proteins by alpha-interferon in hairy cell leukemia.
Brownstein, BH; Golomb, HM; Samuels, BL, 1986
)
0.27
" Dose-response curves were obtained at 2-week intervals from 12 to 40 weeks after irradiation."( Actinomycin D and radiation: effects on mouse lung.
Denekamp, J; Hill, SA; Travis, EL, 1986
)
0.27
" Our data suggest that rhTNF and its muteins represent potentially useful anticancer agents; however, adequate dosing and prolonged exposure may be critical in demonstrating cytotoxicity/cytostasis."( Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines.
Creasey, AA; Doyle, LV; Jung, T; Lin, LS; Reynolds, MT; Vitt, CR, 1987
)
0.27
" A dose-response curve for DEX demonstrated that the minimal effective dose (0."( Glucocorticoid regulation of glycerol phosphate dehydrogenase and ornithine decarboxylase activities in the spinal cord of the rat.
De Nicola, AF; Grillo, C; Moses, DF; Ortí, E, 1987
)
0.27
" In the past, the effect was investigated only in terms of dose-response relationship."( [Time course of the cerebroprotective effect of dexamethasone in experimental head injury].
Manaka, S; Sasaki, M; Takakura, K, 1987
)
0.27
" The dose-response curves for both RNA and enzyme activity inductions were also similar."( Nerve growth factor rapidly induces ornithine decarboxylase mRNA in PC12 rat pheochromocytoma cells.
Coffino, P; Dana, SL; Feinstein, SC; McConlogue, L; Shooter, EM, 1985
)
0.27
" Drug dose-response and time-response curves were plotted, and the IC50 ratio was calculated, for each test compound in order to investigate the mechanism of anticancer action."( [In vitro sensitivity test of a cultured human ovarian cancer cell line to anticancer agents].
Fujiya, S; Hatiya, S; Nakabayashi, Y; Tahira, K; Terashima, Y; Yasuda, M; Yoshioka, M, 1985
)
0.27
" The current phase I trial was undertaken to determine: 1) the maximally tolerated dose; 2) the side effects at the different dosage levels; and 3) to evaluate the antiemetic efficacy of levonantradol in patients receiving emesis-producing chemotherapy."( Phase 1 trial of levonantradol in chemotherapy-induced emesis.
Bordin, LA; Bosl, GJ; Clark, RA; Gralla, RJ; Kris, MG; Tyson, LB, 1985
)
0.27
" A linear dose-response regression curve was obtained by plotting the log of the amount of RNA made, expressed as a percentage of the control, versus the log of the reciprocal of the interferon dilution."( Rapid sensitive assay for interferons based on the inhibition of MM virus nucleic acid synthesis.
Allen, PT; Giron, DJ, 1970
)
0.25
" A time-response and a dose-response study showed that actinomycin D inhibits pulmonary RNA synthesis as efficiently as hepatic RNA synthesis."( Qualitative and quantitative aspects of the biosynthesis of ribonucleic acid and of protein in the liver and the lung of the Syrian golden hamster.
Witschi, H, 1973
)
0.25
"The morphologic effects of actinomycin D (ACTD) on normal and regenerating rat pancreas at three dosage levels were studied."( Pancreas acinar cell regeneration. IX. Effect of actinomycin D on microstructure.
Fitzgerald, PJ; Herman, L; Kobayashi, Y; Marsh, WH; Rosenstock, L; Sato, T; Yamaguchi, K, 1971
)
0.25
"The effect of actinomycin D (ACTD) at three dosage levels on the enzymatic activities of the normal rat pancreas was studied."( Pancreas acinar cell regeneration. X. Effect of actinomycin D on enzymatic activities.
Fitzgerald, PJ; Marsh, WH, 1971
)
0.25
" However, actinomycin D, at a dosage of 250 mug/mouse in vivo and 10 mug/ml in vitro produces breakdown of labeled RNA, thus confirming earlier observations that the drug is not a suitable tool for RNA kinetics determinations."( Pulse labeling of RNA of mammalian cells.
Baserga, R; Berman, S; Rovera, G, 1970
)
0.25
" N-OH-AAF dependent ODC induction displayed an almost linear dose-response in the dose range up to 94."( Induction of ornithine decarboxylase and augmentation of tyrosine aminotransferase activity by N-hydroxy-2-acetylaminofluorene and 2-acetylaminofluorene in rat liver. Influence of sex, retinylacetate, indomethacin, and pentachlorophenol.
Bakker, O; Bisschop, A; Meerman, JH; Stavenuiter, JF; van der Heijden, CA; van Wijk, R, 1984
)
0.27
" A modified method was used to evaluate the in vitro dose-response curves."( Correlation of intralesional in vivo chemotherapy of line 10 hepatoma with in vitro drug sensitivity.
Bier, H; Bier, J; Maurer, HR; Ohanian, S; Osman, FA; Siegel, T, 1983
)
0.27
" It is concluded that methotrexate with folinic acid at the dosage used in this study, while less toxic than methotrexate alone, is less effective than methotrexate alone in the induction of remission of nonmetastatic gestational trophoblastic disease."( Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate--folinic acid.
Hammond, CB; Smith, EB; Tyrey, L; Weed, JC, 1982
)
0.26
" It was determined that the highest longwave UV dosage damaged the HSV-2 virion as well as cross-linking the viral DNA."( Herpes simplex virus types 1 and 2 induce shutoff of host protein synthesis by different mechanisms in Friend erythroleukemia cells.
Hill, TM; Sadler, JR; Sinden, RR, 1983
)
0.27
" The loss of phosphaturic response was not prevented by pretreatment with actinomycin D at a dosage close to full toxicity (0."( Refractoriness to phosphaturic action of parathyroid hormone occurring independent of phosphate depletion in hyperparathyroid rats.
Kimura, S; Ogata, E; Shimazawa, E; Takahashi, H; Yamada, M, 1981
)
0.26
" Synergistic induction was observed at all dosage combinations."( Synergistic induction of microsomal heme oxygenase activity in rat liver and kidney by diethyldithiocarbamate and nickel chloride.
Bibeau, LM; Reid, MC; Sunderman, FW, 1983
)
0.27
" The main problems will always remain: To design inert auxiliary accompanying materials in order to overcome side reactions; To use body-friendly and biodegradable macromolecular carrier materials for the therapeutic system; To miniaturize the dosage form dramatically in the submicroscopic size range in order to eliminate foreign body irritations; To develop ultrafine solid and amorphous vesicular compartments (nanocapsules, nanopellets, nanoparticles) to get stable systems with good tissue transfer and organ targeting properties The actual stand of the incorporation of drugs and biologic active material into ultrafine colloidal solid capsules is reviewed here as for instance: Immunoactive material; Fluorescent indicators in body fluids; Controlled and sustained release systems Nonspecific drug targeting of the first-order (passage through endothelial tissues); Second-order targeting (a specific transparenchymal migration), and a highly specific targeting of the third-order (transcellular passage, especially lysosomal transports)."( Drug targeting by drug entrapment into ultrafine compartments as carriers.
Speiser, P, 1984
)
0.27
" administration of AAF to F-344 rats produced log-linear dose-response curves for epoxide hydrolase elevation, measured with either benzo[a]pyrene-4,5-oxide or styrene oxide substrate."( Elevation of hepatic microsomal epoxide hydrolase activity by 2-acetylaminofluorene: strain and species differences.
Dent, JG; Graichen, ME, 1984
)
0.27
"5mM-Ca2+ (food-deprived) for rats dosed with 1,25-dihydroxycholecalciferol."( Oxygen-dependent 1,25-dihydroxycholecalciferol-induced calcium ion transport in rat intestine.
DeLuca, HF; Kabakoff, B; Kendrick, NC, 1981
)
0.26
" Denervation changes in the muscle were evaluated using the resting membrane potential and dose-response curves obtained by plotting acetylcholine-induced contractures."( Effect of protein synthesis inhibitors on the trophic action of the nerve stump.
Higashimori, E; Komatsu, K; Satoh, S; Uchida, K, 1983
)
0.27
" The dose-response curve is exponential with a D0 of 106 krad."( Gamma radiation inhibits the appearance of induced ornithine decarboxylase activity in Chinese hamster cells.
Ben-Hur, E; Heimer, YM; Riklis, E, 1981
)
0.26
" We conclude that actinomycin D in this dosage and schedule has limited activity in advanced breast cancer."( Actinomycin D in the treatment of advanced breast cancer.
Barnes, PL; Cooper, MR; Grimm, RA; Jackson, DV; Muss, HB; Richards, F; Spurr, CL; Stuart, JJ; White, DR, 1980
)
0.26
"We describe 2 cases of proximal tubular defects induced by the administration of ifosfamide at a dosage of 6 g/m2/course over 2 days in children with a diagnosis of malignant mesenchymal tumors."( Ifosfamide-induced renal tubular defect.
López Pérez, J; Melero, C; Muley, R; Torres Valdivieso, MJ; Vara, J; Vivanco, JL, 1994
)
0.29
" It is necessary, however, to reevaluate the cisplatin dosage and treatment schedule in order to reduce such side effects as bone marrow suppression and renal damage."( [A case report of a 6-year-old boy with intracranial yolk sac tumor treated by VAB-6 regimen].
Horita, S; Kubo, M; Kuroda, E; Munemoto, S; Muramatsu, N; Ohki, T; Taguchi, H; Ueno, Y; Wada, H; Wada, T, 1995
)
0.29
"Gestational trophoblastic neoplasm treated by large dosage of 5-fluorouracil and actinomycin could cause cardiotoxicity."( [Clinical analysis of 6 cases of gestational trophoblastic neoplasms complicated by cardiotoxicity after chemotherapies].
Qian, H; Wu, Y, 1995
)
0.29
" Dose-response curves for both isomers through cellular monolayers had the same shapes, but 5(R)-HETE was more potent than 5(S)-HETE."( 5-Hydroxyeicosatetraenoic acid (HETE)-induced neutrophil transcellular migration is dependent upon enantiomeric structure.
Bittleman, DB; Casale, TB, 1995
)
0.29
" The dose-response characteristics of all-trans and 9-cis retinoic acid were different: all-trans was effective at nanomolar concentrations, whereas 10-fold higher levels of 9-cis retinoic acid were required to achieve comparable induction of RAR-beta and CRABP II."( Differential effects of 9-cis and all-trans retinoic acid on the induction of retinoic acid receptor-beta and cellular retinoic acid-binding protein II in human neuroblastoma cells.
Lovat, PE; Malcolm, AJ; Pearson, AD; Redfern, CP, 1994
)
0.29
" Moreover, a dose-response relationship was detectable: 1/6 patients without lung irradiation vs."( Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies.
Dunst, J; Jürgens, H; Paulussen, M, 1993
)
0.29
" While there was a clear effect of dBcAMP-induced differentiation on the maximal NE-induced PI-response, no effect on the dose-response relationship was detectable, resulting in similar EC50-values for astrocytes cultured either in the absence or presence of dBcAMP."( Dibutyryl cyclic AMP-induced morphological differentiation of rat brain astrocytes increases alpha 1-adrenoceptor induced phosphoinositide breakdown by a mechanism involving protein synthesis.
Fahrig, T; Sommermeyer, H, 1993
)
0.29
" Dose-response curves showed maximal induction of CEA at 500 units/ml for TNF-alpha and at 200 units/ml for IFN-gamma."( Differential regulation of carcinoembryonic antigen and biliary glycoprotein by gamma-interferon.
Hefta, LJ; Okai, Y; Paxton, RJ; Shively, JE; Takahashi, H, 1993
)
0.29
"This dosage regimen of multi-agent chemotherapy for osteosarcoma patients caused a transient, but significant, decline in PFTs within 8-12 months after administration but appears to cause no significant long-term pulmonary function abnormalities."( Long-term pulmonary toxicity of multiagent chemotherapy including bleomycin and cyclophosphamide in osteosarcoma survivors.
Goorin, A; Hallowell, JA; Kharasch, VS; Lipsitz, S; Santis, W, 1996
)
0.29
" Dose-response curves to phenylephrine (PE) 10(-9) to 5 x 10(-6) M) were examined in PA rings as well as response to L-arginine analogues in isolated lungs from CH or normoxic (N) rats after various incubation times."( Induction of nitric oxide synthase activity in pulmonary arteries from normoxic and chronically hypoxic rats.
Adnot, S; Carville, C; Eddahibi, S; Raffestin, B; Rideau, D; Teiger, E, 1997
)
0.3
" The dose-response relationship between NGF concentration and survival after H2O2 treatment resembles that for NGF effects on PC12 survival in serumless medium."( Regulation of antioxidant enzyme expression by NGF.
Perez-Polo, R; Sampath, D, 1997
)
0.3
" A dose-response analysis showed that a 10(-6) M concentration of this vitamin consistently induced a maximal accumulation of 7-fold over the control cells."( Growth inhibition of human breast cancer cells by 1,25-dihydroxyvitamin D3 is accompanied by induction of apolipoprotein D expression.
Alvarez, S; Binderup, L; López-Boado, YS; López-Otín, C; Puente, XS; Tolivia, J, 1997
)
0.3
" The possibility of increasing ILI response rates by using other drugs and drug combinations and by multiple fractionated dosing is being investigated."( Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion.
Harman, CR; Kam, PC; Thompson, JF; Waugh, RC,
)
0.13
" A doubling of the intensity of cyclophosphamide (or ifosfamide equivalent) dosing per cycle between IRS-III and IRS-IV is thought to be a key contributing factor for this improvement."( Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.
Anderson, JR; Baker, KS; Breneman, JC; Crist, WM; Grier, HE; Link, MP; Maurer, HM; Qualman, SJ; Wiener, ES, 2000
)
0.31
" Dose-response studies in fibroblasts indicated that the majority of the suppressive effect required concentrations characteristic of cell-surface GC receptors, a point confirmed by persistent DEX-induced suppression in the presence of RU486, an antagonist of classic cytosolic steroid hormone receptors."( Glucocorticoids induce a near-total suppression of hyaluronan synthase mRNA in dermal fibroblasts and in osteoblasts: a molecular mechanism contributing to organ atrophy.
Liu, C; Watson, CE; Werth, VP; Williams, KJ; Zhang, W, 2000
)
0.31
" Two different mechanisms were proposed for this phenotype: (i) classical mutation of drug metabolizing genes or (ii) chromosome reassortments, catalyzed by cancer- and cell line-specific aneuploidy, which generate, via new gene dosage combinations, a plethora of cancer phenotypes, including drug resistance."( Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy.
Duesberg, P; Hehlmann, R; Stindl, R, 2001
)
0.31
" Extracellular application of 10 microM corticosterone neither shifted the dose-response curve of the peak I(ACh) to the right (dissociation constant (K(d)) = 16."( Rapid nongenomic effect of corticosterone on neuronal nicotinic acetylcholine receptor in PC12 cells.
He, HY; Liu, LA; Shi, LJ; Wang, CA, 2001
)
0.31
" Metastatic low-risk tumors (FIGO Stages II and III, WHO score < 8) should be treated with 5-day dosage schedules of methotrexate or actinomycin D, with cure rates approaching 100%."( Treatment of gestational trophoblastic tumors.
Lurain, JR, 2002
)
0.31
"SV2 cells; kinetics and dose-response studies established that maximal MCAD gene stimulation was reached 4 h after addition of 50 microM oleate (C18:1) in the culture medium."( Effects of fatty acids on mitochondrial beta-oxidation enzyme gene expression in renal cell lines.
Bastin, J; Djouadi, F; Ouali, F, 2002
)
0.31
" With regard to the number of dosage courses, 4 courses are regarded as tolerable after incomplete reduction, and 3 courses as adjuvant treatment after complete extraction."( [Treatment of malignant ovarian germ cell tumor and sex cord tumors].
Kamura, T; Ohta, S; Sugiyama, T; Tomonari, R, 2002
)
0.31
" However, the dose-response relationship was acute."( Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Billups, C; Cheshire, PJ; Fouladi, M; Friedman, HS; Houghton, PJ; Leggas, M; Peterson, JK; Stewart, CF; Woo, MH, 2002
)
0.31
" Since induction of ME activity by JH and JH analogs displayed a dose-response curve, specific for each tested component, we concluded that the hormonal action could be mediated through a receptor."( Regulation of cytosolic malate dehydrogenase by juvenile hormone in Drosophila melanogaster.
Danis, P; Farkas, R; Knopp, J; Mechler, BM; Medved'ová, L, 2002
)
0.31
" Although parameters like drug toxicity, optimal drug dosage or delayed endothelial healing need to be further evaluated, summarizing the today's clinical experience the strategy of drug-coated stents promises a striking benefit in interventional treatment of coronary lesions."( Drug eluting stents: initial experiences.
Büllesfeld, L; Gerckens, U; Grube, E; Müller, R, 2002
)
0.31
" Regulation of gene expression also seems to play an important role in Sir2 functions, since increasing the dosage of Sir2 genes increases genome stability in yeast and Caenorhabditis elegans."( Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases.
Kyrylenko, O; Kyrylenko, S; Salminen, A; Suuronen, T, 2003
)
0.32
" Since low micromolar concentrations of GSNO also increase the maturation and activity of a clinically common CFTR mutant, whereas higher concentrations have the opposite effect, these observations may have implications for dosing of S-nitrosylating agents used in cystic fibrosis clinical trials."( Concentration-dependent effects of endogenous S-nitrosoglutathione on gene regulation by specificity proteins Sp3 and Sp1.
Doctor, A; Gaston, B; Hunt, JF; Palmer, LA; Zaman, K, 2004
)
0.32
" Dose-response analyses showed that induction of cell death and caspase-3 activation is mediated by similar concentration ranges of both drugs."( Drug-induced caspase-3 activation in a Ewing tumor cell line and primary Ewing tumor cells.
Harms-Schirra, B; Kachel, M; Klein-Vehne, A; Körholz, D; Mauz-Körholz, C; Tunn, PU,
)
0.13
" 71% of courses were done in full dosage (83% in low dose and 36% in high dose)."( EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV).
Arab, M; Behtash, N; Ghaemmaghami, F; Hanjani, P; Khanafshar, N; Modares, M; Moosavi, AZ,
)
0.13
" The cells were pretreated with various doses of MTX including therapeutic dosage for RA, and then stimulated by PGD2."( Methotrexate enhances prostaglandin D2-stimulated heat shock protein 27 induction in osteoblasts.
Hirade, K; Ishisaki, A; Ito, H; Kato, K; Kozawa, O; Niwa, M; Shimizu, K; Yoshida, M, 2004
)
0.32
" Analysis of several effector-to-target ratios revealed the ability to determine dose-response effects."( Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry.
Houtenbos, I; Ossenkoppele, GJ; Schuurhuis, GJ; van de Loosdrecht, AA; Westers, TM, 2005
)
0.33
"Data presented suggest that dosing of dactinomycin based on surface area is not optimal, either in younger patients in whom the risk of toxicity is greater, or in older patients where doses are capped."( Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
Beane, C; Boddy, AV; Brennan, B; Chisholm, JC; Cole, M; Elsworth, AM; Errington, J; Glaser, A; Hale, J; Hemsworth, S; Howe, K; Jenner, G; McDowell, H; Nicholson, J; Parry, A; Pearson, AD; Pinkerton, R; Pritchard-Jones, K; Veal, GJ; Waters, F; Wright, Y, 2005
)
0.33
" There was no compelling evidence for increased toxicity of doxorubicin when given at 100% versus 50% dosing (full dose: 20 mg/m(2) day x 3), but the number of patients analyzed was small."( Renal failure does not preclude cure in children receiving chemotherapy for Wilms tumor: a report from the National Wilms Tumor Study Group.
Breslow, NE; Feusner, JH; Green, DM; Norkool, PA; Ritchey, ML; Takashima, JR, 2008
)
0.35
"The data suggest that, in the setting of renal failure, reduction of dosing is not necessary for the three main agents used for treatment of newly diagnosed Wilms tumor, and cure is not precluded."( Renal failure does not preclude cure in children receiving chemotherapy for Wilms tumor: a report from the National Wilms Tumor Study Group.
Breslow, NE; Feusner, JH; Green, DM; Norkool, PA; Ritchey, ML; Takashima, JR, 2008
)
0.35
" Carboplatin dosage was based on glomerular filtration rate (GFR) to achieve targeted systemic exposure (6mg/ml min)."( Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour.
Daw, NC; Gregornik, D; Jenkins, JJ; Jones, DP; Kun, LE; Marina, N; McPherson, V; Rodman, J; Wilimas, J; Wu, J, 2009
)
0.35
" A novel five-drug combination of etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA) was evaluated for high-risk patients, but cumulative chemotherapy dosage and treatment duration were reduced for the remaining individuals as compared with that of the previous trial CWS-86."( Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Bielack, SS; Brecht, I; Dantonello, TM; Dickerhoff, R; Gadner, H; Greiner, J; Greulich, M; Harms, D; Herbst, M; Int-Veen, C; Juergens, H; Kirsch, S; Klingebiel, T; Koscielniak, E; Leuschner, I; Marky, I; Scheel-Walter, HG; Schmelzle, R; Schmidt, BF; Treuner, J, 2009
)
0.35
"The dose-response of multiple SCLC cell lines to actinomycin D in the absence and presence of ABT-737 was followed by the assessment of Bcl-2 family expression and poly ADP ribose polymerase cleavage by Western blot, viability by tetrazolium dye reduction and clonogenic assay, and cell cycle kinetics by flow cytometry."( Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines.
Krystal, GW; Xu, H, 2010
)
0.36
" Using TNFα at a high dosage, a significant increase in the apoptosis rate was observed after 6 h and after 12 h in all dosage groups."( CD95 and TNFα-induced apoptosis in liver metastases of colorectal carcinoma.
Kasper, HU; Kern, M; Konze, E; Stippel, DL,
)
0.13
"To develop a method for drug dosing and pharmacokinetic (PK) sampling in children with cancer from a single indwelling central venous catheter that minimized drug contamination."( Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer.
Adamson, PC; Barrett, JS; Skolnik, JM; Zhang, AY, 2010
)
0.36
"A benchtop system was designed to simulate dosing and clearing actinomycin-D (AMD) and vincristine (VCR) from central venous catheters."( Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer.
Adamson, PC; Barrett, JS; Skolnik, JM; Zhang, AY, 2010
)
0.36
"Dactinomycin (AMD) and vincristine (VCR) have been used for the treatment of childhood cancer over the past 40 years but evidence-based dosing guidance is lacking."( Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.
Arndt, CA; Barrett, JS; Langholz, B; Renbarger, J; Seibel, NL; Skolnik, JM; Zajicek, A, 2011
)
0.37
" Statistical modeling was used to account for differences in AE data collection across studies, develop rate models for grade 3/4 CTCAE v3 hepatic- (AMD) and neuro- (VCR) toxicity, assess variation in toxicity rates over age and other factors, and predict toxicity risk under current dosing guidelines."( Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.
Arndt, CA; Barrett, JS; Langholz, B; Renbarger, J; Seibel, NL; Skolnik, JM; Zajicek, A, 2011
)
0.37
" The statistical model provided estimates for AMD and VCR toxicity risk under current dosing schedules and indicated that patients of smaller body size were at lower risk of VCR toxicity than larger patients of the same age."( Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.
Arndt, CA; Barrett, JS; Langholz, B; Renbarger, J; Seibel, NL; Skolnik, JM; Zajicek, A, 2011
)
0.37
" Current dosing practices result in a fairly uniform toxicity profile within age group."( Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group.
Arndt, CA; Barrett, JS; Langholz, B; Renbarger, J; Seibel, NL; Skolnik, JM; Zajicek, A, 2011
)
0.37
"The binding of drugs to catheters can be a source variation in dosing chemotherapeutics."( Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group.
Barrett, JS; Dombrowsky, E; Edwards, AY; Patel, D; Skolnik, JM, 2012
)
0.38
" The overall responses to anticancer agents and resulting pharmacological dose-response profiles were not affected by the growth of tumor cells in the presence DRAQ7."( Real-time cell viability assays using a new anthracycline derivative DRAQ7®.
Akagi, J; Darzynkiewicz, Z; Dobrucki, J; Errington, R; Kordon, M; Matuszek, A; Smith, PJ; Takeda, K; Wlodkowic, D; Zhao, H, 2013
)
0.39
" Such effects varied with the dosage and duration of cycloheximide treatment."( Cycloheximide stimulates suppressor of cytokine signaling-3 gene expression in 3T3-L1 adipocytes via the extracellular signal-regulated kinase pathway.
Chang, HH; Kao, CC; Kao, YH; Ku, HC; Liu, CW; Tsai, PH, 2013
)
0.39
" Choosing the right combination partner for reovirus and a low dosage of the drug may help to both enhance reovirus-induced cancer elimination and reduce drug toxicity."( Activation of p53 by chemotherapeutic agents enhances reovirus oncolysis.
Ahn, DG; Gujar, S; Lee, PW; Marcato, P; Pan, D; Pan, LZ; Shmulevitz, M, 2013
)
0.39
"The pharmacological dosage of dehydroepiandrosterone (DHEA) protects against chemically induced carcinogenesis."( Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor.
Belic, A; Dvorak, Z; Monostory, K; Orbán, E; Porrogi, P; Rozman, D; Temesvári, M; Tóth, K; Vrzal, R, 2013
)
0.39
" Hematologic and non-hematologic toxicity were similar except relatively lower the mean dosage of G-CSF, red blood cells and platelets transfusion on TAE arm."( [Prospective multicentre study of chemotherapeutic regimen containing pirarubicin on the treatment of relapsed or refractory acute myeloid leukemia in adults].
Bi, K; Chen, F; Fan, J; Hou, M; Liu, G; Ran, X; Wang, J; Wang, L; Wang, M; Wang, X; Wang, Z; Xu, R; Yang, E; Yang, S; Yu, W; Zhao, H, 2014
)
0.4
" Chemotherapy dosing was based on actual body weight regardless of obesity status, except for 5-day courses or pulse regimens of actD."( Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia.
Berkowitz, RS; Bernstein, MR; Goldstein, DP; Horowitz, NS; Maestá, I; Moulder, J; Ramírez, LA, 2015
)
0.42
" Current chemotherapy dosing using BMI seems to be appropriate for overweight/obese patients with low-risk GTN."( Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia.
Berkowitz, RS; Bernstein, MR; Goldstein, DP; Horowitz, NS; Maestá, I; Moulder, J; Ramírez, LA, 2015
)
0.42
" Reluctance to use aggressive local control measures and suboptimal chemotherapy dosing are significant contributory factors."( Rhabdomyosarcoma of the orbit in a four months old infant in Zimbabwe: A case report.
Chitsike, I; Kuona, P; Masanganise, R; Sibanda, D,
)
0.13
"Despite advances in cross-sectional imaging, chemotherapeutic dosing for isolated limb infusion (ILI) in melanoma is currently calculated through cumbersome and potentially imprecise manual measurements."( Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma.
Bashir, MR; Beasley, GM; Bhatti, L; Brys, AK; Jaffe, TA; Mosca, PJ; Nath, NS; Salama, AK; Tyler, DS, 2016
)
0.43
"CT-based limb volume measurement is feasible for chemotherapy dosing in patients undergoing ILI for melanoma and has predictive value with respect to clinical response and toxicity."( Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma.
Bashir, MR; Beasley, GM; Bhatti, L; Brys, AK; Jaffe, TA; Mosca, PJ; Nath, NS; Salama, AK; Tyler, DS, 2016
)
0.43
" A paucity of actinomycin D pharmacokinetic data make it challenging to develop a sound rationale for defining dosing regimens in younger patients."( Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.
Boddy, AV; Bonner, JJ; Ghazaly, EA; Gribben, JG; Johnson, TN; Neuhoff, S; Veal, GJ; Walsh, C, 2016
)
0.43
" These results can be used in the selection of the correct dosage of drugs for the effective\ combined anti-cancer therapy using HDIs and AMD."( SODIUM BUTYRATE ENHANCES THE ANTIPROLIFERATIVE EFFECT OF HIGH CONCENTRATIONS OF ACTINOMYCIN D.
Filippova, EA; Gnedina, OO; Igotti, MV; ospelov, VA; Svetlikova, SB,
)
0.13
"We aimed to identify an optimal regimen for low-risk gestational trophoblastic neoplasia (LR-GTN) providing reduction in dosage and toxicity/side effects, enhancement of therapeutic efficacy, and a shorter treatment duration."( Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Duan, W; Kang, HL; Yang, SL; Zhao, Q, 2019
)
0.51
" Dosage reductions occurred in 3% (MTX), 0% (ACT-D) and 29% (MTX/ACT-D)."( Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis.
Hoskins, PJ; Kim, H; Kumar, A; Le, N; Osborne, RJ; Pina, A; Sabourin, JN, 2020
)
0.56
" We should pay attention to the dosage of 5-FU and ActD, monitor adverse reactions strictly, to reduce occurrence of skin malignant events."( 5-Fluorouracil and actinomycin D lead to erythema multiforme drug eruption in chemotherapy of invasive mole: Case report and literature review.
Li, T; Liu, Y; Wang, M; Wang, S; Wang, Y; Zhang, L; Zhang, X, 2022
)
0.72
" Logistic regression analysis explored the relationship between BSA or weight adjusted MTX dosing and: (i) CR to first-line chemotherapy; (ii) incidence of disease relapse."( Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
Cushen, BF; Hancock, BW; Hills, A; Kandiah, K; Palmer, JE; Parker, VL; Singh, K; Tidy, JA; Winter, MC, 2023
)
0.91
"In LR-GTN patients, BSA and weight adjusted MTX-FA dosing did not influence CR to first-line chemotherapy or the incidence of disease relapse."( Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
Cushen, BF; Hancock, BW; Hills, A; Kandiah, K; Palmer, JE; Parker, VL; Singh, K; Tidy, JA; Winter, MC, 2023
)
0.91
"In the treatment of LR-GTN, dose individualisation using BSA or weight is not required, and fixed dosing continues to be preferred as the UK standard."( Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
Cushen, BF; Hancock, BW; Hills, A; Kandiah, K; Palmer, JE; Parker, VL; Singh, K; Tidy, JA; Winter, MC, 2023
)
0.91
"Combination cancer chemotherapy is one of the most useful treatment methods to achieve a synergistic effect and reduce the toxicity of dosing with a single drug."( Synergistic binding of actinomycin D and echinomycin to DNA mismatch sites and their combined anti-tumour effects.
Chang, CC; Hou, MH; Li, LY; Lin, SH; Neidle, S; Satange, R, 2023
)
0.91
" The normal recommended dosage and administration should be 20 to 50 mg/kg of CZOP at a time, using intravenous injection or intravenous drip infusion 3 to 4 times a day."( [Pharmacokinetic and clinical studies on cefozopran in pediatrics].
Akita, H; Iwata, S; Sato, Y; Sunakawa, K; Yokota, T, 1994
)
0.29
"6% of dose within 6 hours after dosing in the patient aged 5 days."( [Pharmacokinetic, bacteriological and clinical studies on cefozopran in neonates].
Abe, T; Funamoto, N; Hashira, S; Kawaoi, Y; Kondoh, Y; Nagai, S; Nakazato, Y; Nishimura, S; Sugimori, S; Sugiura, M; Tajima, T; Yoshimura, K, 1997
)
0.3
" We have produced a murine model of haematogenous pneumococcal meningitis and have examined its usefulness for determining the required dosage and term of antimicrobial agents."( Therapeutic efficacy of cefozopran in a murine model of haematogenous pneumococcal meningitis.
Hiroe, K; Iizawa, Y; Nakao, M; Okonogi, K,
)
0.13
" Therefore, it could be concluded that, though the cases of evaluation were small in number, adjustment of dosing of CZOP is necessary, particularly in prolongation of intervals of administration, in cases of postnatal age of 1 day or less."( [Pharmacokinetic analysis of cefozopran in neonatal infections--population pharmacokinetics using nonmem].
Fujii, R; Hiramatsu, N; Hishikawa, T; Hujimaki, T; Kuwahara, M; Nagasaki, M; Sagara, Y; Sakurai, Y, 1999
)
0.3
" This tendency inverse correlated to decreasing dosage of PCs."( [The trend and susceptibility to antibacterial agents of enterococcus species from urinary tract infections].
Hoshinaga, K; Ishikawa, K; Miyakawa, S; Naide, Y; Shiroki, R; Tanaka, T, 2004
)
0.32
"Intraoperative repeated antimicrobial dosing is therefore recommended to prevent the surgical wound infection for prolonged colorectal surgery."( The significance of the intraoperative repeated dosing of antimicrobials for preventing surgical wound infection in colorectal surgery.
Fukushima, Y; Hiraoka, N; Morimoto, T; Morita, S; Nishisho, I; Nomura, T; Shibata, N, 2005
)
0.33
" These results should help us to understand the peritoneal pharmacokinetics of cefozopran whilst also helping to choose the appropriate dosage for surgical intra-abdominal infections."( Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients.
Ikawa, K; Ikeda, K; Matsuda, S; Morikawa, N; Ohge, H; Sueda, T; Takesue, Y, 2007
)
0.34
"To establish a cefozopran (a fourth-generation cephem) population pharmacokinetic model using patient data and use it to explore alternative dosage regimens that could optimize the currently used dosing regimen to achieve higher likelihood of pharmacodynamic exposure against pathogenic bacteria."( Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
Fujimoto, Y; Fujita, N; Ikawa, K; Ikeda, K; Kanbayashi, Y; Komori, T; Matsumoto, Y; Morikawa, N; Nomura, K; Shimazaki, C; Shimizu, D; Shimura, K; Taniguchi, K; Taniwaki, M, 2008
)
0.35
"Our study proved that Monte Carlo simulation based on population pharmacokinetics can determine optimized dosage and method."( Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
Fujimoto, Y; Fujita, N; Ikawa, K; Ikeda, K; Kanbayashi, Y; Komori, T; Matsumoto, Y; Morikawa, N; Nomura, K; Shimazaki, C; Shimizu, D; Shimura, K; Taniguchi, K; Taniwaki, M, 2008
)
0.35
"This study aimed to perform a pharmacokinetic-pharmacodynamic (PK-PD) target attainment analysis to create a dosing strategy for cefozopran in Japanese adult patients."( Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients.
Ikawa, K; Ikeda, K; Morikawa, N; Nomura, K; Ohge, H; Sueda, T; Taniwaki, M, 2008
)
0.35
" The bacteriostatic and bactericidal breakpoints were determined as the highest MIC values at which the bacteriostatic and bactericidal probabilities in PF were > or =80%, which values varied with drug and dosing regimen."( Development of breakpoints of cephems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in the peritoneal fluid of patients.
Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sueda, T, 2008
)
0.35
" We consider that these results will help clinicians to better understand the penetration into and exposure of cefozopran in the female genital cavity, while also helping to rationalize the dosage of this agent for gynecological-surgery infections."( Penetration into and exposure of cefozopran in pelvic retroperitoneal space exudate.
Ikawa, K; Ikeda, K; Mikamo, H; Morikawa, N; Tamaya, T, 2008
)
0.35
" The mean estimate and interindividual variance of the model were used in a Monte Carlo simulation to estimate the probabilities of attaining the bactericidal target for cefozopran (the time which the drug concentration remains above the minimum inhibitory concentration for the bacterium is 70% of the dosing interval)."( Population pharmacokinetic modeling and pharmacodynamic assessment of cefozopran in pediatric patients.
Ikawa, K; Ikeda, K; Kobayashi, R; Kozumi, T; Morikawa, N, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
actinomycinA large group of antibiotics isolated from various species of Streptomyces and characterised by having a substituted phenoxazine ring linked to two cyclic heterodetic peptides.
cyclodepsipeptideA depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
L-tryptophan degradation I (via anthranilate)126
actinomycin D biosynthesis519

Protein Targets (92)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency10.26630.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency7.06270.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency6.93650.125919.1169125.8920AID2549; AID2708
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
Chain A, CruzipainTrypanosoma cruziPotency8.28520.002014.677939.8107AID1476
interleukin 8Homo sapiens (human)Potency0.13330.047349.480674.9780AID651758
15-lipoxygenase, partialHomo sapiens (human)Potency12.58930.012610.691788.5700AID887
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency3.08303.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.08550.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency79.43280.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency0.00630.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.00550.000714.592883.7951AID1259368; AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency0.01870.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743042; AID743053; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency0.01600.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.28550.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency0.25120.00137.762544.6684AID2120
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency16.72840.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency0.00100.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency0.03010.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency21.87610.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.11120.000214.376460.0339AID588532; AID588533; AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.01660.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.01460.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.00210.001530.607315,848.9004AID1224841
farnesoid X nuclear receptorHomo sapiens (human)Potency0.69150.375827.485161.6524AID588526; AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency23.68840.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.03790.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency8.36150.001024.504861.6448AID588534; AID588535; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency0.03790.001019.414170.9645AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency3.40130.023723.228263.5986AID588541; AID743222; AID743223
caspase-3Homo sapiens (human)Potency0.01600.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency6.05570.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency0.10590.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.04810.001723.839378.1014AID743083
activating transcription factor 6Homo sapiens (human)Potency0.04220.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.08820.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency1.21340.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency0.26140.006723.496068.5896AID1346980
Bloom syndrome protein isoform 1Homo sapiens (human)Potency12.64560.540617.639296.1227AID2528; AID2585
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.02540.010039.53711,122.0200AID588547
caspase-3Cricetulus griseus (Chinese hamster)Potency0.26140.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.00430.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency0.03160.000618.41981,122.0200AID1688
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency39.81070.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.15820.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency18.20640.00798.23321,122.0200AID2546; AID2551
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency4.54070.005612.367736.1254AID624032; AID624044
survival motor neuron protein isoform dHomo sapiens (human)Potency0.31620.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
caspase-1 isoform alpha precursorHomo sapiens (human)Potency31.62280.000311.448431.6228AID900
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.03840.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency0.93840.00339.158239.8107AID1347407
Cellular tumor antigen p53Homo sapiens (human)Potency0.00370.002319.595674.0614AID651631; AID651743; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.03840.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.02660.026622.448266.8242AID651802
Caspase-7Homo sapiens (human)Potency31.62283.981118.585631.6228AID889
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.63100.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.14930.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency0.14930.011912.222168.7989AID651632
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency12.58930.003245.467312,589.2998AID2517
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency3.16230.125919.1169125.8920AID2549
Fumarate hydrataseHomo sapiens (human)Potency7.42660.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency0.11390.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency0.00210.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency22.38720.180013.557439.8107AID1460
regulator of G-protein signaling 4Homo sapiens (human)Potency8.43680.531815.435837.6858AID504845
polyproteinZika virusPotency7.42660.00308.794948.0869AID1347053
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency11.22020.035520.977089.1251AID504332
survival motor neuron protein isoform dHomo sapiens (human)Potency0.35480.125912.234435.4813AID1458
Interferon betaHomo sapiens (human)Potency0.11390.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAD51Homo sapiens (human)IC50 (µMol)58.55001.399017.721432.1000AID1436; AID1437
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1Saccharomyces cerevisiae S288CKi0.04100.04101.36774.0000AID1799481
Growth factor receptor-bound protein 2Homo sapiens (human)IC50 (µMol)5.00005.00005.00005.0000AID73322
Discoidin domain-containing receptor 2Homo sapiens (human)IC50 (µMol)9.00000.00040.39389.0000AID1202711
Growth factor receptor-bound protein 2 Mus musculus (house mouse)IC50 (µMol)5.00005.00005.00005.0000AID75178
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)270.00000.00011.076810.0000AID695925
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)Km10.00000.01403.717210.0000AID679469
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (262)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
actin cytoskeleton organizationGrowth factor receptor-bound protein 2Homo sapiens (human)
epidermal growth factor receptor signaling pathwayGrowth factor receptor-bound protein 2Homo sapiens (human)
Ras protein signal transductionGrowth factor receptor-bound protein 2Homo sapiens (human)
insulin receptor signaling pathwayGrowth factor receptor-bound protein 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayGrowth factor receptor-bound protein 2Homo sapiens (human)
Schwann cell developmentGrowth factor receptor-bound protein 2Homo sapiens (human)
positive regulation of actin filament polymerizationGrowth factor receptor-bound protein 2Homo sapiens (human)
receptor internalizationGrowth factor receptor-bound protein 2Homo sapiens (human)
endodermal cell differentiationGrowth factor receptor-bound protein 2Homo sapiens (human)
natural killer cell mediated cytotoxicityGrowth factor receptor-bound protein 2Homo sapiens (human)
myelinationGrowth factor receptor-bound protein 2Homo sapiens (human)
signal transduction in response to DNA damageGrowth factor receptor-bound protein 2Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayGrowth factor receptor-bound protein 2Homo sapiens (human)
B cell receptor signaling pathwayGrowth factor receptor-bound protein 2Homo sapiens (human)
branching involved in labyrinthine layer morphogenesisGrowth factor receptor-bound protein 2Homo sapiens (human)
cellular response to ionizing radiationGrowth factor receptor-bound protein 2Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processGrowth factor receptor-bound protein 2Homo sapiens (human)
regulation of MAPK cascadeGrowth factor receptor-bound protein 2Homo sapiens (human)
signal transductionGrowth factor receptor-bound protein 2Homo sapiens (human)
ossificationDiscoidin domain-containing receptor 2Homo sapiens (human)
endochondral bone growthDiscoidin domain-containing receptor 2Homo sapiens (human)
cell adhesionDiscoidin domain-containing receptor 2Homo sapiens (human)
signal transductionDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of extracellular matrix disassemblyDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of fibroblast migrationDiscoidin domain-containing receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen fibril organizationDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of bone mineralizationDiscoidin domain-containing receptor 2Homo sapiens (human)
biomineral tissue developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of collagen biosynthetic processDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of tissue remodelingDiscoidin domain-containing receptor 2Homo sapiens (human)
chondrocyte proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
response to muscle stretchDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayDiscoidin domain-containing receptor 2Homo sapiens (human)
negative regulation of apoptotic processDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of osteoblast differentiationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of protein kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein autophosphorylationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of fibroblast proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to hypoxiaDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of extracellular matrix disassemblyDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of wound healingDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDiscoidin domain-containing receptor 2Homo sapiens (human)
negative regulation of hydrogen peroxide-mediated programmed cell deathDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to angiotensinDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of hepatic stellate cell proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of hepatic stellate cell activationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of neuron projection developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionDiscoidin domain-containing receptor 2Homo sapiens (human)
multicellular organism developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDiscoidin domain-containing receptor 2Homo sapiens (human)
protein foldingPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
glycoprotein catabolic processPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
protein deglycosylationPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (78)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
phosphotyrosine residue bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
RNA bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase adaptor activityGrowth factor receptor-bound protein 2Homo sapiens (human)
guanyl-nucleotide exchange factor adaptor activityGrowth factor receptor-bound protein 2Homo sapiens (human)
epidermal growth factor receptor bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
neurotrophin TRKA receptor bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
protein bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
SH3 domain bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
protein kinase bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
protein phosphatase bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
identical protein bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
insulin receptor substrate bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
ephrin receptor bindingGrowth factor receptor-bound protein 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
ATP bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
protein tyrosine kinase collagen receptor activityDiscoidin domain-containing receptor 2Homo sapiens (human)
peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase activityPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
protein bindingPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
metal ion bindingPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (43)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
nucleusGrowth factor receptor-bound protein 2Homo sapiens (human)
nucleoplasmGrowth factor receptor-bound protein 2Homo sapiens (human)
nucleolusGrowth factor receptor-bound protein 2Homo sapiens (human)
cytoplasmGrowth factor receptor-bound protein 2Homo sapiens (human)
endosomeGrowth factor receptor-bound protein 2Homo sapiens (human)
Golgi apparatusGrowth factor receptor-bound protein 2Homo sapiens (human)
cytosolGrowth factor receptor-bound protein 2Homo sapiens (human)
plasma membraneGrowth factor receptor-bound protein 2Homo sapiens (human)
cell-cell junctionGrowth factor receptor-bound protein 2Homo sapiens (human)
cell cortexGrowth factor receptor-bound protein 2Homo sapiens (human)
vesicle membraneGrowth factor receptor-bound protein 2Homo sapiens (human)
extracellular exosomeGrowth factor receptor-bound protein 2Homo sapiens (human)
COP9 signalosomeGrowth factor receptor-bound protein 2Homo sapiens (human)
Grb2-EGFR complexGrowth factor receptor-bound protein 2Homo sapiens (human)
cytoplasmGrowth factor receptor-bound protein 2Homo sapiens (human)
plasma membraneGrowth factor receptor-bound protein 2Homo sapiens (human)
nucleoplasmGrowth factor receptor-bound protein 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
focal adhesionDiscoidin domain-containing receptor 2Homo sapiens (human)
actin cytoskeletonDiscoidin domain-containing receptor 2Homo sapiens (human)
apical plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
receptor complexDiscoidin domain-containing receptor 2Homo sapiens (human)
plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
cytosolGrowth factor receptor-bound protein 2 Mus musculus (house mouse)
cytoplasmPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
cytosolPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
cytosolPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
nucleusPeptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidaseHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (741)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID257883Cytotoxicity against MOLT3 Leukemia cells after 24 hrs of treatment2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID155044Antitumor activity in P388/S(AMD sensitive) in male BDF1 mice measured as % increase in life span (%ILS) at dose 0.075-2.5 mg/kg/injection, ip1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID43188Activity against advanced carcinoma C38 Tumor in CDF1 Mice at dose 0.60 mg/kg measured as % inhibition of tumor1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID355586Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID465964Binding affinity to poly dA/dT DNA assessed as change in melting temperature by thermal denaturation assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Semi-automated high-throughput fluorescent intercalator displacement-based discovery of cytotoxic DNA binding agents from a large compound library.
AID1632764Binding affinity to recombinant hexa-histidine-tagged human full-length N-GLY1 catalytic domain expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature by thermal shift assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Novel small molecule binders of human N-glycanase 1, a key player in the endoplasmic reticulum associated degradation pathway.
AID1769809Antimicrobial activity against Staphylococcus aureus Sau 745524 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID130981Antitumor activity measured as % increase in life span, for ip administration of compound and ip inoculation of B16 melanoma.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID1459549Antibacterial activity against Staphylococcus aureus ATCC 6538 after incubated for 16 to 48 hrs at 28 to 37 degC by spectrofluorometric method2016Journal of natural products, 10-28, Volume: 79, Issue:10
Antibacterial and Cytotoxic Actinomycins Y
AID695925Inhibition of HIV-1 reverse transcriptase using Poly(rA).p(dT) (12 to 18) as substrate after 30 mins by single point PCR assay2012Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14
Inhibition of therapeutically important polymerases with high affinity bis-intercalators.
AID269026Antiproliferative activity against human MOLT4 cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID172442The formation of adrenochrome from epinephrine in the presence of SOD(super oxide dismutase); + denotes ' Inhibited'1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID465967Cytotoxicity against human SF-767 cells assessed as viable cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Semi-automated high-throughput fluorescent intercalator displacement-based discovery of cytotoxic DNA binding agents from a large compound library.
AID43344Number of toxic deaths/number of mice in a group of non tumored mice treated in parallel with the tumor-bearing mice and observed for 100 days at a dose 0.60 mg/Kg; value given as 4/91988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID775973Inhibition of Mycobacterium tuberculosis pantothenate synthetase2013European journal of medicinal chemistry, Nov, Volume: 69Development of 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel Mycobacterium tuberculosis pantothenate synthetase inhibitors.
AID1124362Antitumor activity against mouse P388 cells allografted in mouse BDF1 mouse assessed as survival time of mouse at 50 ug/kg, iv for 4 days (Rvb = 11.5 days)1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID681511TP_TRANSPORTER: drug sensitivity in MRP1-expressing NIH/3T3 cells1995Cancer research, Nov-15, Volume: 55, Issue:22
Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution.
AID133459Antitumor activity measured as median survival time, for ip administration and ip inoculation of B16 melanoma.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID681686TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Actinomycin D: 100 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID357025Cytotoxicity against human KB cells after 72 hrs by methylene blue assay2001Journal of natural products, Jul, Volume: 64, Issue:7
Taxane diterpenoids from the stem bark of Taxus mairei.
AID677153Induction of apoptosis in human NCI-H157 cells assessed as live cell level at 10 uM incubated for 5 hrs in serum-free medium by annexin V/propidium iodide staining by flow cytometry2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Novel structural insights for imidoselenocarbamates with antitumoral activity related to their ability to generate methylselenol.
AID172441The formation of adrenochrome from epinephrine in the absence of SOD(super oxide dismutase)1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID1124364Antitumor activity against mouse P388 cells allografted in mouse BDF1 mouse assessed as survival time of mouse at 150 ug/kg, iv for 4 days (Rvb = 11.5 days)1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221971Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID153533Antitumor activity measured as %ILS against P388/ADR, in ip implanted CDF1 mice, treated ip, qd 1-91988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID1124351Antitumor activity against mouse P388 cells allografted in mouse BDF1 mouse assessed as increase in survival >50 days at 75 ug/kg, iv for 4 days1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID1139971Cytotoxicity against human Hep2 cells in lag phase of growth after 48 hrs2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID43338Number of toxic deaths/number of mice in a group of non tumored mice treated in parallel with the tumor-bearing mice and observed for 100 days at a dose 0.15 mg/Kg; value given as 1/91988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID83947Antitumor activity against human colon adenocarcinoma HT-29 cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID103273Antitumor activity against human breast adenocarcinoma MCF-7 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1123362Cytotoxicity against mouse L1210 cells at 10 ug/ml after 48 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID15503450% inhibition of incorporation of precursor [3H]thymidine into DNA P388 cell lines1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID1123366Cytotoxicity against mouse L1210 cells at 0.1 ug/ml after 48 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID43336Mean survival time of treated /untreategroup x100. (number of over 100-day survivors/ number of total mice in the group) at a dose 0.45 mg/kg1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID1730561Inhibition of Stenotrophomonas maltophilia SmltD using UDP-MurNAc-L-Ala-L-Glu as substrate in presence of ATP incubated for 5 mins by HPLC2021Bioorganic & medicinal chemistry letters, 03-15, Volume: 36Flavonoids from Woodfordia fruticosa as potential SmltD inhibitors in the alternative biosynthetic pathway of peptidoglycan.
AID94963Inhibitory concentration against Human Jurkat T cells1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID55647Time constant of slowest dissociation step of drug from DNA complex1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
DNA binding studies of 7-bulky-substituted actinomycin analogues.
AID1379650Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID670634Induction of apoptosis in human HeLa cells assessed as phosphatidylserine externalization after 0.5 to 4 hrs using annexin/PI staining by fluorescence microscopy2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID1769821Cytotoxicity against human A549 cells assessed as growth inhibition incubated for 68 hrs by MTT assay
AID1150520Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 0.05 mg/kg/injection, ip administered daily for 9 days (Rvb = 9.6 days)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID94502Concentration required to reduce proliferation of KB subclones passaged in the presence of doxorubicin 0.09 uM (KBMDR) cell line by 50% as determined by the MTT method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
AID150191Number of mice with P-388 lymphocytic leukemia cured( 0.125 mg/kg),ip.; 1/71982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID97825Optimal dose per injection, administered ip on days 1, 5, and 9, ip inoculation with 10E5 L1210 cells per CDF1 mouse on day 0.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID1124363Antitumor activity against mouse P388 cells allografted in mouse BDF1 mouse assessed as survival time of mouse at 75 ug/kg, iv for 4 days (Rvb = 11.5 days)1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID154489Minimum effective dose was determined compared to 7-(2,3-Epoxypropoxy)-actinomycin D against P-388 leukemia in mice(3 days)1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1123381Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.08 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID212910Inhibitory activity against telomerase at 50 uM concentration (Compound released from DNA/DNA heteroduplex derivatized resin [sequence (TTAGGG)3)2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Small molecule/nucleic acid affinity chromatography: application for the identification of telomerase inhibitors which target its key RNA/DNA heteroduplex.
AID1150511Binding affinity to poly[d(DAP-T)] (unknown origin) at 14.3 uM by visible and near-UV CD spectrophotometry1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1702585Antiproliferative activity against human MCF7 cells assessed as cell viability measured after 4 days by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1150517Antibacterial activity against Bacillus subtilis Marburg assessed as growth inhibition1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1769816Antimicrobial activity against Candida albicans assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID355580Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID102589Antitumor activity against human breast adenocarcinoma MCF-7 cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID1123365Cytotoxicity against mouse L1210 cells at 0.5 ug/ml after 48 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1150540Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in life span at 0.3 mg/kg/injection, ip administered intermittently on days 1, 5 and 9 measured on day 601976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1123348Inhibition of Escherichia coli DNA-dependent RNA polymerase at 5 ug/ml using Micrococcus luteus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID130983Antitumor activity measured as % increase in life span, for sc administration of compound and iv inoculation of B16 melanoma.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID338648Cytotoxicity against human MCF7 cells by MTT assay2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID379330Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine assay2000Journal of natural products, Mar, Volume: 63, Issue:3
Structures of five components of the actinomycin Z complex from Streptomyces fradiae, two of which contain 4-chlorothreonine.
AID378057Antimicrobial activity against Bacillus subtilis at 50 ug after 24 hrs by disk diffusion method2006Journal of natural products, Aug, Volume: 69, Issue:8
Actinomycins with altered threonine units in the beta-peptidolactone.
AID38499In vitro inhibitory activity against Shc/Grb2 interactions in B104-1-1 cells at 2 uM2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Natural and synthetic analogues of actinomycin D as Grb2-SH2 domain blockers.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID624622Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1123379Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.18 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID670636Induction of apoptosis in human HeLa cells assessed as phosphatidylserine externalization at 1 uM using annexin/PI staining by fluorescence microscopy2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID377761Cytotoxicity against human A2780 cells2005Journal of natural products, Apr, Volume: 68, Issue:4
Ipomoeassins A-E, cytotoxic macrocyclic glycoresins from the leaves of Ipomoea squamosa from the Suriname rainforest.
AID399051Cytotoxicity against human Hep2 cells in lag-phase after 48 hrs by MTT assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Cytotoxic sesquiterpenes from Aplysia dactylomela.
AID624628Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID398549Cytotoxicity against human NUGC cells2003Journal of natural products, Apr, Volume: 66, Issue:4
Cytotoxic styrylpyrones from Goniothalamus amuyon.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID44372Antitumor activity against human acute B-lymphoblastic leukemia CCRF-SB cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID23702Partition coefficient (logP)1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1379651Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID603203Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as alpha-helix structural changes by circular dichroism spectra analysis (Rvb = 47.93 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID1146806Induction of Escherichia coli omega enzyme-mediated relaxation of Escherichia coli (RR1) pBR313 closed circular DNA at 40 X 10'-12 mol preincubated for 10 mins followed by enzyme-addition measured after 30 mins by agarose gel electrophoretic analysis1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
2-Deaminoactinomycin D, synthesis and interaction with deoxyribonucleic acid.
AID355581Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID38504In vitro inhibitory activity against Shc/Grb2 interactions in B104-1-1 cells at 5 uM2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Natural and synthetic analogues of actinomycin D as Grb2-SH2 domain blockers.
AID670615Induction of apoptosis in human HeLa cells assessed as DNA fragmentation by agarose gel electrophoresis2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID378531Cytotoxicity against human A2780 cells2005Journal of natural products, Mar, Volume: 68, Issue:3
Cytotoxic flavanones of Schizolaena hystrix from the Madagascar rainforest.
AID86210Antitumor activity against Hep-2 larynx carcinoma cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID104317Antitumor activity against CD+ human acute T-lymphoblastic leukemia MT-4 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1124346Antitumor activity against human CCRF-CEM cells assessed as growth inhibition after 48 hrs1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID1379653Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID1134784Binding affinity to calf thymus DNA after 30 mins by ultracentrifugation method1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1134776Antibacterial activity against Bacillus subtilis ATCC 6633 at 0.65 ug/ml by cup-plate diffusion assay1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID1134769Antibacterial activity against Bacillus subtilis ATCC 6633 at 5 ug/ml by cup-plate diffusion assay1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID154808Cytotoxicity for Peripheral blood Lymphocytes2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1379673Induction of apoptosis in human HeLa cells assessed increase in phosphatidylserine externalization by annexin V and propidium iodide staining based flow cytometry2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID7224Antitumor activity against human bladder carcinoma 5637 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID378413Antimicrobial activity against Penicillium griseofulvum DSM 847 after 24 hrs2006Journal of natural products, Aug, Volume: 69, Issue:8
Carneic acids A and B, chemotaxonomically significant antimicrobial agents from the xylariaceous ascomycete Hypoxylon carneum.
AID378060Cytotoxicity against human Hep G2 cells2006Journal of natural products, Aug, Volume: 69, Issue:8
Actinomycins with altered threonine units in the beta-peptidolactone.
AID678092Induction of apoptosis in human NCI-H157 cells assessed as apoptotic cell level at 10 uM incubated for 5 hrs in serum-free medium by annexin V/propidium iodide staining by flow cytometry2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Novel structural insights for imidoselenocarbamates with antitumoral activity related to their ability to generate methylselenol.
AID1139974Cytotoxicity against African green monkey Vero cells in log phase of growth after 48 hrs2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID1221970Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1123377Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.4 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID43342Number of toxic deaths/number of mice in a group of non tumored mice treated in parallel with the tumor-bearing mice and observed for 100 days at a dose 0.45 mg/Kg; value given as 1/91988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID1221975Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID502770Cytotoxicity against human SF268 cells after 72 hrs by MTS reduction assay2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Cytotoxic flavonoids from the leaves of Cryptocarya chinensis.
AID471370Induction of apoptosis in human Jurkat T cells assessed as activation of caspase3 at 0.3 uM after 6 hrs relative to control2009Journal of natural products, Oct, Volume: 72, Issue:10
Structure and cytotoxicity of arnamial and related fungal sesquiterpene aryl esters.
AID230862Molar ratio of DNA to total amount of compound that is bound both intercalatively and covalently to calf thymus DNA helix1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID221824Inhibition of RNA synthesis was evaluated on human Jurkat T-cells after 8 hours.2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID338645Cytotoxicity against human HepG2 cells by MTT assay2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID86369Antitumor activity against human hepatocellular carcinoma HepG2 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID471372Induction of apoptosis in human Jurkat T cells assessed as increase in DNA fragmentation at 0.33 uM after 6 hrs by ELISA relative to control2009Journal of natural products, Oct, Volume: 72, Issue:10
Structure and cytotoxicity of arnamial and related fungal sesquiterpene aryl esters.
AID22278Thermal denaturation (deltaTm) of compound against calf thymus DNA was measured1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
N2- and C-7 substituted actinomycin D analogues: synthesis, DNA-binding affinity, and biochemical and biological properties. Structure-activity relationship.
AID523538Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of late phase mRNA expression after 48 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein.
AID1134783Binding affinity to calf thymus DNA at DNA/drug ratio of 12:1 after 30 mins by ultracentrifugation method1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID1139973Cytotoxicity against African green monkey Vero cells in lag phase of growth after 48 hrs2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID338642Cytotoxicity against human CaSKi cells by MTT assay2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1221980Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID269034Antiproliferative activity against human HeLa cells by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID269029Antiproliferative activity against human MT4 cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID154507Antitumor activity against P-388 lymphocytic leukemia in CDF1 hybrid male mice measured as median survival time (0.25 mg/kg),ip1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1123351Inhibition of Escherichia coli DNA-dependent RNA polymerase at 1 ug/ml using calf thymus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID40769Compound was tested for its antibacterial activity against Bacillus subtilis1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis and properties of some peptide analogues of actinomycin D.
AID1769805Antimicrobial activity against Staphylococcus aureus Sau 6917 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID138379Tested in vivo toxicity in mouse at dose 1 mg/kg when administered intraperitoneally on day 31994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1459550Antibacterial activity against Micrococcus luteus ATCC 15307 after incubated for 16 to 48 hrs at 28 to 37 degC by spectrofluorometric method2016Journal of natural products, 10-28, Volume: 79, Issue:10
Antibacterial and Cytotoxic Actinomycins Y
AID624629Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1202711Inhibition of human DDR2 expressed in HEK293 cells assessed as reduction in collagen-1-induced DDR2 tyrosine phosphorylation pre-incubated for 30 mins by immunoblotting method2015Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
AID1150534Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mean survival time at 0.3 mg/kg/injection, ip administered intermittently on days 1, 5 and 9 (Rvb = 10.5 days)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID153269Antitumor activity against P-388 lymphocytic leukemia in CDF1 hybrid male mice measured as percent increase in lifespan( 0.125 mg/kg),ip1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1123369Cytotoxicity against mouse L1210 cells at 0.001 ug/ml after 48 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1139972Cytotoxicity against human Hep2 cells in log phase of growth after 48 hrs2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID405550Antiproliferative activity against human HT29 cells after 48 hrs by MTT assay2008Journal of natural products, Jun, Volume: 71, Issue:6
Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii.
AID681169TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID96220Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant human nasopharyngeal carcinoma KB cells by 50%2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1123363Cytotoxicity against mouse L1210 cells at 5 ug/ml after 48 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID94511Concentration required to reduce proliferation of KB human nasopharyngeal carcinoma (KBWT) cell line by 50% as determined by the MTT method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
AID357846Binding affinity to yeast tRNA assessed as reduction in tRNA peak by pre-incubation method
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID566964Cytotoxicity against african green monkey Vero cells after 20 hrs by MTS assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Isoxazolidinyl polycyclic aromatic hydrocarbons as DNA-intercalating antitumor agents.
AID1134770Antibacterial activity against Bacillus subtilis ATCC 6633 at 2.50 ug/ml by cup-plate diffusion assay1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID378056Antimicrobial activity against Staphylococcus aureus at 50 ug after 24 hrs by disk diffusion method2006Journal of natural products, Aug, Volume: 69, Issue:8
Actinomycins with altered threonine units in the beta-peptidolactone.
AID1123358Inhibition of Escherichia coli DNA-dependent RNA polymerase at 0.1 ug/ml using Micrococcus luteus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID269035Antiproliferative activity against human Hep2 cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID154505Antitumor activity against P-388 lymphocytic leukemia in CDF1 hybrid male mice measured as median survival time (0.125 mg/kg),ip1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1123349Inhibition of Escherichia coli DNA-dependent RNA polymerase at 2.5 ug/ml using calf thymus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID46885Antitumor activity against human foreskin fibroblasts CRL7065 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID338647Cytotoxicity against human HCT116 cells by MTT assay2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID378058Cytotoxicity against human HM02 cells2006Journal of natural products, Aug, Volume: 69, Issue:8
Actinomycins with altered threonine units in the beta-peptidolactone.
AID603204Binding affinity to Mycobacterium tuberculosis pantothenate synthetase assessed as beta-sheet structural changes by circular dichroism spectra analysis (Rvb = 8.19 %%)2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID405552Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay2008Journal of natural products, Jun, Volume: 71, Issue:6
Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii.
AID354542Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID1769824Cytotoxicity against human BEAS-2B cells assessed as growth inhibition incubated for 68 hrs by MTT assay
AID335874Cytotoxicity against human A2780 cells2002Journal of natural products, Aug, Volume: 65, Issue:8
Two new triterpene esters from the twigs of Brachylaena ramiflora from the Madagascar rainforest.
AID1769811Antimicrobial activity against Staphylococcus aureus ATCC 29213 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID221820Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID1459553Antibacterial activity against Salmonella enterica ATCC 10708 after incubated for 16 to 48 hrs at 28 to 37 degC by spectrofluorometric method2016Journal of natural products, 10-28, Volume: 79, Issue:10
Antibacterial and Cytotoxic Actinomycins Y
AID39884In vivo Antitumor activity against B16 melanoma cells at a optimal dose measured as %ILS (%increase life span)1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID1459557Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay2016Journal of natural products, 10-28, Volume: 79, Issue:10
Antibacterial and Cytotoxic Actinomycins Y
AID501215Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting2010Nature chemical biology, Mar, Volume: 6, Issue:3
Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin.
AID169205DNA-cleaving ability expressed as % of closed circular pBR322 DNA cleaved at 10 uM conc1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID401378Cytotoxicity against human HeLa cells after 3 days by methylene blue assay1998Journal of natural products, Jun-26, Volume: 61, Issue:6
A new taxane diterpenoid from Taxus mairei.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1424103Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 10 days by GFP based fluorescence assay2017Journal of natural products, 04-28, Volume: 80, Issue:4
Antibacterial Compounds from Marine Bacteria, 2010-2015.
AID22300The delta Tm value is a measure of a stabilization of the DNA helical structure as consequence of compound binding1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Synthesis and biological properties of actinomycin D chromophoric analogues substituted at carbon 7 with aziridine and cyclopropyl functions.
AID54964Dissociation time constant (Tau 1) for dissociation of compound and calf thymus DNA complex2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID43185Activity against advanced carcinoma C38 Tumor in CDF1 Mice at dose 0.30 mg/kg measured as % inhibition of tumor1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID670610Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for human MCF7 cells after 48 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID1769804Antimicrobial activity against Staphylococcus aureus Sau 16162 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID1150530Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 0.4 mg/kg/injection, ip administered as single dose1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1459552Antibacterial activity against Mycobacterium aurum ATCC 23366 after incubated for 16 to 48 hrs at 28 to 37 degC by spectrofluorometric method2016Journal of natural products, 10-28, Volume: 79, Issue:10
Antibacterial and Cytotoxic Actinomycins Y
AID379995Cytotoxicity against human HT3 cells after 6 days by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
New lanostanoids of Ganoderma tsugae.
AID1123386Toxicity in mouse P388 cells allografted CDF1 mouse assessed as mortality at 0.4 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID378055Antimicrobial activity against Escherichia coli at 50 ug after 24 hrs by disk diffusion method2006Journal of natural products, Aug, Volume: 69, Issue:8
Actinomycins with altered threonine units in the beta-peptidolactone.
AID356957Cytotoxicity against human HEPA 59T/VGH cells after 72 hrs by methylene blue assay2002Journal of natural products, Dec, Volume: 65, Issue:12
New taxane diterpenoids from the leaves and twigs of Taxus sumatrana.
AID72414Antitumor activity against human skin melanoma G361 cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID1682549Inhibition of PAX3-FOXO1 (unknown origin) stably transfected Rh4 cells co-expressing ALK-Luc after 24 hrs by SteadyLite luciferase assay2020Journal of natural products, 11-25, Volume: 83, Issue:11
Denigrins and Dactylpyrroles, Arylpyrrole Alkaloids from a
AID57470Inhibitory activity against dihydrofolate reductase (DHFR) isolated from murine L5178Y tumor cells resistant and sensitive to methotrexate1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Comparative structure-activity relationships of antifolate triazines inhibiting murine tumor cells sensitive and resistant to methotrexate.
AID227573Relative resistance is the ratio of IC50 values of drug with JTV-519 to that without the reversing agent2004Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID380807Cytotoxicity against human CaSki cells after 6 days by MTT assay1999Journal of natural products, Jul, Volume: 62, Issue:7
Cytotoxic lignans of Justicia ciliata.
AID54430Increase in thermal denaturation temperature of calf thymus DNA1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
DNA binding studies of 7-bulky-substituted actinomycin analogues.
AID221823Apoptotic index calculated using human Jurkat T cells2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID166868Dissociation constant for inhibition of RNA polymerase1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
DNA binding studies of 7-bulky-substituted actinomycin analogues.
AID153530In vitro 50% Growth inhibition of actinomycin resistant P388/ADR cells1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1124347Antitumor activity against mouse P388 cells allografted in mouse BDF1 mouse assessed as increase in survival time of mouse at 75 ug/kg, iv for 4 days relative to untreated control1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID20563Thermal denaturation of calf thymus DNA measured as Tm1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID477411Antibacterial activity against MBX-1090-resistant Staphylococcus aureus isolate d20A1 after 16 to 20 hrs by broth microdilution method2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID378414Antimicrobial activity against Stachybotrys chartarum DSM 2144 after 24 hrs2006Journal of natural products, Aug, Volume: 69, Issue:8
Carneic acids A and B, chemotaxonomically significant antimicrobial agents from the xylariaceous ascomycete Hypoxylon carneum.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID153526Antitumor activity against P388/ADR, in ip implanted CDF1 mice, treated ip, qd 1-9 measured as optimal dose1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID1769823Cytotoxicity against human L02 cells assessed as growth inhibition incubated for 68 hrs by MTT assay
AID1150546Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as mean survival time at 0.3 mg/kg/injection, ip administered intermittently on days 1, 5 and 9 (Rvb = 28 days)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1150528Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in lifespan at 0.3 mg/kg/injection, ip administered intermittently on days 1, 5 and 91976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID680307TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Actinomycin D: 40 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID1123380Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.12 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID26757DNA binding dissociation constant as KD; No data1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics.
AID1221973Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1123359Inhibition of Escherichia coli DNA-dependent RNA polymerase at 0.05 ug/ml using calf thymus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID212911Inhibitory activity against telomerase at 50 uM concentration (Compound released from RNA/DNA heteroduplex derivatized resin [sequence (TTAGGG)3)2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Small molecule/nucleic acid affinity chromatography: application for the identification of telomerase inhibitors which target its key RNA/DNA heteroduplex.
AID269031Antiproliferative activity against human CCRF-CEM cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID38079compound was evaluated in vitro for growth inhibition of B16 (Murine melanoma cell line) cell1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and biological properties of actinomycin D chromophoric analogues substituted at the 7-carbon with aziridine and aminopropoxy functions.
AID670608Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID166398Antitumor activity against human Burkitt lym phoma Raji cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID105507Antitumor activity against human acute T-lymphoblastic leukemia MOLT-4 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID39889In vivo Antitumor activity against B16 melanoma cells at dose 250 ug/Kg /inj measured as Mean survival time (MST)1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID51924Effect on cross resistance of chinese hamster cells resistant to Actinomycin D.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID380443Cytotoxicity against human A2780 cells2006Journal of natural products, Mar, Volume: 69, Issue:3
Bioactive isomalabaricane triterpenoids from Rhabdastrella globostellata that stabilize the binding of DNA polymerase beta to DNA.
AID382904Cell cycle arrest in human CCRF-CEM cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometry2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
DNA threading bis(9-aminoacridine-4-carboxamides): effects of piperidine sidechains on DNA binding, cytotoxicity and cell cycle arrest.
AID653479Cytotoxicity against human A549 cells assessed as reduction of cell number at 0.5 ug/ml after 8 hrs relative to control2012European journal of medicinal chemistry, May, Volume: 51Novel isoxazole polycyclic aromatic hydrocarbons as DNA-intercalating agents.
AID377998Cytotoxicity against human PLC/PRF/5 cells after 6 days by MTT assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Cytotoxic isoprenylated flavans of Broussonetia kazinoki.
AID501214Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy2010Nature chemical biology, Mar, Volume: 6, Issue:3
Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin.
AID502768Cytotoxicity against human MCF7 cells after 72 hrs by MTS reduction assay2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Cytotoxic flavonoids from the leaves of Cryptocarya chinensis.
AID399050Cytotoxicity against human HeLa cells in log-phase after 48 hrs by MTT assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Cytotoxic sesquiterpenes from Aplysia dactylomela.
AID1134771Antibacterial activity against Bacillus subtilis ATCC 6633 at 1.25 ug/ml by cup-plate diffusion assay1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID1702587Antiproliferative activity against human ACHN cells assessed as cell viability measured after 4 days by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
AID1617950Antiproliferative activity against human PC3 cells assessed as cell viability at 20 uM after 72 hrs by alamar blue assay relative to control2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID86974Antitumor activity against HeLa cervical carcinoma cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID184891Stimulation of NADPH oxidation in the presence of rat liver microsomes1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID38501Growth inhibitory activity was tested against B104-1-1 cells2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Natural and synthetic analogues of actinomycin D as Grb2-SH2 domain blockers.
AID7223Antitumor activity against human bladder carcinoma 5637 cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1139969Cytotoxicity against human HeLa cells in lag phase of growth after 48 hrs2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID54966Dissociation time constant (Tau 3) for dissociation of compound and calf thymus DNA complex2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.
AID1221976Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1459551Antibacterial activity against Bacillus subtilis ATCC 6633 after incubated for 16 to 48 hrs at 28 to 37 degC by spectrofluorometric method2016Journal of natural products, 10-28, Volume: 79, Issue:10
Antibacterial and Cytotoxic Actinomycins Y
AID1123385Toxicity in mouse P388 cells allografted CDF1 mouse assessed as mortality at 0.6 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1150544Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as mean survival time at 0.025 mg/kg/injection, ip administered daily for 9 days (Rvb = 28 days)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1769818Cytotoxicity against human HeLa cells assessed as growth inhibition incubated for 68 hrs by MTT assay
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID130067Antitumor activity measured as optimal dose, for ip administration of compound and ip inoculation of B16 melanoma.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID44037In vitro growth inhibition of CCRF-CEM (Human leukemic lymphoblastic) cell1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and biological properties of actinomycin D chromophoric analogues substituted at the 7-carbon with aziridine and aminopropoxy functions.
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1131841Inhibition of DNA synthesis in mouse L1210 cells by [3H]-thymidine incorporation assay1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
A phenazine analogue of actinomycin D.
AID1769808Antimicrobial activity against Staphylococcus aureus Sau 718306 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID269030Antiproliferative activity against human CCRF-SB cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID1123344Inhibition of Escherichia coli DNA-dependent RNA polymerase at 20 ug/ml using Micrococcus luteus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1459556Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay2016Journal of natural products, 10-28, Volume: 79, Issue:10
Antibacterial and Cytotoxic Actinomycins Y
AID1379655Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID86976Antitumor activity against cervix carcinoma Hela cells cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1123352Inhibition of Escherichia coli DNA-dependent RNA polymerase at 1 ug/ml using Micrococcus luteus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID73322Inhibition of GST-Grb2 Tyrosine kinase SH2 domain binding to [3H]labeled-phosphopeptide (Ac-SpYVNK-NH-C(O)-CH2CH2H3)1998Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
Actinomycin D, C2 and VII, inhibitors of Grb2-SHC interaction produced by Streptomyces.
AID355720Cytotoxicity against human A2780 cells2003Journal of natural products, Apr, Volume: 66, Issue:4
New cytotoxic alkaloids from the wood of Vepris punctata from the Madagascar rainforest.
AID1139978Selectivity index, ratio of IC50 for African green monkey Vero cells in log phase of growth to IC50 for human Hep2 cells in log phase of growth2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID1150538Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in life span at 0.05 mg/kg/injection, ip administered daily for 9 days measured on day 601976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID566965Cytotoxicity against human A549 cells assessed as decrease of viable cells at 0.5 ug/ml after 8 hrs relative to control2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Isoxazolidinyl polycyclic aromatic hydrocarbons as DNA-intercalating antitumor agents.
AID677151Induction of apoptosis in human NCI-H157 cells assessed as damaged cell level at 10 uM incubated for 5 hrs in serum-free medium by annexin V/propidium iodide staining by flow cytometry2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Novel structural insights for imidoselenocarbamates with antitumoral activity related to their ability to generate methylselenol.
AID679469TP_TRANSPORTER: ATP hydrolysis in reconstituted proteoliposomes1992Proceedings of the National Academy of Sciences of the United States of America, Sep-15, Volume: 89, Issue:18
Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID257879Cytotoxicity against MOLT3 Leukemia cells by MTS assay2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID268629Ability to displace ethidium bromide from DNA2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation.
AID94357Concentration required to reduce proliferation of KB subclones passaged in the presence of vincristine 0.02 uM (KB7D) cell line by 50% as determined by the MTT method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
AID338369Antimicrobial activity against Candida utilis ATCC 42402 after 2 days
AID355582Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID154490Minimum effective dose was determined compared to 7-(2,3-Epoxypropoxy)-actinomycin D against P-388 leukemia in mice(4 days)1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID235783In vitro growth inhibitory activity for effect on melting temperature of DNA was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1123376Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.6 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID379328Cytotoxicity against human HMO2 cells after 48 hrs by sulforhodamine assay2000Journal of natural products, Mar, Volume: 63, Issue:3
Structures of five components of the actinomycin Z complex from Streptomyces fradiae, two of which contain 4-chlorothreonine.
AID154501Antitumor activity against P-388 lymphocytic leukemia in CDF1 hybrid male mice measured as median survival time ( 0.375 mg/kg),ip1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID104437Antitumor activity against human CD4+T cells expressing the TAT gene of HTLV-1 MT-4 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1769806Antimicrobial activity against Staphylococcus aureus Sau 1862 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID133461Antitumor activity measured as median survival time, for sc administration and iv inoculation of B16 melanoma.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID97886Cytotoxicity against L1210 tumor cell line, activity is expressed as K (inverse value of drug concentration)1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
AID219235Anti tumor activity against human splenic B-lympho blastoid Wil2-NS cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID380080Cytotoxicity against human A2780 cells by clonogenic assay2006Journal of natural products, Feb, Volume: 69, Issue:2
Cytotoxic diterpenes from Cassipourea madagascariensis from the Madagascar rainforest.
AID269038Antiproliferative activity against human KB cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID10043Antitumor activity against human renal adenocarcinoma ACHN cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1134779Binding affinity to calf thymus DNA assessed as bathochromic shift after 30 mins by spectral analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID356956Cytotoxicity against human KB cells after 72 hrs by methylene blue assay2002Journal of natural products, Dec, Volume: 65, Issue:12
New taxane diterpenoids from the leaves and twigs of Taxus sumatrana.
AID257882Cytotoxicity against normal vero kidney cells by MTS assay2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID130491percent increase in median life time (%ILS) measured in mice bearing leukemia L!2101988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID43183Activity against advanced carcinoma C38 Tumor in CDF1 Mice at dose 0.15 mg/kg measured as % inhibition of tumor1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID502769Cytotoxicity against human NCI-H460 cells after 72 hrs by MTS reduction assay2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Cytotoxic flavonoids from the leaves of Cryptocarya chinensis.
AID38076In vitro antitumor activity against murine melanoma cells (B16 melanoma cells)1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Synthesis and biological properties of actinomycin D chromophoric analogues substituted at carbon 7 with aziridine and cyclopropyl functions.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID354543Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID228467Compound was evaluated for the elevation in temperature (degrees Celsius) for thermal denaturation of DNA.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Synthesis and biological properties of actinomycin D chromophoric analogues substituted at the 7-carbon with aziridine and aminopropoxy functions.
AID1134782Binding affinity to calf thymus DNA at DNA/drug ratio of 25:1 after 30 mins by ultracentrifugation method1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID43704Cytotoxicity in human leukemic CCRF-CEM cells.2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.
AID398550Cytotoxicity against human HONE1 cells2003Journal of natural products, Apr, Volume: 66, Issue:4
Cytotoxic styrylpyrones from Goniothalamus amuyon.
AID1150542Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in life span at 0.4 mg/kg/injection, ip administered as single dose measured on day 601976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID150193Number of mice with P-388 lymphocytic leukemia cured( 0.250 mg/kg),ip; 0/71982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1124352Antitumor activity against mouse P388 cells allografted in mouse BDF1 mouse assessed as increase in survival >50 days at 150 ug/kg, iv for 4 days1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID523535Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of late phase mRNA expression after 16 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID75178In vitro binding assay of Shc-derived phosphopeptide to Growth factor receptor bound protein 2 SH2 in B104-1-1 cells was determined2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Natural and synthetic analogues of actinomycin D as Grb2-SH2 domain blockers.
AID1123364Cytotoxicity against mouse L1210 cells at 1 ug/ml after 48 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID72413Antitumor activity against human skin melanoma G-361 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1702586Antiproliferative activity against human HeLa cells assessed as cell viability measured after 4 days by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
AID1769820Cytotoxicity against human RKO cells assessed as growth inhibition incubated for 68 hrs by MTT assay
AID378411Antimicrobial activity against Yarrowia lipolytica HT20after 24 hrs2006Journal of natural products, Aug, Volume: 69, Issue:8
Carneic acids A and B, chemotaxonomically significant antimicrobial agents from the xylariaceous ascomycete Hypoxylon carneum.
AID377999Cytotoxicity against human T24 cells after 6 days by MTT assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Cytotoxic isoprenylated flavans of Broussonetia kazinoki.
AID1131840Binding affinity to calf thymus DNA at 5.2 x 10'-6 M by CD spectra analysis1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
A phenazine analogue of actinomycin D.
AID95088IC80 concentrations of the compounds were used in determining the inhibition of protein synthesis using Jurkat T cells.1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID1139970Cytotoxicity against human HeLa cells in log phase of growth after 48 hrs2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID1150526Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span at 0.05 mg/kg/injection, ip administered daily for 9 days1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1379656Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID379329Cytotoxicity against human HepG2 cells after 48 hrs by sulforhodamine assay2000Journal of natural products, Mar, Volume: 63, Issue:3
Structures of five components of the actinomycin Z complex from Streptomyces fradiae, two of which contain 4-chlorothreonine.
AID380809Cytotoxicity against human HT-3 cells after 6 days by MTT assay1999Journal of natural products, Jul, Volume: 62, Issue:7
Cytotoxic lignans of Justicia ciliata.
AID465965Binding affinity to G/C-rich DNA oligonucleotide assessed as change in melting temperature by thermal denaturation assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Semi-automated high-throughput fluorescent intercalator displacement-based discovery of cytotoxic DNA binding agents from a large compound library.
AID1379674Induction of apoptosis in human HeLa cells assessed increase in necrosis by annexin V and propidium iodide staining based flow cytometry2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID382900Cytotoxicity against human CCRF-CEM cells after 72 hrs2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
DNA threading bis(9-aminoacridine-4-carboxamides): effects of piperidine sidechains on DNA binding, cytotoxicity and cell cycle arrest.
AID150190Number of mice with P-388 lymphocytic leukemia cured( 0.031 mg/kg),ip; 0/71982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID43335Mean survival time of treated /untreategroup x100. (number of over 100-day survivors/ number of total mice in the group) at a dose 0.30 mg/kg1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID379611Antibacterial activity against Bacillus subtilis ATCC 6051 after 18 hrs2000Journal of natural products, Mar, Volume: 63, Issue:3
Structures of five components of the actinomycin Z complex from Streptomyces fradiae, two of which contain 4-chlorothreonine.
AID1131842Inhibition of RNA synthesis in mouse L1210 cells by [3H]-uridine incorporation assay1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
A phenazine analogue of actinomycin D.
AID1123378Antitumor activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.27 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1702588Antiproliferative activity against human SKMEL-28 cells assessed as cell viability measured after 4 days by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
AID399054Cytotoxicity against african green monkey Vero cells in log-phase after 48 hrs by MTT assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Cytotoxic sesquiterpenes from Aplysia dactylomela.
AID603208Binding affinity to Mycobacterium tuberculosis pantothenate synthetase by tryptophan fluorescence quenching assay2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1702584Antiproliferative activity against human HT-29 cells assessed as cell viability measured after 4 days by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
AID1123367Cytotoxicity against mouse L1210 cells at 0.05 ug/ml after 48 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID380590Cytotoxicity against human T24 cells after 6 days by MTT assay1999Journal of natural products, Jul, Volume: 62, Issue:7
Cytotoxic lignans of Justicia ciliata.
AID43182Activity against advanced carcinoma C38 Tumor in CDF1 Mice at dose 0.075 mg/kg measured as % inhibition of tumor1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID43332Mean survival time of treated /untreated group x100. (number of over 100-day survivors/ number of total mice in the group) at a dose 0.60 mg/kg1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID379993Cytotoxicity against human T24 cells after 6 days by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
New lanostanoids of Ganoderma tsugae.
AID380810Cytotoxicity against human PLC/PRF/5 cells after 6 days by MTT assay1999Journal of natural products, Jul, Volume: 62, Issue:7
Cytotoxic lignans of Justicia ciliata.
AID405551Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay2008Journal of natural products, Jun, Volume: 71, Issue:6
Apratoxin E, a cytotoxic peptolide from a guamanian collection of the marine cyanobacterium Lyngbya bouillonii.
AID1769817Cytotoxicity against human HepG2 cells assessed as growth inhibition incubated for 68 hrs by MTT assay
AID355583Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
AID150226Concentration required for 50% inhibition of incorporation of labeled thymidine by p388 cells for synthesis of DNA (in vitro)1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
N2- and C-7 substituted actinomycin D analogues: synthesis, DNA-binding affinity, and biochemical and biological properties. Structure-activity relationship.
AID1134774Antibacterial activity against Bacillus subtilis ATCC 6633 at 3.85 ug/ml by cup-plate diffusion assay1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID338641Cytotoxicity against mouse 212 cells by MTT assay2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID357026Cytotoxicity against human HepA cells after 72 hrs by methylene blue assay2001Journal of natural products, Jul, Volume: 64, Issue:7
Taxane diterpenoids from the stem bark of Taxus mairei.
AID95087IC80 concentrations of the compounds were used in determining the inhibition of RNA synthesis using Jurkat T cells.1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID1150532Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mean survival time at 0.05 mg/kg/injection, ip administered daily for 9 days (Rvb = 10.5 days)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID130069Antitumor activity measured as optimal dose, against C26 colon carcinoma.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID523534Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of early phase mRNA expression after 16 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein.
AID44371Antitumor activity against human acute B-lymphoblastic CCRF-SB leukemia cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID153271Antitumor activity against P-388 lymphocytic leukemia in CDF1 hybrid male mice measured as percent increase in lifespan( 0.250 mg/kg),ip1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID670637Induction of apoptosis in human HeLa cells assessed as necrotic cells at 1 uM using annexin/PI staining by fluorescence microscopy2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID219231Antitumor activity against human splenic B-lymphoblastoid Wil-NS cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID96219Compound concentration required to reduce the cell proliferation of Wild type and Drug- resistant KB subclones passaged in the presence of doxorubicin 0.09 uM by 50%2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1123356Inhibition of Escherichia coli DNA-dependent RNA polymerase at 0.25 ug/ml using Micrococcus luteus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1146801Inhibition of RNA synthesis in mouse L1210 cells assessed as [3H]-uridine incorporation preincubated for 3 hrs before [3H]-uridine addition measured after 1 hr by scintillation spectrometric analysis1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
2-Deaminoactinomycin D, synthesis and interaction with deoxyribonucleic acid.
AID523533Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of immediate early phase mRNA expression after 16 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein.
AID170239Percent of the unconverted metabolite from incubation mixture containing rat microsomes1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID98677In vitro concentration required for growth inhibition of murine L1210 tumor cell1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Structure-activity relationships in a series of newly synthesized 1-amino-substituted ellipticine derivatives.
AID43235In vitro antitumor activity against human lymphoblastic leukemia cells.1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
N2- and C-7 substituted actinomycin D analogues: synthesis, DNA-binding affinity, and biochemical and biological properties. Structure-activity relationship.
AID465966Binding affinity to calf thymus DNA assessed as decrease in ethidium bromide fluorescence by FID assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Semi-automated high-throughput fluorescent intercalator displacement-based discovery of cytotoxic DNA binding agents from a large compound library.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1139976Selectivity index, ratio of IC50 for African green monkey Vero cells in log phase of growth to IC50 for human HeLa cells in log phase of growth2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID1146805Antitumor activity against mouse P388 cells allografted in mouse assessed as increase in life span at 0.108 mg/kg administered qd on day 1, 5 and 9 relative to control1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
2-Deaminoactinomycin D, synthesis and interaction with deoxyribonucleic acid.
AID1123340Binding affinity to calf thymus DNA at 1 x 10'-5 M after 30 mins by circular dichroism analysis1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID355585Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID43334Mean survival time of treated /untreategroup x100. (number of over 100-day survivors/ number of total mice in the group) at a dose 0.15 mg/kg1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID465963Binding affinity to calf thymus DNA assessed as decrease in ethidium bromide fluorescence at 10 uM by HT-FID assay2010Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5
Semi-automated high-throughput fluorescent intercalator displacement-based discovery of cytotoxic DNA binding agents from a large compound library.
AID1702583Antiproliferative activity against human MT-4 cells assessed as cell viability measured after 4 days by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
AID624626Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID380811Cytotoxicity against mouse NIH/3T3-212 cells after 6 days by MTT assay1999Journal of natural products, Jul, Volume: 62, Issue:7
Cytotoxic lignans of Justicia ciliata.
AID1150518Antibacterial activity against Penicillin-resistant Staphylococcus aureus assessed as growth inhibition1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1769819Cytotoxicity against human HL-60 cells assessed as growth inhibition incubated for 68 hrs by MTT assay
AID269036Antiproliferative activity against human ACHN cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID566961Cytotoxicity against human MOLT3 cells after 20 hrs by MTS assay2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Isoxazolidinyl polycyclic aromatic hydrocarbons as DNA-intercalating antitumor agents.
AID1769812Antimicrobial activity against Micrococcus luteus ML01 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID378059Cytotoxicity against human Hep G2 cells2006Journal of natural products, Aug, Volume: 69, Issue:8
Actinomycins with altered threonine units in the beta-peptidolactone.
AID257885Cytotoxicity against MOLT3 Leukemia cells after 72 hrs of treatment2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID338649Cytotoxicity against human MCF7-ras cells by MTT assay2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID378001Cytotoxicity against human HT-3 cells after 6 days by MTT assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Cytotoxic isoprenylated flavans of Broussonetia kazinoki.
AID670603Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID378003Cytotoxicity against human CaSki cells after 6 days by MTT assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Cytotoxic isoprenylated flavans of Broussonetia kazinoki.
AID1123345Inhibition of Escherichia coli DNA-dependent RNA polymerase at 10 ug/ml using calf thymus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID154816Maximum tolerated dose was determined compared to 7-(2,3-Epoxypropoxy)-actinomycin D against P-388 leukemia in mice(3 days)1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID153723Percent of increased life span of P388 cells implanted CDF1 male mice1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
N2- and C-7 substituted actinomycin D analogues: synthesis, DNA-binding affinity, and biochemical and biological properties. Structure-activity relationship.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID154807Cytotoxicity for Peripheral blood Lymphocytes2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID269027Antiproliferative activity against human Wil2-NS cells by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID154679Median survival time of the P388 cells implanted CDF1 male mice in vivo1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
N2- and C-7 substituted actinomycin D analogues: synthesis, DNA-binding affinity, and biochemical and biological properties. Structure-activity relationship.
AID1379654Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID83948Antitumor activity against human colon adenocarcinoma HT-29 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID269037Antiproliferative activity against human 5637 cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID8392950% inhibition of incorporationf precursor [3H]thymidine into DNA HT-29 cell lines1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID1150524Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 0.4 mg/kg/injection, ip administered as single dose (Rvb = 9.6 days)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1183899Cytotoxicity against human primary monocytes assessed as reduction in cell viability at 1 uM after 2 to 5 hrs by inverse MTT assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID96801In vitro cytotoxicity against L1210 cell line as concentration required for 50% inhibition of cell growth1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Antitumor amino-substituted pyrido[3',4':4,5]pyrrolo[2,3-g]isoquinolines and pyrido[4,3-b]carbazole derivatives: synthesis and evaluation of compounds resulting from new side chain and heterocycle modifications.
AID153276Antitumor activity against P-388 lymphocytic leukemia in CDF1 hybrid male mice measured as percent increase in lifespan(0.062 mg/kg),ip1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1459554Antibacterial activity against Escherichia coli ATCC 12435 after incubated for 16 to 48 hrs at 28 to 37 degC by spectrofluorometric method2016Journal of natural products, 10-28, Volume: 79, Issue:10
Antibacterial and Cytotoxic Actinomycins Y
AID98346Inhibition of synthesis of [methyl-14C] thymidine into DNA, in L1210 cells.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID1150554Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase in life span at 0.4 mg/kg/injection, ip administered as single dose measured on day 601976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID202833Antitumor activity against human lung squamous carcinoma SK-MES-1 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1769813Antimicrobial activity against Enterococcus faecium ATCC 35682 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID1146799Binding affinity to calf thymus DNA assessed as change in melting temperature at 5.2 X 10'-6 M by thermal denaturation assay1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
2-Deaminoactinomycin D, synthesis and interaction with deoxyribonucleic acid.
AID130068Antitumor activity measured as optimal dose, for sc administration of compound and iv inoculation of B16 melanoma.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1124348Antitumor activity against mouse P388 cells allografted in mouse BDF1 mouse assessed as increase in survival time of mouse at 150 ug/kg, iv for 4 days relative to untreated control1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID101363Cytotoxicity for lymphoblastoid cell lines2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID402596Cytotoxicity against human A2780 cells2004Journal of natural products, Jun, Volume: 67, Issue:6
Cytotoxic triterpenoids from Acridocarpus vivy from the Madagascar rain forest.
AID1769807Antimicrobial activity against Staphylococcus aureus Sau 991 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID99173Cross resistance profile versus L1210/R71 cells.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1682550Inhibition of PAX3-FOXO1 (unknown origin) stably transfected Rh4 cells co-expressing CMV-Luc after 24 hrs by SteadyLite luciferase assay2020Journal of natural products, 11-25, Volume: 83, Issue:11
Denigrins and Dactylpyrroles, Arylpyrrole Alkaloids from a
AID1123350Inhibition of Escherichia coli DNA-dependent RNA polymerase at 2.5 ug/ml using Micrococcus luteus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID433943Cytotoxicity against human A375 cells assessed as inhibition of RNA synthesis in at 50 ug/mL2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID153536Antitumor activity measured as Median survival time in days against P388/ADR, in ip implanted CDF1 mice, treated ip, qd 1-91988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID318601Cytotoxicity against mouse P388 cells assessed as concentration required for 50% inhibition2008Journal of natural products, Mar, Volume: 71, Issue:3
Antineoplastic agents. 536. New sources of naturally occurring cancer cell growth inhibitors from marine organisms, terrestrial plants, and microorganisms(1a,).
AID212912Inhibitory activity against telomerase at 50 uM concentration (Compound released from underivatized resin2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Small molecule/nucleic acid affinity chromatography: application for the identification of telomerase inhibitors which target its key RNA/DNA heteroduplex.
AID96361Effect on the proliferation Wild -type and Drug- resistant KB subclones passaged uM2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID399053Cytotoxicity against african green monkey Vero cells in lag-phase after 48 hrs by MTT assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Cytotoxic sesquiterpenes from Aplysia dactylomela.
AID86211Antitumor activity against larynx carcinoma Hep-2 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID603207Inhibition of Mycobacterium tuberculosis pantothenate synthetase by high throughput screening method2011Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13
A discovery of novel Mycobacterium tuberculosis pantothenate synthetase inhibitors based on the molecular mechanism of actinomycin D inhibition.
AID1123353Inhibition of Escherichia coli DNA-dependent RNA polymerase at 0.5 ug/ml using calf thymus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID378002Cytotoxicity against human SiHa cells after 6 days by MTT assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Cytotoxic isoprenylated flavans of Broussonetia kazinoki.
AID150203Number of mice with P-388 lymphocytic leukemia cured.( 0.062 mg/kg),ip; 0/71982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1123368Cytotoxicity against mouse L1210 cells at 0.01 ug/ml after 48 hrs1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID170240Percent of the unconverted metabolite from incubation mixture containing tumor cell homogenate(T)1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID670606Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID150230Concentration required for 50% inhibition of incorporation of labeled uridine by P388 cells for the synthesis of RNA (in vitro)1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
N2- and C-7 substituted actinomycin D analogues: synthesis, DNA-binding affinity, and biochemical and biological properties. Structure-activity relationship.
AID1133383Cytotoxicity against human CCRF-CEM cells1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
N7-Substituted 7-aminoactinomycin D analogues. Synthesis and biological properties.
AID1617949Antiproliferative activity against human A549 cells assessed as cell viability at 20 uM after 72 hrs by alamar blue assay relative to control2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID220480Melting temperature of DNA-drug complex minus melting temperature of purified calf-thymus DNA1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Tetracyclic chromophoric analogues of actinomycin D: synthesis, structure elucidation and interconvertibility from one form to another, antitumor activity, and structure-activity relationships.
AID1123387Toxicity in mouse P388 cells allografted CDF1 mouse assessed as mortality at 0.27 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID670635Induction of apoptosis in human HeLa cells assessed as necrotic cells after 0.5 to 4 hrs using annexin/PI staining by fluorescence microscopy2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID401379Cytotoxicity against human Hep3B cells after 3 days by methylene blue assay1998Journal of natural products, Jun-26, Volume: 61, Issue:6
A new taxane diterpenoid from Taxus mairei.
AID1221979Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID379992Cytotoxicity against human PLC/PRF/5 cells after 6 days by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
New lanostanoids of Ganoderma tsugae.
AID477409Antibacterial activity against Staphylococcus aureus NCTC 8325 after 16 to 20 hrs by broth microdilution method2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Efflux-mediated bis-indole resistance in Staphylococcus aureus reveals differential substrate specificities for MepA and MepR.
AID681121TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1134780Binding affinity to calf thymus DNA assessed as reduction in absorbance after 30 mins by spectral analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID44011Antitumor activity against human acute T-lymphoblastic CCRF-CEM leukemia cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID1150522Antitumor activity against mouse L1210 cells allografted in BDF1 mouse assessed as mean survival time at 0.3 mg/kg/injection, ip administered intermittently on days 1, 5 and 9 (Rvb = 9.6 days)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID105506Antitumor activity against human acute T-lymphoblastic MOLT-4 leukemia cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID523536Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of immediate early phase mRNA expression after 48 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein.
AID589500Inhibition of DNA synthesis in human K562 cells assessed as [14C]thymidine incorporation at 4 uM after 120 mins2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID1134775Antibacterial activity against Bacillus subtilis ATCC 6633 at 2.35 ug/ml by cup-plate diffusion assay1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID154660Median survival time observed in P-388 cells infected male CDF1 hybrid mice after intraperitoneal administration at 125 ug/kg optimal dose1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Tetracyclic chromophoric analogues of actinomycin D: synthesis, structure elucidation and interconvertibility from one form to another, antitumor activity, and structure-activity relationships.
AID355579Antiproliferative activity against human HT-29 cells at 10 ug after 48 hrs by two-layer agar-diffusion method
AID357845Binding affinity to calf thymus DNA assessed as reduction in DNA peak by pre-incubation method
AID378410Antimicrobial activity against Bacillus subtilis ATCC 6633 after 18 hrs2006Journal of natural products, Aug, Volume: 69, Issue:8
Carneic acids A and B, chemotaxonomically significant antimicrobial agents from the xylariaceous ascomycete Hypoxylon carneum.
AID129406Male CDF1 hybrid treated mice out of seven which survived over 60 days after the treatment.1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Tetracyclic chromophoric analogues of actinomycin D: synthesis, structure elucidation and interconvertibility from one form to another, antitumor activity, and structure-activity relationships.
AID138378Tested in vivo toxicity in mouse at dose 1 mg/kg when administered intraperitoneally on day 21994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
AID1150536Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mean survival time at 0.4 mg/kg/injection, ip administered as single dose (Rvb = 10.5 days)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID399052Cytotoxicity against human Hep2 cells in log-phase after 48 hrs by MTT assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Cytotoxic sesquiterpenes from Aplysia dactylomela.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID39883In vitro 50% Growth inhibition of sensitive B16 cells.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID589499Inhibition of transcription in human K562 cells at 4 uM after 120 mins2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
In vitro cytotoxicity of melleolide antibiotics: structural and mechanistic aspects.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID202826Antitumor activity against human skin melanoma SKMEK-28 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1123347Inhibition of Escherichia coli DNA-dependent RNA polymerase at 5 ug/ml using calf thymus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1183906Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 1 uM after 18 hrs by inverse MTT assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID403798Cytotoxicity against human A2780 cells2005Journal of natural products, Sep, Volume: 68, Issue:9
Cytotoxic sesquiterpene lactones from Vernonia pachyclada from the Madagascar rainforest.
AID104318Antitumor activity against CD4+ human acute T-lymphoblastic MT-4 leukemia cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID681132TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID153590Percent increase in life span observed in P-388 cells infected male CDF1 hybrid mice after intraperitoneal administration at 125 ug/kg optimal dose1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Tetracyclic chromophoric analogues of actinomycin D: synthesis, structure elucidation and interconvertibility from one form to another, antitumor activity, and structure-activity relationships.
AID154497Antitumor activity against P-388 lymphocytic leukemia in CDF1 hybrid male mice measured as median survival time (0.062 mg/kg),ip1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID205673Compound was tested for its antibacterial activity against Staphylococcus aureus1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis and properties of some peptide analogues of actinomycin D.
AID86368Antitumor activity against human hepatocellular carcinoma HepG-2 cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID15503550% inhibition of incorporation precursor [14C]uridine into RNA P388 cell lines1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID95084Inhibitory concentration against Human Jurkat T cells1999Journal of medicinal chemistry, Apr-22, Volume: 42, Issue:8
Conformational and quantitative structure-activity relationship study of cytotoxic 2-arylidenebenzocycloalkanones.
AID221825Inhibition of protein synthesis was evaluated on human Jurkat T-cells after 8 hours.2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID257884Cytotoxicity against MOLT3 Leukemia cells after 48 hrs of treatment2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1702582Antiproliferative activity against human CCRF-SB cells assessed as cell viability measured after 4 days by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
AID338643Cytotoxicity against human Hep3B cells by MTT assay2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID153268Antitumor activity against P-388 lymphocytic leukemia in CDF1 hybrid male mice measured as percent increase in lifespan( 0.031 mg/kg),ip1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1221977Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID380808Cytotoxicity against human SiHa cells after 6 days by MTT assay1999Journal of natural products, Jul, Volume: 62, Issue:7
Cytotoxic lignans of Justicia ciliata.
AID154817Maximum tolerated dose was determined compared to 7-(2,3-Epoxypropoxy)-actinomycin D against P-388 leukemia in mice(4 days)1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID169331DNA-cleaving ability expressed as % of closed circular pBR322 DNA cleaved at 100 uM conc1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID1221972Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID121026Compound was tested in vivo for its antitumor activity against B16 melanocarcinoma in mice by determining its median survival time at dose of 0.256 mg/Kg1991Journal of medicinal chemistry, Apr, Volume: 34, Issue:4
Synthesis and properties of some peptide analogues of actinomycin D.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1459555Antifungal activity against Saccharomyces cerevisiae ATCC 204508 after incubated for 16 to 48 hrs at 28 to 37 degC by spectrofluorometric method2016Journal of natural products, 10-28, Volume: 79, Issue:10
Antibacterial and Cytotoxic Actinomycins Y
AID91547Antitumor activity against human neuroblastoma IMR32 cells; Not determined2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID269033Antiproliferative activity against human HT29 cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID96221Compound concentration required to reduce the cell proliferation of Wild type and drug-resistant KB subclones passaged in the presence of etoposide 7 uM by 50%2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1702589Antiproliferative activity against human G-361 cells assessed as cell viability measured after 4 days by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
AID354538Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay1996Journal of natural products, Dec, Volume: 59, Issue:12
Cell-based screen for identification of inhibitors of tubulin polymerization.
AID1133382Antitumor activity against mouse P388 cells allografted in BDF1 hybrid mouse assessed as increase of host life span at 75 ug/kg qd for 4 days1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
N7-Substituted 7-aminoactinomycin D analogues. Synthesis and biological properties.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID269032Antiproliferative activity against human G361 cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID1379652Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID1123354Inhibition of Escherichia coli DNA-dependent RNA polymerase at 0.5 ug/ml using Micrococcus luteus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1702581Antiproliferative activity against human CCRF-CEM cells assessed as cell viability measured after 4 days by MTT assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.
AID133462Antitumor activity measured as median survival time, against C26 colon carcinoma.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID681563TP_TRANSPORTER: Cytotoxicity in MT-4 and MT-4/DOX500 cells2003Molecular pharmacology, Jan, Volume: 63, Issue:1
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
AID130985Antitumor activity measured as % increase in life span, against C26 colon carcinoma.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID43186Activity against advanced carcinoma C38 Tumor in CDF1 Mice at dose 0.45 mg/kg measured as % inhibition of tumor1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID43333Mean survival time of treated /untreategroup x100. (number of over 100-day survivors/ number of total mice in the group) at a dose 0.075 mg/kg1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID43340Number of toxic deaths/number of mice in a group of non tumored mice treated in parallel with the tumor-bearing mice and observed for 100 days at a dose 0.30 mg/Kg; value given as 0/91988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID379997Cytotoxicity against human CaSKi cells after 6 days by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
New lanostanoids of Ganoderma tsugae.
AID1150552Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase in life span at 0.3 mg/kg/injection, ip administered intermittently on days 1, 5 and 9 measured on day 601976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1150548Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as mean survival time at 0.4 mg/kg/injection, ip administered as single dose (Rvb = 28 days)1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID269028Antiproliferative activity against human C8166 cell line by MTT assay2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Antitumor agents. 5. synthesis, structure-activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5h-benzopyridophenoxazin-5-ones, and 5h-benzopyridophenoxazin-5-ones with potent antiproliferative activity.
AID44012Antitumor activity against human acute T-lymphoblastic leukemia CCRF-CEM cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID379994Cytotoxicity against mouse 212 cells after 6 days by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
New lanostanoids of Ganoderma tsugae.
AID154496Antitumor activity against P-388 lymphocytic leukemia in CDF1 hybrid male mice measured as median survival time (0.031 mg/kg),ip1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1424082Antibacterial activity against Mycobacterium bovis BCG str. Pasteur 1173P2 incubated for 3 days by GFP based fluorescence assay2017Journal of natural products, 04-28, Volume: 80, Issue:4
Antibacterial Compounds from Marine Bacteria, 2010-2015.
AID94356Concentration required to reduce proliferation of KB subclones passaged in the presence of etoposide 7 uM (KB7D) cell line by 50% as determined by the MTT method2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1221968Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID138380Tested in vivo toxicity in mouse at dose 1 mg/kg when administered intraperitoneally on day 71994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
AID378000Cytotoxicity against human 212 cells after 6 days by MTT assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Cytotoxic isoprenylated flavans of Broussonetia kazinoki.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1123388Toxicity in mouse P388 cells allografted CDF1 mouse assessed as weight loss at 0.18 mg/kg, ip administered on day 1, 5 and 91979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID257881Cytotoxicity against U937 Lymphoma cells by MTS assay2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID378415Antimicrobial activity against Trichoderma harzianum ATCC 64870 after 24 hrs2006Journal of natural products, Aug, Volume: 69, Issue:8
Carneic acids A and B, chemotaxonomically significant antimicrobial agents from the xylariaceous ascomycete Hypoxylon carneum.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1134778Binding affinity to calf thymus DNA assessed as hypochromic shift after 30 mins by spectral analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID42388Antitumor activity against CD+ human acute T-lymphoblastic leukemia C8166 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1139977Selectivity index, ratio of IC50 for African green monkey Vero cells in lag phase of growth to IC50 for human Hep2 cells in lag phase of growth2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID1221969Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko1432011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID678783TP_TRANSPORTER: drug resistance in MRP6-expressing CHO cells2002Cancer research, Nov-01, Volume: 62, Issue:21
Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6).
AID1134777Antitumor activity against mouse P388 cells allografted in CD2F1 mouse assessed as increase in life span at 25 mg/kg administered daily for 9 days1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID1769814Antimicrobial activity against Enterococcus faecalis ATCC 29212 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID358165Cytotoxicity against human PRMI7951 cells by tetrazolium salt-based colorimetric assay1992Journal of natural products, Aug, Volume: 55, Issue:8
Antitumor agents, 129. Tannins and related compounds as selective cytotoxic agents.
AID361135Cytotoxicity against human NUGC cells assessed as cell growth at 5 uM after 3 to 24 hrs by MTS assay2002Journal of natural products, Jul, Volume: 65, Issue:7
New vibsane diterpenes and lupane triterpenes from Viburnum odoratissimum.
AID138377Tested in vivo toxicity in mouse at dose 1 mg/kg when administered intraperitoneally on day 91994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
AID399049Cytotoxicity against human HeLa cells in lag-phase after 48 hrs by MTT assay2005Journal of natural products, Nov, Volume: 68, Issue:11
Cytotoxic sesquiterpenes from Aplysia dactylomela.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID338644Cytotoxicity against human SiHa cells by MTT assay2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID1139975Selectivity index, ratio of IC50 for African green monkey Vero cells in lag phase of growth to IC50 for human HeLa cells in lag phase of growth2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Cytotoxic diterpenes from roots of Crossopetalum gaumeri, a Celastraceae species from Yucatan Peninsula.
AID42389Antitumor activity against CD4+ human acute T-lymphoblastic C8166 leukemia cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID1769822Cytotoxicity against human MCF7 cells assessed as growth inhibition incubated for 68 hrs by MTT assay
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID9851950% Inhibition of growth of L1210 cells in culture.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID378412Antimicrobial activity against Mucor hiemalis DSM 63298 after 24 hrs2006Journal of natural products, Aug, Volume: 69, Issue:8
Carneic acids A and B, chemotaxonomically significant antimicrobial agents from the xylariaceous ascomycete Hypoxylon carneum.
AID1769815Antimicrobial activity against Bacillus thuringiensis BT01 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID54965Dissociation time constant (Tau 2) for dissociation of compound and calf thymus DNA complex2003Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26
Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.
AID1123357Inhibition of Escherichia coli DNA-dependent RNA polymerase at 0.1 ug/ml using calf thymus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID44039In vitro antitumor activity against human leukemic lymphoblastic cells (CCRF-CEM)1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Synthesis and biological properties of actinomycin D chromophoric analogues substituted at carbon 7 with aziridine and cyclopropyl functions.
AID1123355Inhibition of Escherichia coli DNA-dependent RNA polymerase at 0.25 ug/ml using calf thymus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID379996Cytotoxicity against human SiHa cells after 6 days by MTT assay2000Journal of natural products, Apr, Volume: 63, Issue:4
New lanostanoids of Ganoderma tsugae.
AID1134781Binding affinity to calf thymus DNA assessed as isosbestic point after 30 mins by spectral analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Synthesis and evaluation of bis-dipeptide and bis-tripeptide analogues of actinomycin D.
AID89835In vitro growth inhibitory activity against human lymphoblastic leukemia cells1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID257880Cytotoxicity against THP1 Leukemia cells by MTS assay2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1379657Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID152688Optimal dose for antitumor activity was measured in P388 cells of CDF1 male mice in vivo1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
N2- and C-7 substituted actinomycin D analogues: synthesis, DNA-binding affinity, and biochemical and biological properties. Structure-activity relationship.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID355584Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID681130TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID10044Antitumor activity against human renal adenocarcinoma ACHN cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID1150512Binding affinity to calf thymus DNA at 34.5 uM by visible and near-UV CD spectrophotometry1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID624623Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells2001The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2
Rational use of in vitro P-glycoprotein assays in drug discovery.
AID8393050% inhibition of incorporationf precursor [3H]thymidine into RNA HT-29 cell lines1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID54246Apparent number of binding sites per base pairs in DNA1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
N2- and C-7 substituted actinomycin D analogues: synthesis, DNA-binding affinity, and biochemical and biological properties. Structure-activity relationship.
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221978Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1183900Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 1 uM after 2 to 5 hrs by inverse MTT assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID1150519Antibacterial activity against Sarcina subflava assessed as growth inhibition1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1632765Binding affinity to recombinant hexa-histidine-tagged human full-length N-GLY1 catalytic domain expressed in Escherichia coli BL21 (DE3) by thermal shift assay2016Bioorganic & medicinal chemistry, 10-01, Volume: 24, Issue:19
Novel small molecule binders of human N-glycanase 1, a key player in the endoplasmic reticulum associated degradation pathway.
AID644953Binding affinity to human pre-hsa-mir-155 miRNA assessed as inhibition of dicer-catalysed (33P)-labelled pre-miRNA processing at 1 mM after 1 hr by PAGE analysis2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.
AID1146800Inhibition of DNA synthesis in mouse L1210 cells assessed as [3H]-thymidine incorporation preincubated for 3 hrs before [3H]-thymidine addition measured after 1 hr by scintillation spectrometric analysis1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
2-Deaminoactinomycin D, synthesis and interaction with deoxyribonucleic acid.
AID1123341Binding affinity to calf thymus DNA at 1 x 10'-5 M by thermal denaturation assay1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID380442Stabilization of rat DNA polymerase binding to DNA by gel mobility assay2006Journal of natural products, Mar, Volume: 69, Issue:3
Bioactive isomalabaricane triterpenoids from Rhabdastrella globostellata that stabilize the binding of DNA polymerase beta to DNA.
AID221821Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Sequential cytotoxicity: a theory evaluated using novel 2-[4-(3-aryl-2-propenoyloxy)phenylmethylene]cyclohexanones and related compounds.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1150510Binding affinity to poly[d(DAP-A-T)] (unknown origin) at 14.3 uM by visible and near-UV CD spectrophotometry1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1124354Antitumor activity against mouse P388 cells allografted in mouse BDF1 mouse assessed as increase in survival time of mouse at 50 ug/kg, iv for 4 days relative to untreated control1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID677152Induction of apoptosis in human NCI-H157 cells assessed as necrotic cell level at 10 uM incubated for 5 hrs in serum-free medium by annexin V/propidium iodide staining by flow cytometry2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Novel structural insights for imidoselenocarbamates with antitumoral activity related to their ability to generate methylselenol.
AID165907Antitumor activity against human Burkitt lymphoma Raji cells.2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 2. Synthesis, structure-activity relationships, and biological evaluation of substituted 5H-pyridophenoxazin-5-ones with potent antiproliferative activity.
AID98345Inhibition of synthesis of [5-3H]-uridine into RNA in L1210 cells.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Enantiomers of 7-(2,3-epoxypropoxy)actinomycin D as dual-action DNA-acting antitumor agents.
AID43337Number of toxic deaths/number of mice in a group of non tumored mice treated in parallel with the tumor-bearing mice and observed for 100 days at a dose 0.075 mg/Kg; value given as 0/91988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID54622Apparent binding constant calf thymus DNA-drug complex1981Journal of medicinal chemistry, Sep, Volume: 24, Issue:9
N2- and C-7 substituted actinomycin D analogues: synthesis, DNA-binding affinity, and biochemical and biological properties. Structure-activity relationship.
AID1150513Binding affinity to bacteriophage PM2 DNA at 31 uM by visible and near-UV CD spectrophotometry1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID523537Antiviral activity against 0.1 MOI human cytomegalovirus AD169 infected in human HFF assessed as inhibition of early phase mRNA expression after 48 hrs by RT-PCR analysis2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein.
AID155038Antitumor activity in P388/ADR (adriamycin resistant), in male BDF1 mice measured as % increase in life span(%ILS) at dose1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
New actinomycin D analogues as superior chemotherapeutic agents against primary and advanced colon tumors and colon xenografts in nude mice.
AID235576Therapeutic Index measured as the MTD/MED ratio compared to that of compound 41982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID1123360Inhibition of Escherichia coli DNA-dependent RNA polymerase at 0.05 ug/ml using Micrococcus luteus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID248507inhibitory concentration against anti-human coronavirus (HCoV) was determined in MRC-5 cells (human fibroblasts)2004Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18
2-Substituted benzoxazinone analogues as anti-human coronavirus (anti-HCoV) and ICAM-1 expression inhibition agents.
AID338646Cytotoxicity against human HT-29 cells by MTT assay2002Journal of natural products, Mar, Volume: 65, Issue:3
Potent cytotoxic lignans from Justicia procumbens and their effects on nitric oxide and tumor necrosis factor-alpha production in mouse macrophages.
AID1769810Antimicrobial activity against Staphylococcus aureus CCAM 3090 assessed as inhibition of bacterial growth incubated for 16 to 18 hrs by broth micro dilution technique
AID1124358Antitumor activity against mouse P388 cells allografted in mouse BDF1 mouse assessed as increase in survival >50 days at 50 ug/kg, iv for 4 days1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Actinomycin D oxazinones as improved antitumor agents.
AID1150550Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase in life span at 0.025 mg/kg/injection, ip administered daily for 9 days measured on day 601976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some properties and antitumor effects of the actinomycin lactam analog, (di(1-L-alpha, beta-diaminopropionic))actinomycin D1.
AID1183905Cytotoxicity against human primary monocytes assessed as reduction in cell viability at 1 uM after 18 hrs by inverse MTT assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Melleolides induce rapid cell death in human primary monocytes and cancer cells.
AID235575Therapeutic Index measured as the MTD/MED ratio compared to that of compound 31982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Carbon-7 substituted actinomycin D analogues as improved antitumor agents: synthesis and DNA-binding and biological properties.
AID43842Growth inhibitory activity against human lymphoblastic leukemia cells(CCRF-CEM)1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Tetracyclic chromophoric analogues of actinomycin D: synthesis, structure elucidation and interconvertibility from one form to another, antitumor activity, and structure-activity relationships.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID355578Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
AID57907Antitumor activity against human prostate carcinoma DU145 cells2002Journal of medicinal chemistry, Nov-21, Volume: 45, Issue:24
Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.
AID1123361Inhibition of Escherichia coli DNA-dependent RNA polymerase1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1123346Inhibition of Escherichia coli DNA-dependent RNA polymerase at 10 ug/ml using Micrococcus luteus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID670602Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1123343Inhibition of Escherichia coli DNA-dependent RNA polymerase at 20 ug/ml using calf thymus DNA as primer1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological properties of N2-substituted spin-labeled analogues of actinomycin D.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347140qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347138qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347135qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1799481Competition Assay from Article 10.1016/S1074-5521(02)00281-8: \\Neoglycopeptides as inhibitors of oligosaccharyl transferase: insight into negotiating product inhibition.\\2002Chemistry & biology, Dec, Volume: 9, Issue:12
Neoglycopeptides as inhibitors of oligosaccharyl transferase: insight into negotiating product inhibition.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18,165)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012007 (66.10)18.7374
1990's3054 (16.81)18.2507
2000's2006 (11.04)29.6817
2010's921 (5.07)24.3611
2020's177 (0.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.43 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index104.02 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials355 (1.86%)5.53%
Trials37 (32.46%)5.53%
Trials0 (0.00%)5.53%
Reviews633 (3.32%)6.00%
Reviews2 (1.75%)6.00%
Reviews0 (0.00%)6.00%
Case Studies774 (4.06%)4.05%
Case Studies18 (15.79%)4.05%
Case Studies0 (0.00%)4.05%
Observational2 (0.01%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other17,281 (90.74%)84.16%
Other57 (50.00%)84.16%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (52)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma [NCT00075582]Phase 3390 participants (Actual)Interventional2004-09-04Completed
"A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus Pulsed Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia" [NCT00003702]Phase 3240 participants (Actual)Interventional1999-06-30Completed
"A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone (ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol" [NCT00002766]Phase 3170 participants (Actual)Interventional1996-03-31Completed
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor [NCT00352534]Phase 3808 participants (Actual)Interventional2006-10-30Active, not recruiting
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors [NCT00379340]Phase 3395 participants (Actual)Interventional2007-02-26Active, not recruiting
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy [NCT01871766]Phase 298 participants (Actual)Interventional2013-12-04Active, not recruiting
Women's Hospital, Zhejiang University School of Medicine [NCT03885388]Phase 2/Phase 3300 participants (Anticipated)Interventional2019-03-08Recruiting
Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental [NCT03669783]Phase 3110 participants (Anticipated)Interventional2019-01-01Not yet recruiting
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma [NCT04388839]Phase 228 participants (Anticipated)Interventional2020-09-27Recruiting
A Prospective Randomized Multicenter Clinical Control Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor [NCT02639650]Phase 3214 participants (Anticipated)Interventional2016-03-01Recruiting
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) [NCT00354835]Phase 3481 participants (Actual)Interventional2006-12-26Completed
A Pilot Phase II Study for Children With Infantile Fibrosarcoma [NCT00072280]Phase 27 participants (Actual)Interventional2004-11-30Terminated(stopped due to Due to poor accrual)
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma [NCT05304585]Phase 3205 participants (Anticipated)Interventional2022-08-04Recruiting
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance i [NCT04994132]Phase 3118 participants (Anticipated)Interventional2021-09-14Recruiting
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors [NCT01014767]Phase 327 participants (Actual)Interventional2009-11-30Terminated(stopped due to PI departure from coordinating institution)
A Protocol for the Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease [NCT06023641]Phase 1/Phase 2100 participants (Anticipated)Interventional2023-11-30Not yet recruiting
[NCT00541411]10 participants (Anticipated)Interventional2003-06-30Active, not recruiting
Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients With High-Risk Rhabdomyosarcoma [NCT00354744]Phase 3109 participants (Actual)Interventional2006-07-31Completed
Treatment of High Risk Renal Tumors: A Groupwide Phase II Study [NCT00335556]Phase 2291 participants (Actual)Interventional2006-06-30Completed
Phase II Trial of Short VAC1.2 Therapy for Low-Risk A Group Patients With Rhabdomyosarcoma [NCT00245141]Phase 232 participants (Anticipated)Interventional2004-05-31Recruiting
A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) With Melphalan and Dactinomycin for Patients With Locally Advanced or Metastatic Extremity Sarcoma [NCT04332874]Phase 230 participants (Anticipated)Interventional2020-04-01Recruiting
MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood [NCT00002898]Phase 3400 participants (Anticipated)Interventional1995-01-31Completed
A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer [NCT00491946]Phase 424 participants (Anticipated)Interventional2004-06-30Recruiting
Efficacy and Safety of Toripalimab Plus Actinomycin-D as Fist-Line Treatment in Patients With Gestational Trophoblastic Neoplasia With FIGO Score 7: A Single-Arm, Multicenter, Phase II Trial [NCT06020755]Phase 217 participants (Anticipated)Interventional2023-09-30Not yet recruiting
A Prospective,Multicenter,Randomized Trial of Biweekly Single-dose Actinomycin-D Versus Multi-day Methotrexate Protocol for the Treatment of Low-risk Gestational Trophoblastic Neoplasia [NCT04562558]228 participants (Anticipated)Interventional2020-09-29Recruiting
National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study [NCT00002610]Phase 3203 participants (Actual)Interventional1996-01-31Completed
Nephroblastoma Clinical Trial and Study [NCT00003804]Phase 3350 participants (Anticipated)Interventional1993-07-31Active, not recruiting
Phase II Trial of VAC2.2/VA Therapy for Low-Risk B Group Patients With Rhabdomyosarcoma [NCT00245089]Phase 241 participants (Anticipated)Interventional2004-05-31Recruiting
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma [NCT01055314]Phase 2175 participants (Actual)Interventional2010-01-31Completed
A Phase I/II Study of Isolated Limb Infusion and Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma [NCT01531244]Phase 1/Phase 20 participants (Actual)Interventional2014-12-31Withdrawn
EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92] [NCT00002516]Phase 30 participants Interventional1992-07-31Active, not recruiting
European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99) [NCT00020566]Phase 31,200 participants (Anticipated)Interventional2001-02-28Recruiting
MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood [NCT00025441]Phase 20 participants Interventional1998-11-30Completed
International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry Protocol [NCT01464606]156 participants (Actual)Interventional2009-12-22Active, not recruiting
Protocol For The Treatment Of Relapsed And Refractory Wilms Tumour And Clear Cell Sarcoma Of The Kidney (CCSK) [NCT00025103]Phase 275 participants (Anticipated)Interventional2001-05-31Active, not recruiting
Nephroblastoma (Wilms Tumour) Clinical Trial And Study [NCT00047138]Phase 3350 participants (Anticipated)Interventional2001-01-31Recruiting
Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor [NCT00945009]Phase 3249 participants (Actual)Interventional2009-07-13Active, not recruiting
Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia [NCT00003688]Phase 20 participants Interventional1999-10-31Completed
Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma [NCT00003958]Phase 3702 participants (Actual)Interventional2002-09-30Completed
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma [NCT04625907]Phase 1/Phase 21,672 participants (Anticipated)Interventional2020-09-17Recruiting
A Phase II Trial of The Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity [NCT01323517]Phase 226 participants (Actual)Interventional2011-02-28Completed
Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma. [NCT02063022]Phase 3278 participants (Actual)Interventional2009-01-22Completed
NATIONAL WILMS TUMOR STUDY-5 -- THERAPEUTIC TRIAL AND BIOLOGY STUDY [NCT00002611]Phase 33,031 participants (Actual)Interventional1995-07-31Completed
A Phase II Trial of Isolated Limb Infusion With Melphalan and Dactinomycin for Regional Melanoma and Soft Tissue Sarcoma of the Extremity [NCT00004250]Phase 235 participants (Anticipated)Interventional1999-08-31Completed
Actinomycin D and Vincristine With or Without Radiation Therapy, for Newly Diagnosed Patients With Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol [NCT00002995]Phase 3483 participants (Actual)Interventional1997-08-31Completed
A Protocol For Nonmetastatic Rhabdomyosarcoma [RMS-2005] [NCT00379457]Phase 3600 participants (Anticipated)Interventional2006-06-30Recruiting
PROTOCOL FOR THE TREATMENT OF MALIGNANT NON-TESTICULAR GERM CELL TUMORS [NCT00002489]Phase 20 participants Interventional1991-10-31Completed
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia [NCT01535053]Phase 357 participants (Actual)Interventional2012-06-18Completed
"A Phase II Up-Front Window Study of Irinotecan (CPT-11) Followed by Multimodal, Multiagent, Therapy for Selected Children and Adolescents With Newly Diagnosed Stage 4/Clinical Group IV Rhabdomyosarcoma: An IRS-V Study" [NCT00003955]Phase 277 participants (Actual)Interventional1999-09-30Completed
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor [NCT00084838]Phase 225 participants (Actual)Interventional2003-02-28Completed
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS) [NCT02567435]Phase 3321 participants (Actual)Interventional2016-06-01Active, not recruiting
Efficacy and Safety of Actinomycin-D With or Without Toripalimab as Fist-Line Treatment in Patients With Gestational Trophoblastic Neoplasia With FIGO Score 5-6: A Multicenter, Open-label, Randomized Controlled Trial [NCT06028672]40 participants (Anticipated)Interventional2023-09-12Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00002766 (1) [back to overview]Complete Remission (CR)
NCT00003702 (3) [back to overview]Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0
NCT00003702 (3) [back to overview]Number of Patients With a Decline of hCG on Day 1 of Treatment
NCT00003702 (3) [back to overview]Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay
NCT00072280 (1) [back to overview]"Failure-free Survival (FFS) in Chemotherapy Plus Possible Surgery Arm"
NCT00075582 (6) [back to overview]Cumulative Incidence of Patients Who Receive Reduced Doses of Radiation Therapy
NCT00075582 (6) [back to overview]Percentage of Patients With Delayed Surgical Procedures
NCT00075582 (6) [back to overview]Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 1 Failure Free at 5 Years Following Study Entry
NCT00075582 (6) [back to overview]Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 2 Failure Free at 5 Years Following Study Entry
NCT00075582 (6) [back to overview]Percentage of Patients With Stage 1, Clinical Group IIB or C (Node Positive) or Stage 2 Failure Free at 5 Years Following Study Entry
NCT00075582 (6) [back to overview]Cumulative Incidence of Group III Patients Who Received With Reduced Radiotherapy Dose
NCT00084838 (19) [back to overview]Grade 3-4 Infection/Febrile Neutropenia Events
NCT00084838 (19) [back to overview]Grade 3-4 Metabolic/Laboratory Events
NCT00084838 (19) [back to overview]Grade 3-4 Muscloskeletal Events
NCT00084838 (19) [back to overview]Grade 3-4 Neurology Events
NCT00084838 (19) [back to overview]Grade 3-4 Pain Events
NCT00084838 (19) [back to overview]Grade 3-4 Pulmonary Events
NCT00084838 (19) [back to overview]Grade 3-4 Renal/Genitourinary Events
NCT00084838 (19) [back to overview]Grade 3/4 Events
NCT00084838 (19) [back to overview]Pre-Radiation Therapy Chemotherapeutic Response
NCT00084838 (19) [back to overview]Grade 3-4 Hepatic Events
NCT00084838 (19) [back to overview]2-yr Overall Survival
NCT00084838 (19) [back to overview]Grade 3-4 Allergy/Immunology
NCT00084838 (19) [back to overview]Grade 3-4 Auditory/Hearing Events
NCT00084838 (19) [back to overview]Grade 3-4 Blood/Bone Marrow Events
NCT00084838 (19) [back to overview]Grade 3-4 Cardiovascular Events
NCT00084838 (19) [back to overview]Grade 3-4 Constitutional Events
NCT00084838 (19) [back to overview]Grade 3-4 Dermatology Events
NCT00084838 (19) [back to overview]Grade 3-4 Gastrointestinal Events
NCT00084838 (19) [back to overview]Grade 3-4 Hemorrhage Events
NCT00335556 (6) [back to overview]Event Free Survival Probability
NCT00335556 (6) [back to overview]Number of Patients With INI1 Mutations in Renal and Extrarenal Malignant Rhabdoid Tumor by Fluorescent in Situ Hybridization
NCT00335556 (6) [back to overview]Toxicity Rate
NCT00335556 (6) [back to overview]Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors
NCT00335556 (6) [back to overview]Response Rate
NCT00335556 (6) [back to overview]Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT)
NCT00352534 (4) [back to overview]Event Free Survival Probability
NCT00352534 (4) [back to overview]Incidence of Contralateral Kidney Lesions
NCT00352534 (4) [back to overview]Incidence of Renal Failure
NCT00352534 (4) [back to overview]Overall Survival (OS) Probability
NCT00354744 (3) [back to overview]Percentage of Patients Experiencing Adverse Events Due to Concurrent Therapy
NCT00354744 (3) [back to overview]Number of Patients With Complete or Partial Response Assessed by RECIST Criteria
NCT00354744 (3) [back to overview]Percentage of Patients Event Free at 4 Years Following Study Entry
NCT00354835 (13) [back to overview]Incidence of Toxicity Related to VI Treatment in Patients With UGT1A1 Genotype
NCT00354835 (13) [back to overview]Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 15
NCT00354835 (13) [back to overview]Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 4
NCT00354835 (13) [back to overview]Event Free Survival (EFS)
NCT00354835 (13) [back to overview]Event Free Survival (EFS) by PAX Status
NCT00354835 (13) [back to overview]Incidence of Bladder Dysfunction
NCT00354835 (13) [back to overview]Incidence of Toxicity
NCT00354835 (13) [back to overview]Local Failure
NCT00354835 (13) [back to overview]Overall Survival (OS)
NCT00354835 (13) [back to overview]Overall Survival (OS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison
NCT00354835 (13) [back to overview]Acute and Late Effects of VAC as Delivered on This Study to D9803 VAC
NCT00354835 (13) [back to overview]Event Free Survival (EFS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison
NCT00354835 (13) [back to overview]Response Rate (RR)
NCT00379340 (4) [back to overview]Event Free Survival (EFS) Probability
NCT00379340 (4) [back to overview]Event Free Survival Associated With the Burden of Pulmonary Metastatic Disease
NCT00379340 (4) [back to overview]Event Free Survival Probability
NCT00379340 (4) [back to overview]Event Free Survival Probability
NCT00945009 (5) [back to overview]Event-Free Survival (EFS)
NCT00945009 (5) [back to overview]Kidney Preservation After Preoperative Chemotherapy
NCT00945009 (5) [back to overview]Number of Patients Without Complete Removal of at Least One Kidney
NCT00945009 (5) [back to overview]Percentage of Patients Who Experienced Partial Nephrectomy After Preoperative Chemotherapy
NCT00945009 (5) [back to overview]Percentage of Patients Who Had Definitive Surgical Treatment
NCT01055314 (5) [back to overview]Event-Free Survival
NCT01055314 (5) [back to overview]Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment
NCT01055314 (5) [back to overview]Feasibility of the Addition of Temozolomide to Chemotherapy Determined by Patient Enrollment
NCT01055314 (5) [back to overview]Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0
NCT01055314 (5) [back to overview]Response Rate (CR + PR)
NCT01323517 (3) [back to overview]Progression Free Survival at One Year.
NCT01323517 (3) [back to overview]Toxicity of Additional Ipilimumab Will be Evaluated for All Treated Patients Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0
NCT01323517 (3) [back to overview]To Define the Immunologic Events and Signatures at the Tumor Site and in the Periphery That Corresponds to Response to Ipilimumab.
NCT01535053 (6) [back to overview]Number of Participants With CTCAE v4 Graded Adverse Events With Low-risk Gestational Trophoblastic Neoplasia by Arm
NCT01535053 (6) [back to overview]Patient-reported Quality of Life (QOL) After Baseline Visit.
NCT01535053 (6) [back to overview]Patient-reported Quality of Life (QOL) at Baseline
NCT01535053 (6) [back to overview]Percentage of Participants With Complete Response
NCT01535053 (6) [back to overview]The Number of Participants With Post Protocol Multi-agent Chemotherapy Treatment for Each Arm.
NCT01535053 (6) [back to overview]The Number of Participants With Post Protocol Surgical Treatment for Each Arm.

Complete Remission (CR)

complete remission (CR) Disappearance of all clinical evidence of leukemia for a minimum of four weeks. The patient should have a neutrophil count > 1,000 x 10^6/1, a platelet count > 100,000 x 10^9/1, no circulating blasts, and < than or = to blasts on bone marrow differential in a qualitatively normal or hypercellular marrow. Progressive disease or failure: Increasing bone marrow infiltrate or development of organ failure or extramedullary infiltrates due to leukemia. (NCT00002766)
Timeframe: 2 years

,
Interventionparticipants (Number)
Complete RemissionComplete Response (CR)FailureFailure-ProgressionRelapse
All-25014581
L-20501114100

[back to top]

Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 2.0

Number of participants with a maximum grade of 3 or higher during the treatment period. (NCT00003702)
Timeframe: Prior to study entry, weekly during treatment, up to 12 months after normal titer, an average of 7 months.

InterventionParticipants (Count of Participants)
Arm 1: Methotrexate 30 mg/m2 IM Weekly14
Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks20

[back to top]

Number of Patients With a Decline of hCG on Day 1 of Treatment

Number of patients with a decline in hCG on day 1 of treatment relative to the level at enrollment. A decline is defined as a decrease by 1 or more units between enrollment and treatment start. (NCT00003702)
Timeframe: Prior to study entry and on Day 1 of treatment

InterventionParticipants (Count of Participants)
Enrolled Participants72

[back to top]

Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay

Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements. (NCT00003702)
Timeframe: Endpoint was assessed by hCG measurements taken weekly, once normal, treatment was bi-weekly, then monthly, up to 12 months.

,
InterventionParticipants (Count of Participants)
Complete/CureNon-responseInevaluable
Arm 1: Methotrexate 30 mg/m2 IM Weekly57482
Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks76294

[back to top]

"Failure-free Survival (FFS) in Chemotherapy Plus Possible Surgery Arm"

Failure is defined as the occurrence of one of the following: disease progression, defined as at least a 20% increase in the disease measurement, taking as reference the smallest disease measurement recorded since the start of treatment, or the appearance of one or more new lesions; relapse (defined with same criteria as for disease progression) after response; or death as a first event. Data will be summarized as number of eligible patients in each of the following categories at the time of data cutoff for analyses of 5-year FFS: 1)Failed; 2)Failure-free through 5 years of follow-up; 3)Failure-free until data cutoff (if less than 5 years of follow-up); 4)Withdrew from study; 5)Lost to follow-up. NOTE: Reported data are through March 2008 (see Caveats section). (NCT00072280)
Timeframe: Study enrollment until failure, completion of follow-up, or completion of 5-year FFS analyses (up to 5 years)

Interventionparticipants (Number)
FailedFailure-free through 5 years of follow-upFailure-free at cutoff (if < 5 years follow-up)Withdrew from studyLost to follow-up
Chemotherapy Plus Possible Surgery10100

[back to top]

Cumulative Incidence of Patients Who Receive Reduced Doses of Radiation Therapy

The local failure rate will be estimated using cumulative incidence curves. (NCT00075582)
Timeframe: From enrollment up to 5 years

Interventionstimated percentage of participants (Number)
Regimen I (Chemotherapy, Radiotherapy)0.081
Regimen II (Chemotherapy, Radiotherapy, Surgery)0.115

[back to top]

Percentage of Patients With Delayed Surgical Procedures

The decision to perform second-look surgery should be based on the physical examination and imaging studies at Week 12 and should only be considered if a reasonable functional and cosmetic result is anticipated. (NCT00075582)
Timeframe: At 13 weeks after induction

Interventionpercentage of participants (Number)
Regimen II (Stage I Group III Nonorbit or Stage III Group I/II0.49

[back to top]

Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 1 Failure Free at 5 Years Following Study Entry

Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00075582)
Timeframe: From enrollment up to 5 years

InterventionEstimated percentage of participants (Number)
Regimen I (Chemotherapy, Radiotherapy)87
Regimen II (Chemotherapy, Radiotherapy, Surgery)67

[back to top]

Percentage of Patients With Low-risk Rhabdomyosarcoma in Subset 2 Failure Free at 5 Years Following Study Entry

Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00075582)
Timeframe: From enrollment up to 5 years

InterventionEstimated percentage of participants (Number)
Regimen II (Chemotherapy, Radiotherapy, Surgery)67

[back to top]

Percentage of Patients With Stage 1, Clinical Group IIB or C (Node Positive) or Stage 2 Failure Free at 5 Years Following Study Entry

Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00075582)
Timeframe: From enrollment up to 5 years

InterventionEstimated percentage of participants (Number)
Regimen I (Chemotherapy, Radiotherapy)90

[back to top]

Cumulative Incidence of Group III Patients Who Received With Reduced Radiotherapy Dose

The local failure rate will be estimated using cumulative incidence curves for Group III patients who received reduced doses of radiation therapy after second look surgical resection. (NCT00075582)
Timeframe: From enrollment up to 20 weeks

InterventionEstimated percentage of participants (Number)
Regimen II (Stage I Group III Nonorbit or Stage III Group I/II0

[back to top]

Grade 3-4 Infection/Febrile Neutropenia Events

All Grade 3-4 Infection/Febrile Neutropenia events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)49

[back to top]

Grade 3-4 Metabolic/Laboratory Events

All Grade 3-4 Metabolic/Laboratory events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)128

[back to top]

Grade 3-4 Muscloskeletal Events

All Grade 3-4 Muscloskeletal events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)8

[back to top]

Grade 3-4 Neurology Events

All Grade 3-4 Neurology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)45

[back to top]

Grade 3-4 Pain Events

All Grade 3-4 Pain events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)31

[back to top]

Grade 3-4 Pulmonary Events

All Grade 3-4 Pulmonary events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)4

[back to top]

Grade 3-4 Renal/Genitourinary Events

All Grade 3-4 Renal/Genitourinary events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)4

[back to top]

Grade 3/4 Events

All Grade 3-4 events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)1021

[back to top]

Pre-Radiation Therapy Chemotherapeutic Response

"Response pre-RT/post-CT was defined as follows with overall response defined as achieving PR or CR.~Complete Response (CR): Complete resolution of all initially demonstrable tumor on MRI or CT evaluation w/o appearance of any new areas of disease; negative CSF cytology. Partial Response (PR): >/= 50% decrease in the sum of the products of the maximum perpendicular diameters of the tumor (sum LD) relative to baseline w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Stable Disease (SD): <50% decrease in the sum LD w/o appearance of any new areas of disease; CSF cytology unchanged from that at diagnosis or clearing after being initially positive Progressive Disease (PD): >/= 25% increase in the sum LD relative to baseline, or the appearance of any new areas of disease or appearance of positive cytology after two consecutive negative samples." (NCT00084838)
Timeframe: Assessed at study entry and pre-RT/post-CT at week 7.

Interventionproportion of evaluable patients (Number)
Multi-agent Intrathecal and Systemic CT With RT (Modified IRS0.58

[back to top]

Grade 3-4 Hepatic Events

All Grade 3-4 Hepatic events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)8

[back to top]

2-yr Overall Survival

Overall survival is defined as the time from date of diagnosis to death or date of last follow-up. 2-year overall survival is the probability of patients remaining alive at 2-years from study entry estimated using Kaplan-Meier (KM) methods which censors patients at date of last follow-up. Precision of this conditional probability estimate was measured in terms of standard error. Median OS, the original primary endpoint, was not estimable based on the Kaplan-Meier method because of insufficient follow-up. (NCT00084838)
Timeframe: Patients are followed for survival up to 5 yrs post-therapy completion or death; As of this analysis, median follow-up among survivors was 31 months with the longest follow-up being 40 months.

Interventionprobability (Number)
Multi-agent Intrathecal and Systemic CT With RT (Modified IRS0.70

[back to top]

Grade 3-4 Allergy/Immunology

All Grade 3-4 Allergy/Immunology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)1

[back to top]

Grade 3-4 Auditory/Hearing Events

All Grade 3-4 Auditory/Hearing events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)8

[back to top]

Grade 3-4 Blood/Bone Marrow Events

"All Grade 3-4 Blood/Bone Marrow events based on CTCAEv2 as reported on case report forms.~Arm Name" (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)564

[back to top]

Grade 3-4 Cardiovascular Events

All Grade 3-4 Cardiovascular events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)6

[back to top]

Grade 3-4 Constitutional Events

All Grade 3-4 Constitutional events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)22

[back to top]

Grade 3-4 Dermatology Events

All Grade 3-4 Dermatology events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)3

[back to top]

Grade 3-4 Gastrointestinal Events

All Grade 3-4 Gastrointestinal events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)139

[back to top]

Grade 3-4 Hemorrhage Events

All Grade 3-4 Hemorrhage events based on CTCAEv2 as reported on case report forms. (NCT00084838)
Timeframe: Assessed during therapy up to 30 days post-therapy completion which is approximately 55 weeks for patients who completed therapy.

Interventionadverse events (Number)
Multi-agent Intrathecal and Systemic CT With RT (Mod IRS III)1

[back to top]

Event Free Survival Probability

Event-free survival will be informally compared to that seem for similar patients treated on NWTS-5 (NCT00002610). (NCT00335556)
Timeframe: 4 years

InterventionPercent Probability 4 Year EFS (Number)
Regimen DD-4A100.0

[back to top]

Number of Patients With INI1 Mutations in Renal and Extrarenal Malignant Rhabdoid Tumor by Fluorescent in Situ Hybridization

(NCT00335556)
Timeframe: At baseline

InterventionCount participants (Number)
UH-123
Window/UH-11

[back to top]

Toxicity Rate

Percentage of participants with Grade 4 cardiac toxicities, Grade 4 Sinusoidal Obstruction Syndrome (SOS), and treatment-related deaths determined using CTCAE v4. (NCT00335556)
Timeframe: Up to 4 years

InterventionPercentage of patients (Number)
Cardiac toxicitiesTreatment-related deathsSinusoidal Obstruction Syndrome
Combined UH-2, UH-1, Window/UH-14.94.90

[back to top]

Long-term Survival of Patients With Stage I-IV Malignant Rhabdoid Tumors

The outcome of these patients will be compared with a fixed outcome based on that seen for similar patients treated with NWTS-5 regimen (NCT00002610). (NCT00335556)
Timeframe: 4 years

InterventionPercentage of 4-year OS (Number)
UH-138.9

[back to top]

Response Rate

Criteria for response assessed by three-dimensional measurement: Complete Response (CR), Disappearance of all index lesions and non-index lesions. No new lesions; Partial Response (PR), At least a 65% decrease in the sum of the volumes of the index lesions. No new lesions; Response rate (RR) = CR+PR of patients who received window therapy. (NCT00335556)
Timeframe: Up to 2 months

InterventionPercentage of participants (Number)
Combined Window/UH-1 and UH-271

[back to top]

Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT)

Compare the outcome of patients treated with alternating CyCE/VDCy chemotherapy (with or without vincristine/irinotecan cycles) to a fixed outcome based on that seen for similar patients treated with NWTS-5 (NCT00002610). (NCT00335556)
Timeframe: 4 years

InterventionPercentage of 4-year OS (Number)
UH-176.1
Window/UH-125.0
UH-287.5

[back to top]

Event Free Survival Probability

Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00352534)
Timeframe: 4 years

InterventionProbability (Number)
Very Low Risk0.88
Standard Risk, Stage I or II, With LOH0.87
Standard Risk, Stage III0.88

[back to top]

Incidence of Contralateral Kidney Lesions

Number of contralateral kidney lesions during follow-up. (NCT00352534)
Timeframe: During follow-up

InterventionLesions (Number)
Very Low Risk1

[back to top]

Incidence of Renal Failure

Number of renal failures defined as requiring dialysis or renal transplant as determined by low GFR during follow-up (NCT00352534)
Timeframe: During follow-up

InterventionIncidents (Number)
Very Low Risk0

[back to top]

Overall Survival (OS) Probability

Probability of being alive after 4 years in the study. (NCT00352534)
Timeframe: 4 years

InterventionProbability (Number)
Very Low Risk1.00
Standard Risk, Stage I or II, With LOH1.00
Standard Risk, Stage III0.97

[back to top]

Percentage of Patients Experiencing Adverse Events Due to Concurrent Therapy

Adverse events are reported for patients receiving concurrent irinotecan hydrochloride and radiotherapy. (NCT00354744)
Timeframe: From enrollment to up to 2 years

Interventionpercentage of patients (Number)
Course 1Course 2Course 3Course 4
High_Risk_Rhabdomyosarcoma53.368.479.355.7

[back to top]

Number of Patients With Complete or Partial Response Assessed by RECIST Criteria

"Volumetric measurements of the primary tumor using an elliptical model (0.5 x the product of the 3 largest perpendicular diameters) to assess response to neoadjuvant therapy. The RECIST (Response Evaluation Criteria in Solid Tumors) from the NCI will be used for assessment of the size of measurable metastases, including nodal metastases. Primary Tumor Measurement: Technical guidelines for cross-sectional imaging computed tomography (CT) slice thickness should be 5mm or less and the diameter of the measurable mass should be at least twice the reconstructed slice thickness. Smaller masses are considered detectable, but will be counted as non-measurable. Complete Response (CR): Complete disappearance of the tumor confirmed at >4 weeks. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Progressive Disease (PD): At least 40% increase in tumor volume compared to the smallest volume obtained since the beginning." (NCT00354744)
Timeframe: Protocol week 6 evaluation

Interventionpercentage of participants (Number)
High_Risk_Rhabdomyosarcoma63

[back to top]

Percentage of Patients Event Free at 4 Years Following Study Entry

Event-free survival: Time to recurrence, second malignancy, or death as a first event, estimated from a Kaplan Meier curve (NCT00354744)
Timeframe: 4 years

InterventionPercentage of patients (Number)
High_Risk_Rhabdomyosarcoma36

[back to top] [back to top]

Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 15

4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study) (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
% Change in SUVmax From Baseline to Week 15 < 40%0.6667
% Change in SUVmax From Baseline to Week 15 >= 40%0.5686

[back to top]

Compare Event Free Survival (EFS) With Respect to the Level of % Change in FDG PET Maximum Standard Uptake Value (SUVmax) at Week 4

4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study). (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
% Change in SUVmax From Baseline to Week 4 < 40%0.2857
% Change in SUVmax From Baseline to Week 4 >= 40%0.6364

[back to top]

Event Free Survival (EFS)

Probability of no relapse, secondary malignancy, or death after 4 year in the study (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.6255
VAC Alternating With Vincristine, Irinotecan (VI)0.5874

[back to top]

Event Free Survival (EFS) by PAX Status

(NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
PAX30.51
PAX70.66

[back to top]

Incidence of Bladder Dysfunction

Number of patients with a summary score greater than 8.5 (NCT00354835)
Timeframe: 3-6 years after enrollment

InterventionParticipant (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)2
VAC Alternating With Vincristine, Irinotecan (VI)1

[back to top]

Incidence of Toxicity

Grade 3 or 4 nausea, diarrhea, dehydration, radiation dermatitis, mucositis due to radiation. Severe and undesirable adverse event is considered as grade 3; Life-threatening or disabling adverse event is grade 4. Grade 4 is worse than grade 3. (NCT00354835)
Timeframe: Up to 15 weeks

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.2072
VAC Alternating With Vincristine, Irinotecan (VI)0.3673

[back to top]

Local Failure

Compare 2-year local failure rate to the historical rate of 0.13 with IRSI-V. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.13. (NCT00354835)
Timeframe: 2 years

InterventionProportion of participants (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.1757

[back to top]

Overall Survival (OS)

Probability of being alive after 4 years in the study. (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.7293
VAC Alternating With Vincristine, Irinotecan (VI)0.7223

[back to top]

Overall Survival (OS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison

Compare 4-year OS using eligible participants only to the historical rate of 0.70 with IRSI-V. The 4-year OS is probability of being alive after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.70. (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.7293

[back to top]

Acute and Late Effects of VAC as Delivered on This Study to D9803 VAC

The toxicity rates will be estimated for each phase and course of treatment, and will be compared to the fixed rates under D9803 using one-sided lower confidence intervals for a single proportion without adjustment for multiple comparisons. (NCT00354835)
Timeframe: Up to 43 weeks

,
Interventionparticipants (Number)
AnemiaFebrile NeutropeniaNausea or HepatopathyPlatelet Count DecreasedVomiting
VAC (Weeks 1-15)58306279
VAC (Weeks 31 - 43)54171632

[back to top]

Event Free Survival (EFS) Probability VAC and Early (Week 4) Radiotherapy Compared to Delayed (Week 10) Radiotherapy, Using IRSIV for Historic Comparison

Compare 4-year EFS using eligible participants only to the historical rate of 0.65 with IRSI-V. The 4-year EFS is probability of no relapse, secondary malignancy, or death after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.65. (NCT00354835)
Timeframe: 4 years

InterventionProbability (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.6255

[back to top]

Response Rate (RR)

Proportion of patients with complete or partial response. Complete Response (CR): Complete disappearance of the tumor confirmed at > 4 weeks; Partial Response (PR): At least 64% decrease in volume compared to the baseline; Overall Response (OR) = CR + PR. (NCT00354835)
Timeframe: Reporting Period 1 (Weeks 1 - 15)

InterventionProportion (Number)
Vincristine, Dactinomycin, Cyclophosphamide (VAC)0.6667
VAC Alternating With Vincristine, Irinotecan (VI)0.6726

[back to top]

Event Free Survival (EFS) Probability

Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00379340)
Timeframe: At 4 years

InterventionProbability of EFS at 4 years (Number)
Stage IV and Slow Incomplete Response (SIR) of Lung Metastases0.89

[back to top]

Event Free Survival Associated With the Burden of Pulmonary Metastatic Disease

Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00379340)
Timeframe: At 4 years

InterventionProbability (Number)
Lung Mets <= 1cm0.88
Lung Mets > 1cm0.82

[back to top]

Event Free Survival Probability

Probability of no relapse, secondary malignancy, or death after 4 year in the study (NCT00379340)
Timeframe: At 4 years

InterventionProbability of EFS at 4 years (Number)
Stage III/IV With LOH 1p and 16q Treated With Regimen M0.90
Stage IV With Non-lung Disease Treated With Regimen M0.73

[back to top]

Event Free Survival Probability

Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00379340)
Timeframe: 4 years

InterventionProbability (Number)
Stage IV and Rapid Complete Response (RCR) of Lung Metastases0.79

[back to top]

Event-Free Survival (EFS)

Probability of no relapse, secondary malignancy, or death whichever occurs first (NCT00945009)
Timeframe: 4 years from study enrollment

InterventionProbability (Mean)
Arm 1 (Bilateral Wilms Tumors)0.82

[back to top]

Kidney Preservation After Preoperative Chemotherapy

Prevention of complete removal of at least one kidney in 50% of patients with bilateral Wilms tumor (BWT). (NCT00945009)
Timeframe: 12 weeks from study entry

InterventionPercentage of patients (Number)
Arm 1 (Bilateral Wilms Tumors)39

[back to top]

Number of Patients Without Complete Removal of at Least One Kidney

To evaluate the efficacy of chemotherapy in preserving renal units in children with diffuse hyperplastic perilobar nephroblastomatosis (DHPLN) and preventing Wilms tumor development. (NCT00945009)
Timeframe: 12 weeks from the study entry

InterventionParticipants (Count of Participants)
Arm 3 (DHPLN)7

[back to top]

Percentage of Patients Who Experienced Partial Nephrectomy After Preoperative Chemotherapy

Percentage of patients who experienced partial nephrectomy in lieu of nephrectomy in 25% of children with unilateral tumors and aniridia, Beckwith-Wiedemann syndrome (BWS), hemihypertrophy or other overgrowth syndromes, by using prenephrectomy 2-drug chemotherapy induction with vincristine and dactinomycin. (NCT00945009)
Timeframe: 12 weeks from study entry

Interventionpercentage of patients (Number)
Arm 2 (Unilateral High Risk Tumors Bilaterally Predisposed)57

[back to top]

Percentage of Patients Who Had Definitive Surgical Treatment

Percentage of Bilateral Wilms Tumor (BWT) patients who undergo definitive surgery by week 12 after initiation of chemotherapy. (NCT00945009)
Timeframe: 12 weeks from study entry

Interventionpercentage of participants (Number)
Arm 1 (Bilateral Wilms Tumors)85

[back to top]

Event-Free Survival

Probability of no relapse, secondary malignancy, or death after 3 years in the study. (NCT01055314)
Timeframe: 3 years

InterventionProbability (Number)
IMC-A120.1627
Temozolomide0.1919

[back to top]

Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment

Proportion of no Grade 3+ cardiac toxicity. (NCT01055314)
Timeframe: From start to week 26 of therapy

InterventionProportion of Participants (Number)
IMC-A120.9390

[back to top]

Feasibility of the Addition of Temozolomide to Chemotherapy Determined by Patient Enrollment

Proportion of no Grade 4+ non-hematologic toxicity. (NCT01055314)
Timeframe: From start to week 26 of therapy

InterventionProportion of Participants (Number)
Temozolomide0.7097

[back to top]

Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0

Number of patients with grade 3+ adverse events (AE) during therapy. (Grade 3+) = (Grade 3 + Grade 4 + Grade 5) . Grade 3: Severe and undesirable AE; Grade 4: Life threatening or disabling AE; Grade 5: Death related to AE. (NCT01055314)
Timeframe: Up to 54 weeks

InterventionParticipants (Number)
IMC-A1289
Temozolomide61

[back to top]

Response Rate (CR + PR)

Proportion of patients with complete or partial response. Complete Response (CR): Complete disappearance of the tumor confirmed at > 4 weeks. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment; Overall Response (OR) = CR + PR. (NCT01055314)
Timeframe: From the start of treatment until a maximum of 2 cycles (21 days per cycle) of treatment in the absence of disease progression or unacceptable toxicities

InterventionProportion of Participants (Number)
IMC-A120.7667
Temozolomide0.7846

[back to top]

Progression Free Survival at One Year.

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT01323517)
Timeframe: 1 year

Interventionpercentage of participants PFS at 1 year (Number)
Ipilimumab, Melphalan and Dactinomycin58

[back to top]

Toxicity of Additional Ipilimumab Will be Evaluated for All Treated Patients Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0

(NCT01323517)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Ipilimumab, Melphalan and Dactinomycin26

[back to top]

To Define the Immunologic Events and Signatures at the Tumor Site and in the Periphery That Corresponds to Response to Ipilimumab.

Summaries of antibody response, comparison of pretreatment with post-ipilimumab and end of treatment will be assessed for percent of CD4, CD8, and CD68 positive cells (NCT01323517)
Timeframe: 2 years

Interventionpercent of positive cells (Mean)
Pretreatment CD4Posttreatment CD4Pretreatment CD8Posttreatment CD8Pretreatment CD68Posttreatment CD68
Ipilimumab, Melphalan and Dactinomycin328271018

[back to top]

Number of Participants With CTCAE v4 Graded Adverse Events With Low-risk Gestational Trophoblastic Neoplasia by Arm

Maximum grade of physician assessed adverse events reported during treatment (NCT01535053)
Timeframe: Assessed throughout the treatment period and within 2-4 weeks after discontinuation of treatment

,
Interventionparticipants (Number)
Grade 1Grade 2Grade 3Grade 4Grade 5
Regimen I (Dactinomycin)714600
Regimen II (Methotrexate)4101000

[back to top]

Patient-reported Quality of Life (QOL) After Baseline Visit.

Patient reported quality of life was measured with the Functional Assessment of Cancer Therapy - Generic (FACT-G). The FACT-G is a scale for assessing general QOL of cancer patients. It consists of four subscales: Physical Well Being, Functional Well Being, Social/Family Well-Being, and Emotional Well-Being. Each item in the FACT-G was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements, reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The FACT-G score is calculated as the sum of the subscale scores. The FACT-G score ranges 0-108. A larger score suggests better QOL. (NCT01535053)
Timeframe: Prior to cycle 3 (4 weeks after cycle 1 if off study treatment prior to cycle 3). Prior to cycle 5, Prior to cycle 7, 26 weeks after starting study treatment.

,
Interventionunits on a scale (Least Squares Mean)
Pre-cycle 3Pre-cycle 5Pre-cycle 726 weeks
Regimen I (Dactinomycin)78.375.585.091.2
Regimen II (Methotrexate)81.678.984.590.9

[back to top]

Patient-reported Quality of Life (QOL) at Baseline

Patient reported quality of life was measured with the Functional Assessment of Cancer Therapy - Generic (FACT-G). The FACT-G is a scale for assessing general QOL of cancer patients. It consists of four subscales: Physical Well Being, Functional Well Being, Social/Family Well-Being, and Emotional Well-Being. Each item in the FACT-G was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements, reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the subscale. The FACT-G score is calculated as the sum of the subscale scores. The FACT-G score ranges 0-108. A larger score suggests better QOL. (NCT01535053)
Timeframe: Prior to cycle 1

Interventionunits on a scale (Mean)
Regimen I (Dactinomycin)82.3
Regimen II (Methotrexate)81.9

[back to top]

Percentage of Participants With Complete Response

Complete Response is defined as 3 consecutive bi-weekly values of hCG<5 over a minimum of 4 weeks of normal hCG values with no values greater than 5 mIU/ml (NCT01535053)
Timeframe: hCG testing is performed prior to each cycle to treatment until treatment is completed, up to 10 months. For patients who have responded to treatment hCG must be obtained every 4 weeks for 1 year after completing treatment.

Interventionpercentage of participants (Number)
Regimen I (Dactinomycin)78.6
Regimen II (Methotrexate)88.5

[back to top]

The Number of Participants With Post Protocol Multi-agent Chemotherapy Treatment for Each Arm.

(NCT01535053)
Timeframe: Anytime during post treatment follow-up for up to 2 years from study entry.

Interventionparticipants (Number)
Regimen I (Dactinomycin)0
Regimen II (Methotrexate)0

[back to top]

The Number of Participants With Post Protocol Surgical Treatment for Each Arm.

(NCT01535053)
Timeframe: Anytime during post treatment follow-up for up to 2 years from study entry.

Interventionparticipants (Number)
Regimen I (Dactinomycin)0
Regimen II (Methotrexate)0

[back to top]